PNP 2015-029, Annual Radioactive Effluent Release and Waste Disposal Report
| ML15118A527 | |
| Person / Time | |
|---|---|
| Site: | Palisades, Big Rock Point File:Consumers Energy icon.png |
| Issue date: | 04/27/2015 |
| From: | Hardy J Entergy Nuclear Operations |
| To: | Document Control Desk, Office of Nuclear Material Safety and Safeguards, Office of Nuclear Reactor Regulation |
| References | |
| PNP 2015-029 | |
| Download: ML15118A527 (108) | |
Text
PNP 2015-029 April 27,2015 U. S. Nuclear Regulatory Commission ATTN: Document Control Desk Washington, DC 20555-0001 Entergy Nuclear Operations, Inc.
Palisades Nuclear Plant 27780 Blue Star Memorial Highway Covert, MI 49043 Tel 269 7642000 Jeffery A. Hardy Regulatory Assurance Manager 10 CFR 50.36a
Subject:
2014 Annual Radioactive Effluent Release and Waste Disposal Report Palisades Nuclear Plant Docket 50-255 License No. DPR-20
Dear Sir or Madam:
Big Rock Point Dockets 50-155 and 72-043 License No. DPR-6 Attached are the Entergy Nuclear Operations, Inc. 2014 Annual Radioactive Effluent Release and Waste Disposal Reports for Palisades Nuclear Plant (PNP) and Big Rock Point (BRP) Independent Spent Fuel Storage Installation (ISFSI). These reports are submitted in accordance with 10 CFR 50.36a(a)(2). contains the report for PNP. Attachment 2 contains the report for the BRP ISFSI.
These reports provide a summary of the quantities of radioactive liquid and gaseous effluent releases and solid radioactive waste processed during the period of January 1, 2014, through December 31, 2014.
PNP 2015-029 Document Control Desk Page 2 This letter contains no new commitments and no revision to existing commitments.
Sincerely, JAH/bed : Palisades Nuclear Plant 2014 Radioactive Effluent Release Report : Big Rock Point Independent Spent Fuel Storage Installation 2014 Radioactive Effluent Release Report CC Administrator, Region III, USNRC Project Manager, Palisades, USNRC (w/o Attachments)
Resident Inspector, Palisades, USNRC (w/o Attachmens)
NRC NMSS Project Manager, USNRC (w/o Attachments)
American Nuclear Insurers (ANI)
Palisades Nuclear Plant 2014 Radioactive Effluent Release Report 2014 Plant Operating History Palisades Nuclear Plant (PNP) entered the reporting period online on January 1, 2014, at nominal full power (NFP). PNP commenced a controlled shutdown on January 19, 2014, for refueling outage 1 R23. The unit attained criticality on March 15, 2014, and returned to NFP on March 18, 2014. PNP performed a planned shutdown on June 20, 2014, to address P-50C Primary Coolant Pump mechanical seal leakage. The unit attained criticality on June 26, 2014, and returned to NFP on June 30, 2014. PNP was on line for the remainder of 2014. The unit generated 5,830,363 MWHrs of net electrical energy during 2014.
A. Gaseous Effluents Tables 1 A, "Gaseous Effluents - Summation of All Discharges," 1 B, "Gaseous Effluents - Ground-Level Release - Batch Mode," and 1 C, "Gaseous Effluents -
Ground-Level Release - Continuous Mode," list and summarize gaseous effluents released during this reporting period.
B. Liquid Effluents Tables 2A, "Liquid Effluents - Summation of All Discharges," 2B, "Liquid Effluents -
Batch Mode," and 2C, "Liquid Effluents - Continuous Mode," list and summarize liquid effluents released during this reporting period.
C. Solid Waste Storage and Shipments Table 3, "Low-Level Waste for Waste Classification A, Band C, summarizes solid radioactive waste shipped for processing or burial in 2014 for the following waste streams: resins, filters and evaporator bottoms, dry active waste, irradiated components and other waste.
D. Dose Assessments Tables 4, "Dose Assessments, 10 CFR Part 50, Appendix 1," and 5, "EPA 40 CFR Part 190, Individual in the Unrestricted Area," lists annual dose to the members of the public.
Page 1 of 8
E. Supplemental Information
- 1. Regulatory Limits
- a.
Noble Gases The air dose in unrestricted areas due to noble gas released in gaseous effluents shall be limited to the following:
- During the calendar quarter, to :s; 5 mrad for gamma radiation and :5 10 mrad for beta radiation.
- During the calendar year, to :s; 10 mrad gamma radiation and
- s; 20 mrad for beta radiation.
- b.
lodines - Particulates The dose to a member of the public from radioiodines, radioactive material in particulate form with half-lives greater than eight days, and radionuclides other than noble gas, e.g., tritium, in gaseous effluents released to unrestricted areas shall be limited to the following:
During any calendar quarter, to :s; 7.5 mrem to any organ During any calendar year, to :s; 15 mrem to any organ
- c.
Liquid Effluents The dose or dose commitment to an individual from radioactive material in liquid effluents released to unrestricted areas shall be limited to the following:
During any calendar quarter to :s; 1.5 mrem to the total body and
- s; 5 mrem to any organ.
During any calendar quarter to :s; 3 mrem to the total body and :s; 10 mrem to any organ.
- d.
Total Dose The dose or dose commitment to a real individual from all uranium fuel cycle sources is limited to :s; 25 mrem to the total body or any organ (except the thyroid, which is limited to :5 75 mrem) over a period of 12 consecutive months.
Page 2 of 8
- 2.
Maximum Permissible Concentrations (Effluent Concentration Limits)
- a.
Gaseous Effluents The dose rate due to radioactive material released in gaseous effluents from the site shall be limited to the following:
For noble gases: s 500 mrem/yr to the total body and S 3000 mrem/yr to the skin.
For all radioiodines and for all radioactive materials in particulate form with half-lives greater than eight days and for radionuclides other than noble gases: s 1500 mrem/yr to any organ.
The above limits are provided to ensure that radioactive material discharged in gaseous effluents will not result in the exposure of an individual in an unrestricted area to annual average concentrations exceeding the limits of 10 CFR 20, Appendix B, Table 2, Column 1.
- b.
Liquid Effluents The concentration of radioactive material released at any time from the site to unrestricted areas shall be limited to the concentrations specified in 10 CFR 20, Appendix B, Table 2, Column 2, for radionuclides other than dissolved or entrained noble gases. For dissolved or entrained noble gases, the concentration shall be limited to 2E-4 jJCilml total activity.
- 3.
Average Energy The average energy ( E) of the radionuclide mixture in releases of fission and activation gases as defined in Regulatory Guide 1.21, Appendix B, Section A.3 is not applicable because the limits used for gaseous releases are based on calculated dose to members of the public.
- 4.
Measurements and Approximations of Total Radioactivity Palisades upgraded to a 8192 channel analyzer from a 4096 channel analyzer in the second quarter of 2014.
- a.
Fission and activation gases are sampled and then analyzed on a 8192 channel analyzer with a high purity germanium (HpGe) detector.
- b.
lodines are sampled and then analyzed on a 8192 channel analyzer with a HpGe detector.
Page 3 of 8
- c.
Particulates are sampled and then analyzed on a 8192 channel analyzer with a HpGe detector.
- d.
Liquid effluents are sampled and then analyzed on a 8192 channel analyzer with a HpGe detector. Tritium analysis is performed using liquid scintillation. Fe-55, Ni-63, Sr-89, and Sr-90 analyses are performed by an offsite vendor.
- 5.
Batch Releases - 2014 For PNP, these totals are not directly proportional to actual release volumes due to PNP having two sets of tanks with different volumes in both the gaseous and liquid release systems that are utilized for batch releases. The number of batches performed in this section will fluctuate from year to year due to the utilization of the smaller and larger tanks in different frequencies.
This information is better quantified in the tables contained later in this report. Reporting average stream flow during periods of release of effluent into a flowing stream is not required as PNP's releases are made into Lake Michigan, and not a flowing stream of water.
- a.
Liquid Number of batch releases for each quarter: 5 in the 18t quarter 6 in the 2nd quarter 2 in the 3rd quarter 1 in the 4th quarter Total time period for batch releases: 15222 minutes Maximum time period for a batch release: 2409 minutes Average time period for a batch release: 1087.2 minutes Minimum time period for a batch release: 170 minutes
- b.
Gaseous Number of batch releases for each quarter: 11 in the 18t quarter 11 in the 2nd quarter 1 in the 3rd quarter 1 in the 4th quarter Page 4 of 8
Total time period for batch releases: 7637 minutes Maximum time period for a batch release: 2317 minutes Average time period for a batch release: 318 minutes Minimum time period for a batch release: 62 minutes
- 6.
Abnormal Discharges
- a.
Liquid Number of releases for each quarter 1 st Quarter 2nd Quarter 3rd Quarter 4th Quarter o
0 0
0 Total activity released in Curies (Ci) 1 st Quarter 2nd Quarter 3rd Quarter 4th Quarter o
0 0
0
- b.
Gaseous Number of releases for each quarter 1 st Quarter 2nd Quarter 3rd Quarter 4th Quarter o
0 0
0 Total activity released in Curies (Ci) 1 st Quarter 2nd Quarter 3rd Quarter 4th Quarter o
0 0
0
- 7.
Non-Routine Planned Discharges None.
- 8.
Radioactive Waste Treatment System Changes None.
- 9. Annual Land Use Census Changes The garden critical receptor is unchanged and remains located in the SSE sector at.69 miles. The residence critical receptor has changed and is now located in the SSW sector at 0.49 miles. The goats are now located in the NE sector at 2.45 miles and are fed stored feed. Beef cattle remain located in the SE sector at 4.27 miles. There are no dairy cows located within five miles of the plant.
Page 5 of 8
- 10. Effluent Monitoring System Inoperability Three effluent monitors were out of service for greater than 30 days during the reporting period.
RIA-0631, condenser off-gas monitor, was declared inoperable on November 5,2013, due to failing to respond to a source check during performance of MR-14, Process Monitor Function Checks - Monthly.
Compensatory sampling was initiated per the ODCM. Troubleshooting remained in progress entering 2014. Compensatory actions were performed until the monitor was returned to service on March 6, 2015.
RIA-5211, turbine building sump effluent monitor was out of service for two separate periods of greater than 30 days. The monitor was initially declared non-functional on February 7, 2014, after displaying a false high reading.
Compensatory sampling was initiated in accordance with the ODCM until the monitor was declared functional on March 19, 2014. RIA-5211 was then removed from service on March 23, 2014, due to the return of false high readings. Compensatory daily sampling was performed until the monitor was returned to service on June 6, 2014.
RIA-1113, waste gas discharge monitor, was declared inoperable on March 26, 2014, due to failing to meet acceptance criteria during a source check following calibration. Compensatory sampling was initiated per the ODCM, and continued until RIA-1113 was returned to service on October 14, 2014. The extended delay was caused by a parts issue.
- 11. Offsite Dose Calculation Manual (ODCM) Changes The Offsite Dose Calculation Manual and Offsite Dose Calculation Manual Appendix A were revised in 2014 to update 1 O-year X/Q data. The General Manager Plant Operations approval is documented on the procedure cover page. The description and evaluation of the changes are documented on the Offsite Dose Calculation Manual Change Reviews and are supplied with the copies of the revisions. These revisions did not reduce the accuracy or reliability of dose calculations or setpoint determinations. Enclosure 1 contains a copy of the ODCM revision with changes indicated by marginal markings.
- 12. Process Control Program Changes None.
- 13. Errata/Corrections to Previous Reports None.
Page 6 of 8
- 14. Other Groundwater Monitoring PNP has 21 ground water monitoring wells (MW) strategically placed within the owner controlled area to allow for detection of radioactive contamination of ground water due to leaks or spills from plant systems, four of which were installed in December, 2014, for monitoring starting in 2015. PNP added 18 temporary wells (TW) in 2009 to determine the potential source of tritium in groundwater in the vicinity of MW-3. Tanks T-90, primary makeup tank, T-91, utility water storage tank, and associated underground piping between these tanks and the auxiliary building addition are in this area. TW-15 is most indicative of a historic leak that continues to be monitored and addressed through piping repairs.
Tritium levels in TW-15 trended downward until October, 2014, when tritium peaked at 101,000 pCi/L due to washout from rising groundwater levels. No indications were present of any new underground piping leaks in 2014.
Monitoring of the groundwater tritium plume continues to assess repair effectiveness and follow the site hydrology data. Well locations are depicted in Figure 1.
Depth to Local Water Table - The depth is approximately eight to nine feet.
Classification of Subsurface Aquifers - Not used for drinking water.
Expected MovemenUMobility of Groundwater Plume - Westerly direction down-gradient toward Lake Michigan at approximately two feet per day.
Land Use Characteristics - PNP site property, water not used for drinking or irrigation.
NRC Notification, Date and contact Organization - The NRC was notified on December 10,2007, by PNP.
Page 7 of 8
Carbon-14 In 2010, PNP and other facilities participated in an EPRI task force to build a model to accurately estimate gaseous C-14 releases, given some key site-specific plant parameters (mass of the primary coolant, average thermal neutron cross section, rated MW, etc). This work was completed in November 2010. The estimates for C-14 were constructed using the aforementioned EPRI methodology contained with EPRI 1021106, Estimation of Carbon-14 in Nuclear Power Plant Gaseous Effluents. Using the C-14 curie estimates, the annual dose to man was derived from guidance contained within Regulatory Guide 1.109. Because the dose contribution of C-14 from liquid radioactive waste is much less than that contributed by gaseous radioactive waste, evaluation of C-14 in liquid radioactive waste is not required.
Annual C-14 release PNP and subsequent doses for 2014:
Total Gaseous C-14 Released Curies =
Gaseous C-14 as C02 Curies =
Effective Child TB Dose, C-14 mrem =
Effective Child Bone Dose, C-14 mrem =
7.11 2.13 0.052 0.26 The quarterly curies released are provided in Table 1 B. Airborne doses due to C-14 are grouped under the category of Particulate, Iodine, and Tritium which are contained in Table A-4.
Meteorological Data Meteorological Data recovery was at 97.05%. The two most frequently occurring directions for the year at the 10 meter level were SSE and SE, accounting for over 21 % of all observations. At 60 meters, the two predominant directions were Sand SW, accounting for over 17% of all observations. The highest average speeds were associated with ESE winds at 10 meters and W winds at 60 meters. The mean speed for all directions at 10 meters was 3.17 mls (7.09 mph), and at 60 meters was 6.03 mls (13.49 mph). When compared to last year, the 10 meter average is 0.09 mls (0.20 mph) lower while the 60 meter average is 0.02 mls (0.04mph) lower. Data from this report and the annual meteorological data (Hourly Average Data or Joint Frequency Distribution) will be maintained on site in a file that shall be provided to the NRC upon request.
Page 8 of 8
FIGURE 1 GROUNDWATER MONITORING WELL LOCATIONS figum4.t Page 1 of 1
Summation of All Releases Units Fission and Activation Gases Ci Average Release Rate
% of Limit 1-131 Average Release Rate 0/0 of Limit Particulates Average Release Rate 0/0 of Limit Tritium Average Release Rate 0/0 of Limit Gross Alpha Average Release Rate 0/0 of Limit ATTACHMENT 1 Palisades - Table 1A 2014 Gaseous Effluents - Sum of All Releases Quarter 1 Quarter 2 Quarter 3 Quarter 4 6.2BE+OO 1.S1 E+OO S.B7E-01 1.46E+OO 7.B7E-01 1.91 E-01 7.20E-02 1.7SE-01 B.99E-03 7.2BE-04 9.73E-04 1.71 E-03 1.24E-04 3.26E-OS 4.76E-OS 3.36E-OS 1.S9E-OS 4.1SE-06 S.99E-06 4.22E-06 1.B2E-07 4.73E-OB 6.B3E-OB 4.B1 E-OB 7.79E-06 7.30E-06 2.34E-07 1.03E-02 1.00E-06 B.4SE-07 2.34E-OB 1.S4E-07 2.2BE-07 7.90E-07 S.34E-09 7.02E-07 4.3SE+OO 3.0BE+OO 1.SSE+OO 1.9BE+OO S.60E-01 3.91 E-01 1.9SE-01 2.49E-01 1.2BE-03 B.92E-04 4.44E-04 S.6BE-04 NO NO NO
.7BE+OO 1.7BE+OO 1.7BE+OO 1.7BE+OO 2.29E-01 2.26E-01 2.24E-01 2.24E-01 1.74E-06 1.72E-06 1.70E-06 1.70E-06 Page 1 of 1 Uncertainty Total
(%)
9.B4E+OO B.7B 3.12E-01 3.07E-03 2.3BE-04 7.S4E-06 B.S9E-OB 1.03E-02 3.2BE-04 4.31 E-07 1.10E+01 3.47E-01 7.92E-04 9.66E-07 7.12E+OO 2.26E-01 1.72E-06
ATTACHMENT 1 Palisades - Table 1 B 2014 Gaseous Effluents - Ground Level Release, Continuous Mode Fission and Activation Units Gases Ar-41 Ci Kr-85 Ci Kr-85m Ci Kr-87 Ci Kr-88 Ci Xe-131m Ci Xe-133 Ci Xe-133m Ci Xe-135 Ci Xe-135m Ci Xe-138 Ci Total Ci lodines/Halogens Units 1-131 Ci 1-132 Ci 1-133 Ci 1-134 Ci 1-135 Ci Total Ci Particulates Units Co-58 Ci Co-6O Ci Na-24 Ci Cr-51 Ci Mn-56 Ci Y-88 Ci Sr-92 Ci Cs-138 Ci Nb-95 Ci Zr-95 Ci Mn-54 Ci Ag-110m Ci Total Ci I Tritium I Ci I Gross Alpha I Ci I C-14 I Ci NO = Measurements performed but no activity detected.
NA = Analysis not required & not performed Quarter 1 Quarter 2 3.59E-02 NO NO NO NO NO NO NO NO NO 1.74E-03 5.75E-03 8.46E-01 9.92E-01 NO 6.99E-03 7.61 E-03 1.66E-02 NO NO NO NO 8.91 E-01 1.02E+OO Quarter 1 Quarter 2 1.52E-08 1.52E-06 NO 8.28E-07 2.88E-06 1.49E-06 NO NO NO NO 2.90E-06 3.84E-06 Quarter 1 Quarter 2 NO 4.90E-06 8.71E-11 1.10E-06 NO NO NO NO NO NO NO NO NO NO NO NO NO 6.41 E-07 NO 3.87E-07 NO 8.27E-08 NO 2.71 E-07 8.71 E-11 7.38E-06 I 3.12E-02 I 4.97E-01 I I 4.83E-07 I NO I
NA NA Page 1 of 1 Quarter 3 NO NO NO NO NO NO NO NO NO NO NO O.OOE+OO Quarter 3 NO NO NO NO NO O.OOE+OO Quarter 3 1.86E-07 NO NO NO NO NO NO NO NO 4.79E-08 NO NO 2.34E-07 NO NO NA' Quarter 4 NO NO NO NO NO NO 1.57E-04 NO NO NO NO 1.57E-04 Quarter 4 NO NO NO NO NO O.OOE+OO Quarter 4 NO 1.22E-06 NO NO NO 9.34E-03 NO 9.80E-04 NO NO NO NO 1.03E-02 NO NO NA
ATTACHMENT 1 Palisades - Table 1 C 2014 Gaseous Effluents - Ground Level Release, Continuous Mode Fission and Activation Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 Gases Ar-41 Ci 1.96E+OO 9.39E-02 1.98E-01 1.33E-01 Kr-85 Ci NO NO NO NO Kr-85m Ci 8.87E-03 1.02E-04 2.44E-03 4.18E-02 Kr-87 Ci 6.33E-02 2.43E-02 2.98E-02 1.07E-01 Kr-88 Ci 4.59E-01 1.95E-02 2.09E-02 9.28E-02 Xe-131m Ci NO NO NO NO Xe-133 Ci 6.91 E-02 4.71 E-02 1.12E-02 1.36E-01 Xe-133m Ci NO NO NO NO Xe-135 Ci 2.06E+OO 1.32E-01 1.46E-01 3.90E-01 Xe-135m Ci 3.46E-01 9.19E-03 1.94E-03 6.91 E-03 Xe-137 Ci 1.67E-01 NO 1.43E-02 6.86E-02 Xe-138 Ci 2.63E-01 1.58E-01 1.62E-01 4.85E-01 Total Ci 5.39E+OO 4.84E-01 5.87E-01 1.46E+OO lodines/Halogens Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 1-131 Ci 1.24E-04 3.11 E-05 4.76E-05 3.36E-05 1-132 Ci 1.13E-03 1.51 E-05 NO NO 1-133 Ci 1.02E-04 4.85E-05 8.68E-05 1.00E-04 1-134 Ci NO NO NO NO 1-135 Ci NO NO NO NO Total Ci 1.36E-03 9.48E-05 1.34E-04 1.34E-04 Particulates Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 Co-58 Ci 7.79E-06 NO NO NO Co-60 Ci NO NO NO NO Mn-54 Ci NO NO NO NO Cr-51 Ci NO NO NO NO Co-57 Ci NO NO NO NO Nb-95 Ci NO NO NO NO Zr-95 Ci NO NO NO NO Ag-110m Ci NO NO NO NO Sn-113 Ci NO NO NO NO Sb-125 Ci NO NO NO NO Cs-137 Ci NO NO NO NO Ce-144 Ci NO NO NO NO Total Ci 7.79E-06 O.OOE+OO O.OOE+OO O.OOE+OO I Tritium I Ci 4.32E+OO I 2.58E+OO I 1.55E+OO I 1.98E+OO I I Gross Alpha I Ci 4.83E-071 O.OOE+OO I O.OOE+OO I O.OOE+OO I I C-14 I Ci 1.78E+OO I 1.78E+OO I 1.78E+OO I 1.78E+OO I NO = Measurements performed but no activity detected.
Page 1 of 1
ATTACHMENT 1 Palisades - Table 2A 2014 Liquid Effluents - Sum of All Releases Summation of All Uncertainty Liquid Releases Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 Total Fission and Activation Products (excluding tritium, gases, and gross al Ci 1.02E-02 B.9BE-03 1.59E-03 1.4BE-04 2.09E-02 6.54 Average Concentration Cilml 5.B5E-10 2.42E-10 3.97E-11 3.BOE-12 1.57E-10 0/0 of Limit 4.91 E-03 4.0BE-03 7.01 E-04 9.25E-05 2.01 E-03 Tritium 7.B9E+01 3.79E+01 9.64E+01 2.73E+01 2.40E+02 Average Concentration Cilml 4.52E-06 1.02E-06 2.40E-06 7.02E-07 1.BOE-06 0/0 of Limit 0/0 4.52E-01 1.02E-01 2.40E-01 7.02E-02 1.BOE-01 Dissolved and Entrained Gases Ci B.66E-05 O.OOE+OO O.OOE+OO O.OOE+OO B.66E-05 Average Concentration 4.96E-12 O.OOE+OO O.OOE+OO O.OOE+OO 6.49E-13
% Of Limit 2.4BE-06 O.OOE+OO O.OOE+OO O.OOE+OO 3.24E-07 0.00 O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO O.OOE+OO Volume of Primary System Liquid Effluent (Before Dilution Liters B.06E+05 7.21 E+05 3.B3E+05 1.45E+05 2.05E+06 Dilution Water Used for Above Liters 1.74E+10 3.71 E+1 0 4.01 E+10 3.BBE+10 1.33E+11 Volume of Secondary or Balance-of-Plant Liquid Effluent (e.g.,
low-activity or unprocessed)
Before Dilution Liters 5.94E+09 B.23E+09 1.02E+10 B.01E+09 3.24E+10 Average Stream Flow m3/s 2.24E+00 4.71E+00 5.05E+00 4.BBE+00 4.22E+00 Dilution flow rate (gal/qtr) = # of Dilution pumps running x days running/qtr x 40,000 gpm/pump x min/day Page 1 of 1
Fission and Activation Products Cr-51 Mn-54 Fe-55 Fe-59 Co-57 Co-58 Co-60 Sr-89 Sr-90 Nb-95 Ag-110m Sn-113 Sb-124 Sb-125 1-131 1-133 1-135 Cs-134 Cs-137 Ni-63 Zn-65 Zr-95 La-140 Totals Dissolved and Entrained Gases Kr-85 Kr-85m Kr-88 Xe-131m Xe-133 Xe-133m Xe-135 Xe-135m Totals I Tritium I Gross Alpha ND = None Detected ATTACHMENT 1 Palisades - Table 2B 2014 liquid Effluents - Batch Mode Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 Ci ND ND ND ND Ci ND ND 3.78E-05 ND Ci 1.33E-04 ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci 6.60E-03 4.23E-03 7.44E-04 3.74E-05 Ci 1.20E-03 1.05E-03 5.13E-04 9.40E-05 Ci ND ND ND ND Ci ND ND ND ND Ci 1.38E-04 2.10E-04 ND ND Ci 5.60E-04 1.02E-03 2.72E-04 1.62E-05 Ci ND ND ND ND Ci ND ND ND ND Ci 4.20E-04 9.21 E-04 ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND 7.36E-04 2.64E-05 ND Ci 1.14E-03 8.14E-04 ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci 1.02E-02 8.98E-03 1.59E-03 1.48E-04 Units Quarter 1 Quarter 2 Quarter 3 Quarter 4 Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci 8.66E-05 ND ND ND Ci ND ND ND ND Ci ND ND ND ND Ci ND ND ND ND 8.66E-05 O.OOE+OO O.OOE+OO O.OOE+OO Ci 7.89E+01 3.79E+01 9.64E+01 2.46E+01 ND ND ND ND Page 1 of 1
Fission and Activation Products Cr-51 Mn-54 Fe-55 Fe-59 Co-57 Co-58 Co-60 Sr-89 Sr-90 Nb-95 Ag-110m Sn-113 Sb-124 Sb-125 1-131 1-133 1-135 Cs-134 Cs-137 Ni-63 Zn-65 Zr-95 La-140 Totals Dissolved and Entrained Gases Kr-85 Kr-85m Kr-88 Xe-131m Xe-133 Xe-133m Xe-135 Xe-135m Totals I Tritium I Gross Alpha N D = None Detected ATTACHMENT 1 Palisades - Table 2C 2014 liquid Effluents - Continuous Mode Units Quarter 1 Quarter 2 Quarter 3 Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci O.OOE+OO O.OOE+OO O.OOE+OO Units Quarter 1 Quarter 2 Quarter 3 Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND Ci ND ND ND O.OOE+OO O.OOE+OO O.OOE+OO I Ci ND 2.16E-02 3.02E-02 I Ci ND ND ND Page 1 of 1 Quarter 4 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND O.OOE+OO Quarter 4 ND ND ND ND ND ND ND ND O.OOE+OO 2.67E+OO ND
ATTACHMENT 1 Palisades - Table 3 2014 Low-Level Waste
- 1. Solid waste shipped offsite for burial or disposal (not irradiated fuel)
- 1. Type of waste Unit Estimated amount
- a. Spent resin, filters, m;j 1.38E+01 evaporator bottoms, etc.
Curies 3.01E+00
- b. Dry compressible waste, m;j 3.27E+02 contaminated equipment, etc.
Curies 5.41 E+OO
- c. Irradiated components, m;j O.OOE+OO control rods, etc.
Curies O.OOE+OO
- d. Other (describe) m;j 2.34E+01 DAW / Metal Waste / Oil Curies 1.22E-02
- 2. Estimate of Major Nuclide composition (by type of waste), list nuclides as needed
- a.
Fe-55 5.50/0 Ag-110m 5.1%)
Co-58 11 %
Sb-125 3.6%
Co-60 30%
Cs-137 2.8%)
Ni-63 390/0
- b.
Cr-51 130/0 Ni-63 60/0 Fe-55 4%
Zr-95 5%
Co-58 39%
Nb-95 8%
Co-60 13.50/0 Ag-110m 4%
- c.
- d.
C-14 2%
Co-60 17%
Cr-51 7%
Zr-95 50/0 Fe-55 12%
Nb-95 8%
Co-58 28%
Ag-110m 5%
Page 1 of 2 Est Total Error, %
25 25 0
25 Cs-137 10/0 Cm-243 1 %
- 3. Solid waste disposition N umber of shipments 1
20 1
ATTACHMENT 1 Palisades - Table 3 2014 Low-Level Waste Mode of transportation Truck Destination Kingston, Tn Truck Oakridge, Tn Truck Erwin, Tn Irradiated fuel shipments (disposition)
Number of shipments o
Mode of transportation N/A Page 2 of 2 Destination N/A
ATTACHMENT 1 Palisades - Table 4 2014 Dose Assessments, 10 CFR Part 50, Appendix I Quarter 1 Quarter 2 Quarter 3 Quarter 4 Yearly Liquid Effluent Dose Limit, Total 1.5 mrem 1.5 mrem 1.5 mrem 1.5 mrem 3 mrem Body Total Body Dose 1.37E-03 1.31 E-03 2.99E-04 5.47E-05 3.03E-03 0/0 Of Limit 0.09%)
0.090/0 0.02%
0.00%
0.10%
Liquid Effluent Dose Limit, Any 5 mrem 5 mrem 5 mrem 5 mrem 10 mrem Organ Organ Dose 2.65E-03 2.33E-03 2.97E-04 5.58E-05 5.33E-03
% of Limit 0.05%
0.05%)
0.010/0 0.00%
0.050/0 Gaseous Effluent Dose Limit, 5 mrad 5 mrad 5 mrad 5 mrad 10 mrad Gamma Air Gamma Air Dose 2.49E-03 2.50E-04 3.04E-04 6.41 E-04 3.69E-03 0/0 of Limit 0.05%
0.01 %
0.01 0/0 0.01 %
0.04%
Gaseous Effluent Dose Limit, 10 mrad 10 mrad 10 mrad 10 mrad 20 mrad Beta Air Beta Air Dose 1.33E-03 1.99E-04 1.72E-04 4.52E-04 2.15E-03 0/0 of Limit 0.013%
0.0020/0 0.002%
0.005%
0.011 %
Gaseous Effluent Dose Limit, Any 7.5 mrem 7.5 mrem 7.5 mrem 7.5 mrem 15 mrem Organ (Iodine, Tritium, Particulates with >8 day half-life)
Gaseous Effluent Organ Dose 1.18E-02 3.83E-03 3.69E-03 2.22E-02 4.16E-02 (Iodine, Tritium, Particulates with
>8-Day half-life)
% of Limit 0.16%
0.050/0 0.05%
0.300/0 0.28%
Palisades - Table 5 2014 EPA 40 CFR Part 190, Individual in the Unrestricted Area Whole Body Thyroid Any Other Organ Dose Limit 25 mrem 75 mrem 25 mrem Dose 1.51 E-01 2.01 E-02 5.33E-03 0/0 of Limit 0.61%
0.03%
0.02%
Page 1 of 1
ENCLOSURE 1 PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL, REVISION 26 OFFSITE DOSE CALCULATION MANUAL APPENDIX A, REVISION 18 144 Pages Follow
ENCLOSURE 1 PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL, REVISION 26 OFFSITE DOSE CALCULATION MANUAL APPENDIX A, REVISION 18 78 Pages Follow
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL ODCM Revision 26 Issued Date 7/30/14 TITLE: OFFSITE DOSE CALCULATION MANUAL I Process Applicability Exclusion D
AKGennrich 1
7/30/14 Procedure Sponsor Date MESoja 1
6/22/14 Technical Reviewer Date CLJones 1
7/29/14 User Reviewer Date ALWiliiams 1
7/29/14 General Manager Plant Operations Date
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 Table of Contents I.
GASEOUS EFFLUENTS............................................................................................... 1 A.
ALARMITRIP SETPOINT METHOD.............................................................. 1
- 1.
Allowable Concentration................................... 2
- 2.
Monitor Response............................................. 3 B.
DOSE RATE CALCULATION........................................................................ 4 C.
GASEOUS RADWASTE TREATMENT SYSTEM OPERATION................. 19
- 1.
System Description......................................... 19
- 2.
Determination of Satisfactory Operation....... 19 D.
RELEASE RATE FOR OFFSITE EC........................................................... 20 E.
PARTICULATE AND IODINE SAMPLING.................................................. 20 F.
NOBLE GAS SAMPLING............................................................................ 21 G.
TRITIUM SAMPLING................................................................................... 21 H.
FIGURE - GASEOUS EFFLUENTS FLOW PATHS................................... 22 II.
LIQUID EFFLUENTS................................................................................................... 23 A.
CONCENTRATION...................................................................................... 23
- 1.
Requirements................................................... 23
- 2.
Prerelease Analysis......................................... 23
- 3.
Effluent Concentration (EC) - Sum of the Ratios................................................................ 24 B.
INSTRUMENT SETPOINTS......................................................................... 25
- 1.
Setpoint Determination................................... 25
- 2.
Composite Samplers....................................... 25
- 3.
Post-Release Analysis.................................... 26 C.
DOSE........................................................................................................... 26
- 1.
RETS Requirement.......................................... 26
- 2.
Release Analysis............................................. 26 D.
OPERABILITY OF LIQUID RADWASTE EQUIPMENT.............................. 30 E.
RELEASE RATE FOR OFFSITE EC (50 MREMNR).................................. 30 F.
FIGURES..................................................................................................... 31
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 Table of Contents III.
URANIUM FUEL CYCLE DOSE.................................................................................. 33 A.
SPECiFiCATION.......................................................................................... 33 B.
ASSUMPTIONS........................................................................................... 33 C.
DOSE CALCULATION................................................................................ 34 IV.
SOURCE REFERENCE DOCUMENTS....................................................................... 34,,,,,,,,
Attach ment 9, "Palisades Gaseous And Liquid Source Terms, CurieslYear" "Basic RadionuC/ide Data" "Dose Factors for Submersion in Noble Gases" "Stable Element Transfer Data" "Inhalation Dose Commitment Factors" "External Dose Factors for Standing on Contaminated Ground (DFGi)
(mrem/hr per pCilm2)"
"Bioaccumulation Factors (jJCilgm per jJCilml)"
"Ingestion Dose Commitment Factors" "Palisades 1 0 Year X/Q - D/Q Data"
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 I.
GASEOUS EFFLUENTS A.
ALARM/TRIP SETPOINT METHOD Appendix A, Section I/I.B.1 requires that the dose rate due to radioactive materials released in gaseous effluents from the site to areas at and beyond the SITE BOUNDARY shall be limited to the following:
For noble gases: Less than or equal to 500 mrems/yr to the total body and less than or equal to 3000 mrems/yr to the skin, and For iodine-131, for iodine-133, for tritium, and for all radionuclides in particulate form with half lives greater than 8 days: Less than or equal to 1500 mrems/yr to any organ.
Appendix A, Section /I I.A.1 requires gaseous effluent monitors to have alarm/trip setpoints to ensure that offsite concentrations, when averaged over 1 hour1.157407e-5 days <br />2.777778e-4 hours <br />1.653439e-6 weeks <br />3.805e-7 months <br />, will not be greater than Appendix A, Section I/I.B.1. This section of the aDeM describes the methodology that will be used to determine these setpoints.
The methodology for determining alarm/trip setpoints is divided into two major parts.
The first consists of calculating an allowable concentration for the nuclide mixture to be released. The second consists of determining monitor response to this mixture in order to establish the physical settings on the monitors.
1
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 1.
Allowable Concentration NOTE:
If a batch release is made while a continuous release or another batch release is in progress, the sum of all values of Rk must be less than 10.0.
The total EC-fraction (Rk) for each release point will be calculated by the relationship defined by Note 4 of Appendix B, 10 CFR 20:
(1.1 )
where:
Cj
=
Actual or measured concentration, at ambient temperature and pressure of nuclide i (/-lCilcc)
ECj
=
The EC of nuclide i from 10 CFR 20, Appendix B, Table 2 R(k)
=
The total EC-fraction for release point k X/Q
=
Most conservative sector site boundary dispersion (sec/m3)
(listed in site procedure CH 6.41, "Land Use Census")
F
=
Release flow rate (83,000 cfm = 39.2 m3/sec) for stack monitor considerations; variable for other monitors 2
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 2.
Monitor Response Normal radioactivity releases consist mainly of well-decayed fission gases.
Therefore, monitor response calibrations are performed to fission gas typical of normal releases (mainly Xe-133). Response of monitors used to define fission product release rates under accident conditions may vary from that of Xe-133, however. Monitor response for the two categories of monitor is determined as follows:
- a.
Normal Release (aged fission gasses)
Total gas concentration (IlCilcc) at the monitor is calculated. The detector response to isotopic activities (cpmIIlCilcc) is applied to determine cpm expected. The setting for monitor alarms is established at some factor (b) greater than 1 but less than 1 IRk (Equation 1.1) times the measured concentration (c):
s=bxc
- b.
Accident Releases Monitors are preset to alarm at or before precalculated offsite dose rates would be achieved under hypothetical accident conditions.
(1.2)
These setpoints are established in accordance with Emergency Plan requirements for defining Emergency Action Levels and associated actions. Emergency Implementing Procedures contain monitor-specific curves or calibration constants for conversion between cpm and IlCilcc (or Rlhr and IlCilcc), depending on monitor type, for fission product mixtures as a function of mixture decay time.
When these monitors are utilized for other than accident conditions, either an appropriately decayed "accident" conversion curve may be used, or a decayed fission gas calibration factor may be applied. In these cases, setpoints are established as in 1.A above.
Setpoints of accident monitors (if set to monitor normal releases) are reset to the accident alarm settings at the end of normal release.
Setpoints of other release monitors are maintained at the level used at the latest release (well below the level which would allow 10 times EC to be'exceeded at the site boundary), or are reset to approximately three times background in order to detect leakage or inadvertent releases of low level gases.
3
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 B.
DOSE RATE CALCULATION
- 1.
Dose rates are calculated for (1) noble gases and (2) iodines and particulates.
Dose rates as defined in this section are based on 10 CFR 50 Appendix I limits of mrem per quarter and millirem per year. All dose pathways of major importance in the Palisades environs are considered. NRCDose is the Effluent Dose Calculation software that supports LADTAP, GASPAR, and XOQDOQ which perform the actual dose calculations using the equations supplied here.
- a.
Equations and assumptions for calculating doses from noble gases are as follows:
- 1)
Assumptions a)
Doses to be calculated are the maximum offsite point in air, total body and skin.
b)
Exposure pathway is submersion within a cloud of noble gases.
c)
Noble gas radionuclide mix is based on the historically observed source term given in Attachment 2, plus additional nuclides.
d)
Basic radionuclide data are given in Attachment 2.
e)
All releases are treated as ground-level.
f)
Meteorological data expressed as joint-frequency distribution of wind speed, wind direction, and atmospheric stability for the period resulting in X/Q's and D/Q's shown in site procedure CH 6.41, "Land Use Census."
g)
Raw meteorological data consists of wind speed and direction measurements at 10m and temperature measurements at 10m and 60m.
h)
Dose is to be evaluated at the offsite exposure points where maximum concentrations are expected to exist (overland sector site boundaries), and nearest residents.
4
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 i)
Potential maximum population (resident) exposure points are identified in site procedure CH 6.41, "Land Use Census."
j)
A semi-infinite cloud model is used.
k)
Radioactive decay is considered for the plume.
I)
Building wake effects on effluent dispersion are considered.
m)
A sector-average dispersion equation is used.
n)
The wind speed classes that are used are as follows:
Wind Speed Class Number 1
2 3
4 5
6 7
Range (m/s) 0.0-0.4 0.4-1.5 1.5-3.0 3.0-5.0 5.0-7.5 7.5-10.0
> 10.0 Midpoint (m/s) 0.2 0.95 2.25 4.0 6.25 8.75
- 0)
The stability classes that will be used are the standard A through G classifications. The stability classes 1-7 will correspond to A=1, B=2,..., G=7.
p)
Terrain effects are not considered.
5
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 2)
Equations To calculate the dose for anyone of the exposure points, the following equations are used.
For determining the air concentration of any radionuclide:
9 7
Xi = L L (2 )1/2 Qi P [exp- (Ai ~J]
j = 1 k = 1 rc L::k U j (2rc xln)
Uj (1.3) where:
=
=
Oi
=
P
=
~zk
=
Uj
=
x
=
n
=
Ai
=
2nx/n =
Air concentration of radionuclide i, f.lCilm3.
Joint relative frequency of occurrence of winds in wind speed class j, stability class k, blowing toward this exposure point, expressed as a fraction.
Average release rate of radionuclide i, f.lCils.
Fraction of radionuclide remaining in plume.
Vertical dispersion coefficient for stability class k (m).
Midpoint value of wind speed class interval j, m/s.
Downwind distance, m.
Number of sectors, 16.
Radioactive decay coefficient of radionuclide i, S-1.
Sector width at point of interest, m.
6
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 For determining the total body dose rate:
where:
OTB Xi OFBi
=
=
=
(1.4)
Total body dose rate, mrem/y.
Air concentration of radionuclide I, /-lCilm3.
Total body dose factor due to gamma radiation, mrem/y per /-lCilm3 (Attachment 3).
For determining the skin dose rate:
where:
Os
=
Xi
=
OFSi =
1.11
=
(1.5)
Skin dose rate, mrem/y.
Air concentration of radionuclide i, /-lCilm 3 Skin dose factor due to beta radiation, mrem/y per
/-lCilm3 (Attachment 3).
The average ratio of tissue to air energy absorption coefficients, mrem/mrad.
Gamma-to-air dose factor for radionuclide i, mrad/y per /-lCilm 3 (Attachment 3).
For determining dose rate to a point in air:
(1.6) where:
=
Air dose rate, mrad/yr.
Air dose factor for beta radiation (Attachment 3).
7
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- b.
Equations and assumptions for calculating doses from radioiodines and particulates are as follows:
- 1)
Assumptions a)
Dose is to be calculated for the critical organ, thyroid, and the critical age groups (adult, teen, child, infant), infant (milk) and child (green, leafy vegetables).
b)
Exposure pathways from iodines and particulates are milk ingestion, ground contamination, green leafy vegetables from home gardens, and inhalation.
c)
The radioiodine and particulate mix is based on the historically observed source term given in Attachment 2.
d)
Basic radionuclide data are given in Attachment 3.
e)
All releases are treated as ground-level.
f)
Mean annual average X/Q's are given in site procedure CH 6.41, "Land Use Census."
g)
Raw meteorological data for ground-level releases consist of wind speed and direction measurements at 1 Om and temperature measurements at 1 Om and 60m.
h)
Dose is to be evaluated at the potential offsite exposure points where maximum doses to man are expected to exist.
i)
Real cow, goat and garden locations are considered.
j)
Potential maximum exposure points (site procedure CH 6.41, "Land Use Census") considered are the nearest cow, goat, and home garden locations in each sector.
k)
Terrain effects and open terrain recirculation factors are not considered.
I)
Building wake effects on effluent dispersion are considered.
8
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 m)
Plume depletion and radioactive decay are considered for air-concentration calculations.
n)
Radioactive decay is considered for ground-concentration calculations.
- 0)
Deposition is calculated based on the curves given in Figure 1.2.
p)
Milk cows and goats obtain 100% of their food from pasture grass May through October of each year. Use default values of 0.58 for cows and 0.67 for goats for fraction of year on pasture.
- 2)
Equations To calculate the dose for anyone of the potential maximum-exposure points, the following equations in Section 1.2.2 are used.
a)
Inhalation Equation for calculating air concentration, Xj is the same as in the Noble Gas Section (Equation 1.3).
For determining the organ dose rate:
where:
OJ
=
Xj
=
DFh =
BR
=
9 (1.7)
Organ dose rate due to inhalation, mrem/y.
Air concentration of radionuclide i, /-lCi/m 3.
Inhalation dose factor, mrem/pCi (Attachment 5).
Breathing rate 1400 m3/y infant; 3700 m3/y child; or 8000 m3/y teen and adult.
pCiI/-lCi conversion factor.
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 b)
Ground Contamination For determining the ground concentration of any nuclide; where:
k
=
DR
=
x
=
n
=
2nx/n =
=
=
3.15x107
=
10 Ground concentration of radionuclide i,
/-lCi/m2.
Stability class.
Joint relative frequency of occurrence of winds in stability class k blowing toward this exposure point, expressed as a fraction.
Average release rate of radionuclide i,
/-lCi/s.
Relative deposition rate, m-1 (Fig 1.2).
Downwind distance, m.
Number of sectors, 16.
Sector width at point of interest, m.
Radioactive decay coefficient of radionuclide i, y-1.
Time for buildup of radionuclides on the ground, 15 y.
sly conversion factor.
-a:
w t-W :I a:
w
~
w l-e(
a:
Z 0
t=
en
~
w 0 w j:
e(
....I W a:
~
10-4 10-5
,0-6
,0-7 0.1
"'l1lI PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 Figure 1.2
'Ira... '"'-'-'-,~
~~
iii:
""""IIIiO:
""'" ~
" "'II,
.... r\\.
,~
1~O Corrected January 1971 I
Ii! 1 I
I i!
II I i I I
i 1
1 I
I
,~
I
~
I
.~
I I
I I
II
! I i,
I IIIII I,
II 'I i
100.0 200.0 PLUME TRAVEL DISTANCE (KILOMETERS)
Figure 7. Rllative Deposition for Ground Level RaiuMS (All Atmospheric Stability Classes) 11
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 For determining the total body or organ dose rate from ground contamination:
where:
=
=
8,760 =
1x106 =
0.7
=
Dose rate due to ground contamination, mrem/y.
Ground concentration of radionuclide i, JlCilm2.
(1.9)
Dose factor for standing on contaminated ground, mrem/h per pCi/m2 (Attachment 6).
Occupation time, h/y.
pCilJlCi conversion factor.
Shielding factor accounting for a distance of 1.0 meter above ordinary ground, dimensionless.
c)
Milk and Vegetation Ingestion For determining the concentration of any nuclide (except C-14 and H-3) in and on vegetation:
7
-3600 "
fk DR (r[l-eXP(-AEite)]
Biv[l-eXp(-A/b)]J~[
(
)))
CVi -,
L.
+
U exp - Aih (2IT xln)
Y v AEi P Ai k = 1 (1.10) where:
CVj
=
k
=
fk
=
12 Concentration of radionuclide i in and on vegetation, JlCi/kg.
Stability class.
Frequency of this stability class and wind direction combination, expressed as a fraction.
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 Oi
=
Average release rate of radionuclide i,
/-lei/so DR =
Relative deposition rate, m-1 (Figure 1.2).
x
=
Downwind distance, m.
n
=
Number of sectors, 16.
2nx/n =
Sector width at point of interest, m.
r
=
Fraction of deposited activity retained on vegetation (1.0 for iodines, 0.2 for particulates ).
AEi
=
Effective removal rate constant, AEi = Ai + Aw, where Ai is the radioactive decay coefficient, h-1, and Aw is a measure of physical loss by weathering (Aw = 0.0021 h-).
te
=
Period over which deposition occurs, 720 h.
Yv
=
Agricultural yield, 0.7 kg/m2.
Biv
=
Transfer factor from soil to vegetation of radionuclide i (Attachment 4).
Ai
=
Radioactive decay coefficient of radionuclide i, h-1.
tb
=
Time for buildup of radionuclides on the ground, 1.31 x1 05 h (15Y).
P
=
Effective surface density of soil, 240 kg/m 2.
3,600 =
s/h conversion factor.
th
=
Holdup time between harvest and consumption of food (2,160 hours0.00185 days <br />0.0444 hours <br />2.645503e-4 weeks <br />6.088e-5 months <br /> for stored food).
13
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 For determining the concentration of C-14 in vegetation:
CV14 = 1 x 1 03 X14 (0.11 I 0.16)
(1.11) where:
CV14 =
X14
=
0.11 =
0.16 =
1 x1 03 =
Concentration of C-14 in vegetation, JlCilkg.
Air concentration of C-14, JlCilm3.
Fraction of total Plant mass that is natural carbon.
Concentration of natural carbon in the atmosphere, g/m 3.
g/kg conversion factor.
For determining the concentration of H-3 in vegetation:
CVT = 1 x 103 XT (0.75)(0.5 IH)
( 1.12) where:
CVT =
XT
=
0.75 =
0.5 =
H
=
14 Concentration of H-3 in vegetation, JlCi/m3.
Air concentration of H-3, JlCilm3.
Fraction of total Plant mass that is water.
Ratio of tritium concentration in Plant water to tritium concentration in atmospheric water.
Absolute humidity of the atmosphere, g/m3.
g/kg conversion factor.
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 For determining the concentration of any nuclide in cow's or goat's milk:
where:
CMj =
CVj =
FMj =
Qf
=
=
=
15 (1.13)
Concentration of radionuclide i (including C-14 and H-3) in milk, ~Ci/I.
Concentration of radionuclide i in and on vegetation, ~Cilkg.
Transfer factor from feed to milk for radionuclide i, d/I (Attachment 4).
Amount of feed consumed by the milk animal per day, kg/d (cow, 50 kg/d or goat 6 kg/d).
Radioactive decay coefficient of radionuclide i, d-1.
Transport time of activity from feed to milk to receptor, 2 days.
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 For determining the organ dose rate from ingestion of green leafy vegetables and milk:
where:
0
=
CM j =
DFj
=
UM
=
(1.14)
Organ dose rate due to ingestion, mrem/y.
Concentration of radionuclide i in vegetables or milk, JlCilkg (or liters).
Ingestion dose factor, mrem/pCi (Attachment 8).
Ingestion rate for milk, 330 lIy; for vegetables 26 kg/yr (child), no ingestion by infant.
pCilJlCi conversion factor.
d)
Meat Ingestion (BeeD To calculate the concentration of a nuclide in animal flesh:
where:
Cfj
=
16
( 1.15)
Concentration of nuclide i in the animal flesh, pCilkg.
Fraction of animal's daily intake which appears in each kg of flesh, days/kg (Attachment 4).
Concentration of radionuclide i in the animal's feed (Equation 1.10).
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
=
=
Amount of feed consumed by the cow per day, 50 kg/d.
Average time from slaughter to consumption, 20 days.
To determine the organ dose from ingestion of beef:
where:
=
=
Ingestion dose factor for age group, mrem/pCi (Attachment 8) for nuclide i.
Ingestion rate of meat for age group, kg/y (child-41, teen-65, adult-11 0).
( 1.16) e)
Organ Dose Rates For determining the total body and organ dose rate from iodines and particulates:
(1.17) where:
0
=
Total organ dose rate, mrem/y.
0 1
=
Dose rate due to inhalation, mrem/y.
=
Dose rate due to ground contamination, mrem/y.
=
Dose rate due to milk ingestion, mrem/y.
Dv
=
Dose rate due to vegetable ingestion, mrem/y.
OF
=
Dose rate due to beef ingestion, mrem/y.
17
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 3)
The maximum organ dose rate, maximum total body dose rate, and maximum skin dose rate calculated in the previous section (Sec I.B) are used to calculate design basis quantities as described in Section I.B.1.3.
- c.
Land Use Census Appendix A, Sections J.3.b and J.3.c describe the requirements for an annual land use census. Changes will be effective on January 1 of the year following the year of the survey.
- d.
Gaseous Releases From the Steam Generator Blowdown Vent and Atmosphere Release Valves Releases from the steam generator blowdown vent and atmospheric relief valves are difficult to quantify as there are no sampling capabilities on these steam release systems. However, neither system is a normal release path. The steam generator blowdown vent is normally routed to the main condenser and recirculated. Radioactive releases will be calculated by analyzing steam generator blowdown liquid and assuming that 100 percent of Noble Gases, 10 percent of the lodines and 1 percent of the Particulates will be released to the environment in the steam phase. Volumes will be released to the environment in the steam phase. Volumes will be calculated using water balances or alternate means as available.
18
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 C.
GASEOUS RADWASTE TREATMENT SYSTEM OPERATION The gaseous radwaste treatment system (GRTS) described below shall be maintained and operated to keep releases ALARA.
- 1.
System Description
A flow diagram for the GRTS is given in Figure 1-1. The system consists of three waste-gas compressor packages, six gas decay tanks, and the associated piping, valves, and instrumentation. Gaseous wastes are received from the following: degassing of the reactor coolant and purging of the volume control tank prior to a cold shutdown and displacing of cover gases caused by liquid accumulation in the tanks connected to the vent header.
Design of the system precludes hydrogen explosion by means of ignition source elimination (diaphragm valves, low flow diaphragm compressors and system electrical grounding), and minimization of leakage outside the system.
Explosive mixtures of hydrogen and oxygen have been demonstrated compatible with the system by operational experience.
- 2.
Determination of Satisfactory Operation Doses will be calculated for batch and continuous releases as described in Section LB. These calculations will be used to ensure that the GRTS is operating as designed. Because the Plant was designed to collect and hold for decay a vast majority of the high level gases generated within the primary system, and because the operating history of the Plant has demonstrated the system's consistent performance well below Appendix I limits, no additional operability requirements are specified.
19
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 D.
RELEASE RATE FOR OFFSITE EC 10 CFR 20.1302 requires radioactive effluent releases to unrestricted areas be in concentrations less than the limits specified in Appendix B, Table 2 when averaged over a period not to exceed one year. (Note: there are no unrestricted areas anywhere within the site boundary as defined by Figure 1-1.) Concentrations at this level if inhaled or ingested continuously for one year will result in a dose of 50 mrem whole body except for submersion dose isotopes (gaseous tritium and noble gasses) which will results in a dose of 100 mrem whole body. 10 CFR 50.36a requires that the release of radioactive materials be kept as low as reasonably achievable.
However, the section further states that the licensee is permitted the flexibility of operation, to assure a dependable source of power even under unusual operating conditions, to release quantities of material higher than a small percentage of 10 CFR 20.1302 limits but still within those limits. Appendix I to 10 CFR 50 provides the numerical guidelines on limiting conditions for operations to meet the as low as reasonably achievable requirement.
The GASPAR code has been run to determine the dose due to external radiation and inhalation. The source term used is listed in Attachment 2. The meteorology data is given in site procedure CH 6.41, "Land Use Census." Dose using annual average meteorology, to the most limiting organ of the person assume to be residing at the site boundary with highest X/Q, is 2.15E-02 mrem (for one year). The release rate which would result in a dose rate equivalent to 50 mrem/year (using the more conservative total body limit) is the curies/year given in Attachment 2 multiplied by 50/2. 15E-02 or 0.11 Ci/sec.
E.
PARTICULATE AND IODINE SAMPLING Particulate and iodine samples are obtained from the continuous sample stream pulled from the Plant stack. Samples typically are obtained to represent an integrated release from a gas batch (waste gas decay tank or Containment purge, for example), or a series of samples are obtained to follow the course of a release.
In any event, sample intervals are weekly, at a minimum.
Because HEPA filters are present between most source inputs to the stack and the sample point, releases of particulates normally are significantly less than pre-release calculations indicate. This provides for conservatism in establishing setpoints and in estimation of pre-release dose calculations. However, for the sake of maintaining accurate release totals, monitor results (for gases) and sample results (for particulates and iodines) utilized rather than the pre-release estimates, for cumulative records.
20
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 Gamma analytical results for particulate and halogen filters are combined for determination of total activity of particulates and halogens released. Sampling and analysis will be performed per Appendix A, Table B-1 requirements.
F.
NOBLE GAS SAMPLING Noble gases will be sampled from Waste Gas Decay Tanks prior to release and the Containment prior to purging. Analysis of these samples will be used for accountability of noble gases. Off gas will be sampled at least weekly and used to calculate monthly noble gas releases. Non-routine releases will be quantified from the stack noble gas monitor (RE 2326) which has a LLD of 1 E-06 JlCilcc. Sampling and analysis will be performed per Appendix A, Table B-1 requirements.
G.
TRITIUM SAMPLING Tritium has a low dose consequence to the public because of low energy decay.
The major contributors to tritium effluents are evaporation from the fuel pool and reactor cavity (when flooded). Because of the low dose impact, gaseous tritium sampling will not be required. Tritium effluents will be estimated using conservative evaporation rate calculations from the fuel pool and reactor cavity.
21
N N
T-a lOWuva 1
I I
_J Mn13 e e Omt ** '-M mAllf GaeERATOIII GAS COlLECTION*
Il_r__
n I
SUFPl V --...IJI'LI HEPAlCMAltCOAl (REFUflltfG' RES1U*
STACK
~
fG8'A
.tln
_.'tV eM.D.I7I1 MID Inllll11' SIUfPl V MID 0. Of r.-\\) E~
F lCM IS NOT T£"""'" no PALISADES EFFLUENT FLOW PATHS GASEOUS
- r:
Q C
- 0 m
I Q >>
en m
0 0
c en "T1 "T1 m
~'"tJ
-I>>
rnr-r c en c
0 >>
m CJ) c z
- 0 rn rn
-I
(\\)
(") CJ) en
>> z (ii' r-C 0'
(") (")
r
- l C r-0 N
r-rn
~
0-,
- j ;;0 "tJ 0 '"tJ z r-
-I 3:>>
- r:
>>z en z-l c >>
r-
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 II.
LIQUID EFFLUENTS A.
CONCENTRATION
- 1.
Requirements Appendix A,Section III.G requires that the concentration of radioactive material released at any time from the site to unrestricted areas shall be limited to ten times the Effluent Concentration (EC) specified in 10 CFR 20, Appendix B, Table 2, Column 2 for nuclides other than dissolved or entrained noble gases. For dissolved or entrained noble gases, the concentration shall be limited to 2E-04 IlCilml total activity. To ensure compliance, the following approach will be used for each release.
- 2.
Prerelease Analysis Most tanks will be recirculated through two volume changes prior to sampling for release to the environment to ensure that a representative sample is obtained. The appropriate recirculation time for those tanks too large to provide two volume changes will be the time that the suspended particulate concentration reaches steady state. Either a one-time test, or prior sampling data, may be used to determine appropriate recirculation time.
Prior to release, a grab sample will be analyzed for each release, and the concentration of each radionuclide determined.
C
=
where:
C
=
=
Total concentration in the liquid effluent at the release point, IlCi/ml.
Concentration of a single radionuclide i, IlCUml.
23 (2.1 )
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 3.
Effluent Concentration (EC) - Sum of the Ratios The EC-Fraction (Rj) for each release point will be calculated by the relationship defined by Note 4 of Appendix B, 10 CFR 20:
Rj where:
Cj ECj Rj
=
=
=
Effluent concentration of radionuclide i, JiCi/ml.
The EC of radionuclide i, 10 CFR 20, Appendix B, Table 2, Column 2 - JiCilml.
The Total EC-Fraction for the release point.
(2.2)
The sum of the ratios at the discharge to the lake must be :::; 10 due to the releases from any or all concurrent releases. The following relationship will assure this criterion is met:
f 1 (R 1 -1) + f 2 (R2 -1) + f 3 (R3 -1) :s; F (2.3) where:
=
=
F
=
The effluent flow rate (gallons/minute) for the respective releases, determined by Plant personnel.
The Total EC-Fractions for the respective releases as determined by Equation 2.2.
Minimum required dilution flow rate. Normally, a conservatively high dilution flow rate is used, that is, flow rate used = (bj)(F) where bj is a conservative factor greater than 1.0.
24
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 B.
INSTRUMENT SETPOINTS
- 1.
Setpoint Determination Appendix A,Section III.F requires alarm setpoints for each liquid effluent monitor will be established using Plant instructions to ensure the requirements of Appendix A,Section III.G are not exceeded. Concentration, flow rate, dilution, principal gamma emitter, geometry, and detector efficiency are combined to give an equivalent setpoint in counts per minute (cpm). The identification number for each liquid effluent radiation detector is contained in Figure 2-2.
The respective alarm/trip setpoints at each release point will be set such that the sum of the ratios at each point, as calculated by Equation 2.2, will not be exceeded. The value of R is directly related to the total concentration calculated by Equation 2.1. An increase in the concentration would indicate an increase in the value of R. A large increase would cause the limits specified in Section 2.1.1 to be exceeded. The minimum alarm/trip setpoint value is equal to the release concentration, but for ease of operation it may be desired that the setpoint (S) be set above the effluent concentration (C) by the same factor (b) utilized in setting dilution flow. That is:
S
=
bxC (2.4)
Liquid effluent flow paths and release points are indicated in Figure 2.1.
- 2.
Composite Samplers Effluent pathways, Turbine Sump and Service Water, are equipped with continuous compositors to meet the requirements of Appendix A, Table 0-1.
These compositors are adjustable and normally set in a time mode and collect three to six samples hourly, 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> a day with a total collection of approximately one gallon per day. A representative sample is collected daily from the compositor and saved for the weekly, monthly, and quarterly analysis requirements of Appendix A, Table 0-1. In the event that a compositor is not operational, effluent releases via this pathway may continue provided that grab samples are collected and analyzed for gross beta or gamma radioactivity at least once per 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> per Appendix A, Table C-1, Action 3.
25
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- 3.
Post-Release Analysis
- c.
DOSE A post-release analysis will be done using actual release data to ensure that the limits specified in Section 1 were not exceeded.
A composite list on concentrations (Ci), by isotope, will be used with the actual liquid radwaste (f) and dilution (F) flow rates (or volumes) during the release. The data will be substituted into Equation 2.3 to demonstrate compliance with the limits in Section 1. This data and setpoints will be recorded in auditable records by Plant personnel.
- 1.
RETS Requirement Appendix A,Section III.H.1 requires that the quantity of radionuclides released by limited such that the dose or dose commitment to an individual from radioactive materials in liquid effluents release to unrestricted areas from the reactor (see Figure 2-1) will not exceed:
- a.
During any calendar quarter, 1.5 mrem to the total body and 5 mrem to any organ, and
- b.
During any calendar year, 3 mrem to the total body and 10 mrem to any organ.
To ensure compliance, quantities of activity of each radionuclide released will be summed for each release and accumulated for each quarter as follows in Section 2.
- 2.
Release Analysis Dose calculations shall be performed for each batch release, and weekly for continuous releases unless documentation exists to demonstrate an activity below which dose limits of Section II.C.1 will not be exceeded.
- a.
Water Ingestion The dose to an individual from ingestion of radioactivity from any source as described by the following equation:
Dj I (DCF)jj x Ii i = I 26 (2.5)
(DCF)ij PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 where:
=
Dose for the /h organ from radionuclides releases, mrem.
=
The organ of interest.
=
Ingestion dose commitment factor for the jth organ from the ith radionuclide mrem/pCi, see Attachment 8.
=
Activity ingested of the ith radionuclide, pCi.
Ii is described by:
. = (Aj)(V)(36S) (1E06)
I, (1000)(d)
(2.6) where:
365
=
v
=
d
=
1000 =
1E06 =
Days per year.
Annual activity released of ith radionuclide, /-lCi.
Average rate of water consumption (2000 mild - adult, 1400 mild - teen and child, 900 mild - infant, ICRP 23, P 358).
Dilution water flow for year, ml.
Dispersion factor from discharge to nearest drinking water supply.
Conversion /-lCi to pCi.
The dose equation then becomes:
i
- (3.6SEOS)(V) "" (DCF)
Dj-L...
jjxAjmrem d
. 1 1=
(2.7) 27
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- b.
Fish Ingestion The dose to an individual from the consumption of fish is described by Equation 2.10. In this case, the activity ingested of the ith radionuclide (Ii) is described by:
- AiBjF(1E09) -
C' h-15d
-p I where:
=
=
Annual released of ith radionuclide, /-lCi.
Fish concentration factor of ith radionuclide (see Attachment 7).
I-lCilgm JlCilml (2.8)
F
=
Amount of fish eaten per year (21 kg adult, 16 kg teen, 6.9 kg child, none infant).
15
=
Dispersion factor from discharge to fish exposure point.
d
=
Dilution water flow for year, ml.
1E09 =
Conversion of /-lCi, gm, and Kg to pCi.
Substitution of Equation 2.8 into Equation 2.5 gives:
i (6.7E07)F Dj=
d I AiXBjXDCFimrem i=1 28 (2.9)
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26
- c.
Annual Analysis A complete analysis utilizing the NRC computer code LADTAP with the total source release will be done annually in conjunction with the annual environmental report. This analysis will provide estimates of dose to the total body and various organs in addition to the dose limiting organs considered in the method of Section 2. The following approach is utilized on LADTAP. The dose to the /h organ from m radionuclides, OJ, is described by:
m OJ= I Oijmrem i = 1 m
= I (OCF)ij x Ij mrem i=1 where:
(2.10)
(2.11 )
=
Dose to the jth organ from the ith radionuclide, mrem.
=
(DCFh =
=
The organ of interest (bone, GI tract, thyroid, liver, kidney, lung, or total body).
Adult ingestion dose commitment factor for the /h organ from the ith radionuclide, mrem/pCi (see Attachment 8).
Activity ingested of the ith radionuclide, J..lCi.
h for water ingestion is described by:
and for fish ingestion Ii is described by:
1-AiBiFr CI*
i-v d I-i 29 (2.12)
(2.13)
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 where:
Ai
=
V
=
r
=
v
=
d
=
Bi
=
F
=
Activity release of /h radionuclide during the year, /-lCi.
Average rate of water consumption (2000 mild).
Number of days during the year (365 d).
Dispersion factor from point of discharge to point of exposure.
Dilution water volume (ml).
Fish concentration factor of the ith radionuclide, JlCilgm,
JlCilml Amount of fish eaten per day (57.5 gm/d).
D.
OPERABILITY OF LIQUID RADWASTE EQUIPMENT The Palisades liquid radwaste system is designed to reduce the radioactive materials in liquid wastes prior to their discharge (through deep bed filtration and ion exchange) so that radioactivity in liquid effluent releases to unrestricted areas (see Figure 2-1) will not exceed the limits of Appendix A, III.H.1.
E.
RELEASE RATE FOR OFFSITE EC (50 MREMIYR) 10 CFR 20.1302 requires radioactive effluent releases to unrestricted areas be less than the limits specified in Appendix B, Table 2 when averaged over a period not to exceed one year. Concentrations at this Effluent Concentration (EC) level, if ingested for one year, will result in a dose of 50 millirem to the total body. In addition, 10 CFR 50.36a requires that the release of radioactive materials be kept as low as is reasonably achievable. Appendix I to 10 CFR 50 provides the numerical guidelines on limiting conditions for operations to meet the as low as is reasonably achievable requirement.
The LADT AP code has been run to determine the dose due to drinking water at Plant discharge concentration (1,000 x nearest drinking water intake concentration).
The nominal average source term used is given in Attachment 2. Dose to the most limiting organ of the person hypothetically drinking this water is 3.88E-03 mrem.
This is only 0.13%) of the more conservative 50 mrem/yr total body value.
30
co N
s:: o
'iii
'S;
~
(f)
W
~
- l
(!)
u::
LL j
\\
\\
\\
\\
\\
\\
\\
\\
I
~
"l
<J I
I
/
I
/
/
/
/
,,\\ NNW I
N NNE I
W
\\
/
/
,,\\
/
,/
WNW....
\\.
N'
/
,/
Y I' i
,//
'./.
GASEOUS II A--/ \\~
\\1' STACK EfFLUENTS OU'O O,sdH 7.,.,,,
SURF ACE rl ARGE I
.. /'
!)86L.1..... - l' ",.:' i I* -,. - ~.,.
/
- . -" i' "';';
[
.f".'. / I \\ \\.
.//.1'
\\......
1..... *
/'
l
/
/
\\
./
I l
I I' I
\\
"E Sf
...-./
~w/I
/
I
/
\\
\\
I.J.J
/
I
\\
/
/
\\
\\
~E 4:-
/
/
\\
i V
I.
I I". \\
- f.
I
\\
\\
I
\\
\\
/
./
/'
L
.6 8
./
./
/'
./
./
./
6 14
/'
,/
611
/.'
'I I
\\
\\
/;
I
\\
\\
A
\\
\\
\\
\\
\\
\\
A 19\\
\\
lJNRESTRICTEO AAEA SI fF BOUNOAHV
- 18.
./
....~
./
,/
/'
if I
"-1
- )
1
./
~
I": 715 MflfHS SITE ENVIRONMENT TLD STATIONS PALISADES NUCLEAR PLANT SITE 80UNDAR Y FIGURE 2 - I
~
C")
<<)
N s:: o
'iii
'S;
<l>
~ ;
PALISADES RADWASTE EFFLUENTS - lIOUID CI.FAN W/\\SH:
SYSllM TRrA/En WASTE TANKS(7j MIseI' L I ANEOUS WASTf SYSTEM IOlfll Y WASTf}
lAUNDRY "YSHM FILHRrn WASH TANK UTILITY WATFR STORAGE TANI<
T*91 PRIMARY SYSTEM STORAGE TANK 190 STEAMGEN RE oeJJ
- Ar;~~E "'&"...1---4'"--.
LAKE SERVICE WATER LAKE INLET Xl.
C\\I M
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 III.
URANIUM FUEL CYCLE DOSE A.
SPECIFICATION In accordance with Appendix A, Section 111.1.1, if either liquid or gaseous quarterly releases exceed the quantity which would cause offsite doses more than twice the limit of Appendix A, Sections III.C.1, 111.0.1, or III.H.1, then the cumulative dose contributions from combined release plus direct radiation sources (from the reactor unit and radwaste storage tanks) shall be calculated. The dose is to be determined for the member of the public protected to be the most highly exposed to these combined sources.
B.
ASSUMPTIONS
- 1.
The full time resident determined to be maximally exposed individual (excluding infant) is assumed also to be a fisherman. This individual is assumed to drink water and ingest local fish at the rates specified in Sections II.C.2.1 and II.C.2.2.
- 2.
Amount of shore line fishing (at accessible shoreline adjacent to site security fence) is conservatively assumed as 48 hours5.555556e-4 days <br />0.0133 hours <br />7.936508e-5 weeks <br />1.8264e-5 months <br /> per quarter (average of approximately 112 hour0.0013 days <br />0.0311 hours <br />1.851852e-4 weeks <br />4.2616e-5 months <br /> per day each day of the quarter) for the second and third quarters of the year, 36 hours4.166667e-4 days <br />0.01 hours <br />5.952381e-5 weeks <br />1.3698e-5 months <br /> for the fourth quarter and 16 hours1.851852e-4 days <br />0.00444 hours <br />2.645503e-5 weeks <br />6.088e-6 months <br /> for the first quarter.
33
PALISADES NUCLEAR PLANT OFFSITE DOSE CALCULATION MANUAL Revision 26 C.
DOSE CALCULATION Maximum doses to the total body and internal organs of an individual shall be determined by use of LADT AP and GASPAR computer codes, and doses to like organs and total body summed. Added to this sum will be a mean dose rate, calculated or measured for the shoreline due to Plant present curing the quarter in question, times the assumed fishing time.
0 40
=
(2.15) where:
0 40
=
40 CFR 190 dose (mrem).
=
Limiting dose to an individual from gaseous source term (mrem).
DL
=
Limiting dose to an individual from liquid source term (mrem).
=
Mean dose rate calculated to be applicable to Lake Michigan shoreline adjacent to Plant site (mrem/hr).
T
=
Assumed shoreline fishing time for the quarter in questions (hours).
IV.
SOURCE REFERENCE DOCUMENTS
- 1. Regulatory Guide 1.21, Measuring, Evaluating, and Reporting Radioactivity in Solid Wastes and Releases of Radioacitve Materials in Liquid and Gaseous Effluents from Light-Water-Cooled Nuclear Power Plants, R1.
- 2. Regulatory Guide 1.109, Calculation of Annual Doses to Man from Routine Releases of Reactor Effluents for the Purpose of Evaluating Compliance with 10 CFR Part 50, Appendix I, R1.
- 3. NUREG-1301, affsite Dose Calculation Manual Guidance: Standard Radiological Effluent Controls for Pressurized Water Reactors, April 91.
- 4. NUREG-0472, Standard Radiological Effluent Technical Specifications for Pressurized Water Reactors, R3.
- 5. NUREG/CR-4013, LADTAP " - Technical Reference and User Guide, April 86.
- 6. NUREG/CR-4653, GASPAR" - Technical Reference and User Guide, March 87.
- 7. CH 6.61, Revising the aDCM and aDCM Appendix A.
34
Proc No ODeM Revision 26 Page 1 of 1 PALISADES GASEOUS AND LIQUID SOURCE TERMS. CURIESNEAR (1)
Nuclide H-3 Kr-85 Kr-85m Kr-87 Kr-88 Ar-41 Xe-131 m Xe-133 Xe-133m Xe-135 Xe-135m 1-131 1-132 1-133 1-134 1-135 Na-24 Cr-51 Mn-54 Co-57 Co-58 Fe-59 Co-60 Se-75 Nb-95 Zr-95 Mo-99 Ru-103 Sb-127 Cs-134 Cs-136 Cs-137 8a-140 La-140 Unidentified beta Gaseous(2) 5.5 4.1 0.12 8.4E-02 2.1 E-01 3.1 E-02 2.2 1493 0.43 1.11 0.3 0.025 2.91 E-03 6.5E-03 4.8E-04 1.84E-02 1.5E-06 2.5E-04 4.1E-04 2.1 E-06 8.6E-04 6.6E-06 1.1 E-03 3.7E-06 2.4E-05 4.7E-06 1.5E-07 0.3E-07 NA 4.5E-05 NA 2.6E-04 2.8E-07 7.5E-07 3.9E-04 Liquid(2) 159 NA NA NA NA NA NA NA NA NA NA 3.21 E-03 NA 4.7E-05 NA NA NA 3.9E-03 7.8E-03 3.2E-05 2.9E-02 4.1 E-04 1.24E-02 NA 4.53E-04 1.79E-04 NA 0.1 E-05 3.5E-05 0.7 1.8E-06 1.36E-02 NA 1.1 E-04 3.3E-03 (1)
Data derived from taking the effluents released during July-December 1978 through January-June 1982 and dividing by 4.
(2)
Nuclide values listed as NA have not been observed at detectable levels in these waste streams.
Proc No aDeM Revision 26 Page 1 of2 BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA1
~
1.1L§}
(MEV/DIS)
(MEV/DIS) 1 Tritium 4.49E 03 1.79E-09 S.68E-03 0.0 2
C-14 2.09E 06 3.84E-12 4.9SE-02 0.0 3
N-13 6.94E-03 1.16E-03 4.91 E-01 1.02E 00 4
0-19 3.36E-04 2.39E-02 1.02E 00 1.0SE 00 S
F-18 7.62E-02 1.0SE-04 2.S0E-01 1.02E 00 6
NA-24 6.33E-01 1.27E-OS S.SSE-01 4.12E 00 7
P-32 1.43E 01 S.61 E-07 6.9SE-01 0.0 8
AR-41 7.63E-02 1.0SE-04 4.64E-01 1.28E 00 9
CR-S1 2.78E 01 2.89E-07 3.86E-03 3.28E-02 10 MN-S4 3.03E 02 2.6SE-08 3.80E-03 8.36E-01 11 MN-S6 1.07E-01 7.S0E-OS 8.29E-01 1.69E 00 12 FE-S9 4.S0E 01 1.78E-07 1.18E-01 1.19E 00 13 CO-S8 7.13E 01 1.12E-07 3.41 E-02 9.78E-01 14 CO-60 1.92E 03 4.18E-09 9.68E-02 2.S0E 00 1S ZN-69m S.7SE-01 1.39E-OS 2.21E-02 4.16E-01 16 ZN-69 3.96E-02 2.03E-04 3.19E-01 0.0 17 BR-84 2.21 E-02 3.63E-04 1.28E 00 1.77E 00 18 BR-8S 2.08E-03 3.86E-03 1.04E 00 6.60E-02 19 KR-8Sm 1.83E-01 4.38E-OS 2.S3E-01 1.S9E-01 20 KR-8S 3.93E 03 2.04E-09 2.S1 E-01 2.21 E-03 21 KR-87 S.28E-02 1.S2E-04 1.32E 00 7.93E-01 22 KR-88 1.17E-01 6.86E-OS 3.61 E-01 1.96E 00 23 KR-89 2.21 E-03 3.63E-03 1.36E 00 1.83E 00 24 RB-88 1.24E-02 6.47E-04 2.06E 00 6.26E-01 2S RB-89 1.07E-02 7.S0E-04 1.01 E 00 2.0SE-00 26 SR-89 S.20E 01 1.S4E-07 S.83E-01 8.4SE-OS 27 SR-90 1.03E 04 7.79E-10 1.96E-01 0.0 28 SR-91 4.03E-01 1.99E-OS 6.S0E-01 6.9SE-01 29 SR-92 1.13E-01 7.10E-OS 1.9SE-01 1.34E 00 30 SR-93 S.S6E-03 1.44E-03 9.20E-01 2.24E 00 31 Y-90 2.67E 00 3.00E-06 9.36E-01 0.0 32 Y-91m 3.47E-02 2.31 E-04 2.73E-02 S.30E-01 33 Y-91 S.88E 01 1.36E-07 6.06E-01 3.61 E-03 34 Y-92 1.47E-01 S.46E-OS 1.44E 00 2.S0E-01 3S Y-93 4.29E-01 1.87E-OS 1.17E 00 8.94E-02 36 ZR-9S 6.S0E 01 1.23E-07 1.16E-01 7.3SE-01 37 NB-9Sm 3.7SE 00 2.14E-06 1.81 E-01 6.06E-02 38 NB-9S 3.S0E 01 2.29E-07 4.44E-02 7.64E-01 39 MO-99 2.79E 00 2.87E-06 3.96E-01 1.S0E-01 40 TC-99m 2.S0E-01 3.21 E-OS 1.S6E-02 1.26E-01
41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 Proc No aDeM Revision 26 Page 2 of 2 BASIC RADIONUCLIDE DATA NUCLIDE HALF-LIFE LAMBDA BETA1 GAMMA1
~
(1/s)
(MEV/DIS)
(MEV/DIS)
TC-99 7.74E 07 1.04E-13 8.46E-02 0.0 TC-104 1.25E-02 6.42E-04 1.60E 00 1.95E 00 RU-106 3.67E 02 2.19E-08 1.01 E-02 0.0 TE-132 3.24E 00 2.48E-06 1.00E-01 2.33E-01 1-129 6.21 E 09 1.29E-15 5.43E-02 2.46E-02 1-131 8.05E 00 9.96E-07 1.94E-01 3.81 E-01 1-132 9.58E-02 8.37E-05 4.89E-01 2.24E 00 1-133 8.75E-01 9.17E-06 4.08E-01 6.02E-01 1-134 3.61 E-02 2.22E-04 6.16E-01 2.59E 00 1-135 2.79E-01 2.87E-05 3.68E-01 1.55E 00 XE-131m 1.18E01 6.80E-07 1.43E-01 2.01 E-02 XE-133m 2.26E 00 3.55E-06 1.90E-01 4.15E-02 XE-133 5.27E 00 1.52E-06 1.35E-01 4.60E-02 XE-135m 1.08E-02 7.43E-04 9.58E-02 4.32E-01 XE-135 3.83E-01 2.09E-05 3.17E-01 2.47E-01 XE-137 2.71 E 03 2.96E-03 1.77E 00 1.88E-01 XE-138 9.84E-03 8.15E-04 6.65E-01 1.10E 00 CS-134 7A8E 02 1.07E-08 1.63E-01 1.55E 00 CS-135 1.10E09 7.29E-15 5.63E-02 0.0 CS-136 1.30E 01 6.17E-07 1.37E-01 2.15E 00 CS-137 1.10E 04 7.29E-10 1.71E-01 5.97E-01 CS-138 2.24E-02 3.58E-04 1.20E 00 2.30E 00 BA-139 5.76E-02 1.39E-04 8.96E-01 3.53E-02 BA-140 1.28E 01 6.27E-07 3.15E-01 1.71E-01 LA-140 1.68E 00 4.77E-06 5.33E-01 2.31 E 00 CE-144 2.84E 02 2.82E-08 9.13E-02 1.93E-02 PR-143 1.36E 01 5.90E-07 3.14E-01 0.0 PR-144 1.20E-02 6.68E-04 1.21EOO 3.18E 00 Average energy per disintegration values were obtained from ICRP Publication No 38, Radionuclide Transformations: Energy and Intensity of Emissions 1983 and NUREG/CR-1413 (ORNLINUREG-70), a Radionuclide Decay Data Base - Index and Summary Table, DC Kocher, May 1980.
Proc No aDeM Revision 26 Page 1 of 1 DOSE FACTORS FOR SUBMERSION IN NOBLE GASES*
Gamma body Gamma air Beta skin Beta air dose1 dose2 dose1 dose2 Kr-85m 1.17E3 1.23E3 1.46E3 1.97E3 Kr-85 1.61 E1 1.72E1 1.34E3 1.95E3 Kr-87 5.92E3 6.17E3 9.73E3 1.03E4 Kr-88 1.47E4 1.52E4 2.37E3 2.93E3 Kr-89 1.66E4 1.73E4 1.01 E4 1.06E4 Xe-131m 9.15E1 1.56E2 4.76E2 1.11 E3 Xe-133m 2.51 E2 3.27E2 9.94E2 1.48E3 Xe-133 2.94E2 3.53E2 3.06E2 1.05E3 Xe-135m 3.12E3 3.36E3 7.11 E2 7.39E3 Xe-135 1.81 E3 1.92E3 1.86E3 2.46E3 Xe-137 1.42E3 1.51 E3 1.22E4 1.27E4 Xe-138 8.83E3 9.21 E3 4.13E3 4.75E3 Ar-41 8.84E3 9.30E3 2.69E3 3.28E3
- 1.
mrem/y per IlCi/m3
- 2.
mrad/y per IlCilm3
- Oose factors for exposure to a semi-infinite cloud of noble gases. Values were obtained from USNRC Regulatory Guide 1.109, Revision 1 (October 1977).
ELEMENT H
C Na P
Cr Mn Fe Co Ni Cu Zn Rb Sr Y
Zr Nb Mo Te Ru Rh Ag Te I
Cs Ba La Ce Pr Nd W
Np STABLE ELEMENT TRANSFER DATA Fm - MILK (COW)
Fm - MILK (GOAT)
Ff - MEAT (DAYS/L)
(DAYS/L)
(DAYS/KG) 1.0E-02 1.7E-01 1.2E-02 1.2E-02 1.0E-01 3.1 E-02 4.0E-02 4.0E-02 3.0E-02 2.5E-02 2.5E-01 4.6E-02 2.2E-03 2.2E-03 2.4E-03 2.5E-04 2.5E-04 8.0E-04 1.2E-03 1.3E-04 4.0E-02 1.0E-03 1.0E-03 1.3E-02 6.7E-03 6.7E-03 5.3E-02 1.4E-02 1.3E-02 8.0E-03 3.9E-02 3.9E-02 3.0E-02 3.0E-02 3.0E-02 3.1 E-02 8.0E-04 1.4E-02 6.0E-04 1.0E-05 1.0E-05 4.6E-03 5.0E-06 5.0E-06 3.4E-02 2.5E-03 2.5E-03 2.8E-01 7.5E-03 7.5E-03 8.0E-03 2.5E-02 2.5E-02 4.0E-01 1.0E-06 1.0E-06 4.0E-01 1.0E-02 1.0E-02 1.5E-03 5.0E-02 5.0E-02 1.7E-02 1.0E-03 1.0E-03 7.7E-02 6.0E-03 6.0E-02 2.9E-03 1.2E-02 3.0E-01 4.0E-03 4.0E-04 4.0E-04 3.2E-03 5.0E-06 5.0E-06 2.0E-04 1.0E-04 1.0E-04 1.2E-03 5.0E-06 5.0E-06 4.7E-03 5.0E-06 5.0E-06 3.3E-03 5.0E-04 5.0E-04 1.3E-03 5.0E-06 5.0E-06 2.0E-04 Proc No aDeM Revision 26 Page 1 of 1 Biv (VEG/SOIL) 4.8E-OO 5.5E-OO 5.2E-02 1.1 E-OO 2.5E-04 2.9E-02 6.6E-04 9.4E-03 1.9E-02 1.2E-01 4.0E-01 1.3E-01 1.7E-02 2.6E-03 1.7E-04 9.4E-03 1.2E-01 2.5E-01 5.0E-02 1.3E+01 1.5E-01 1.3E-OO 2.0E-02 1.0E-02 5.0E-03 2.5E-03 2.5E-03 2.5E-03 2.4E-03 1.8E-02 2.5E-03
INHALATION DOSE COMMITMENT FACTORS Proc No aDeM Revision 26 Page 1 of 16 INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRSTYR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3*
O.
4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 BE10 9.49E-04 1.25E-04 2.65E-05 O.
O.
1.49E-03 1.73E-05 C14 1.B9E-05 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 3.79E-06 N13 4.39E-OB 4.39E-OB 4.39E-OB 4.39E-OB 4.39E-OB 4.39E-OB 4.39E-OB F1B 3.92E-06 O.
3.33E-07 O.
O.
O.
6.10E-07 NA22 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 7.37E-05 NA24 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 7.54E-06 P32 1.45E-03 B.03E-05 5.53E-05 O.
O.
O.
1.15E-05 AR39 O.
O.
O.
O.
O.
1.00E-OB O.
AR41 O.
O.
O.
O.
O.
3.14E-OB O.
CA41 7.4BE-05 O.
B.16E-06.
O.
O.
6.94E-02 2.96E-07 SC46 3.75E-04 5.41 E-04 1.69E-04 O.
3.56E-04 O.
2.19E-05 CR51 O.
O.
6.39E-OB 4.11 E-OB 9.45E-09 9.17E-06 2.55E-07 MN54 O.
1.B1 E-05 3.56E-06 O.
3.56E-06 7.14E-04 5.04E-06 MN56 O.
1.10E-09 1.5BE-10 O.
7.B6E-10 B.95E-06 5.12E-05 FE55 1.41 E-05 B.39E-06 2.3BE-06 O.
O.
6.21 E-05 7.B2E-07 FE59 9.69E-06 1.6BE-05 6.77E-06 O.
O.
7.25E-04 1.77E-05 C057 O.
4.65E-07 4.5BE-07 O.
O.
2.71 E-04 3.47E-06 C05B O.
B.71 E-07 1.30E-06 O.
O.
5.55E-04 7.95E-06 C060 O.
5.73E-06 B.41 E-06 O.
O.
3.22E-03 2.2BE-05 NI59 1.B1 E-05 5.44E-06 3.10E-06 O.
O.
5.4BE-05 6.34E-07 NI63 2.42E-04 1.46E-05 B.29E-06 O.
O.
1.49E-04 1.73E-06 NI65 1.71 E-09 2.03E-10 B.79E-11 O.
O.
5.BOE-06 3.5BE-05 CU64 O.
1.34E-09 5.53E-10 O.
2.B4E-09 6.64E-06 1.07E-05 ZN65 1.3BE-05 4.47E-05 2.22E-05 O.
2.32E-05 4.62E-04 3.67E-05 ZN69M B.9BE-09 1.B4E-OB 1.67E-09 O.
7.45E-09 1.91 E-05 2.92E-05 ZN69 3.B5E-11 6.91 E-11 5.13E-12 O.
2.B7E-11 1.05E-06 9.44E-06 SE79 O.
2.25E-06 4.20E-07 O.
2.47E-06 2.99E-04 3.46E-06 BRB2 O.
O.
9.49E-06 O.
O.
O.
O.
BRB3 O.
O.
2.72E-07 O.
O.
O.
O.
BRB4 O.
O.
2.B6E-07 O.
O.
O.
O.
BRB5 O.
O.
1.46E-OB O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
2.50E-09 O.
KRB5M O.
O.
O.
O.
O.
1.31 E-OB O.
KRB5 O.
O.
O.
O.
O.
1.16E-OB O.
KRB7 O.
O.
O.
O.
O.
6.59E-OB O.
KRBB O.
O.
O.
O.
O.
1.3BE-07 O.
KRB9 O.
O.
O.
O.
O.
B.67E-OB O.
RBB6 O.
1.36E-04 6.30E-05 O.
O.
O.
2.17E-06 RBB7 O.
7.11 E-05 2.64E-05 O.
O.
O.
2.99E-07 RBBB O.
3.9BE-07 2.05E-07 O.
O.
O.
2.42E-07 RBB9 O.
2.29E-07 1.47E-07 O.
O.
O.
4.B7E-OB SRB9 2.B4E-04 O.
B.15E-06 O.
O.
1.45E-03 4.57E-05 SR90 2.92E-02 O.
1.B5E-03 O.
O.
B.03E-03 9.36E-05 SR91 6.B3E-OB O.
2.47E-09 O.
O.
3.76E-05 5.24E-05 SR92 7.50E-09 O.
2.79E-10 O.
O.
1.70E-05 1.00E-04
- Includes a 50% increase to account for percutaneous transpiration.
INHALATION DOSE COMMITMENT FACTORS Proc No aDeM Revision 26 Page 2 of 16 INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.3SE-06 O.
6.30E-OB O.
O.
1.92E-04 7.43E-OS Y91M 2.91E-10 O.
9.90E-12 O.
- o.
1.99E-06 1.6BE-06 Y91 4.20E-04
- o.
1.12E-OS
- o.
- o.
1.7SE-03 S.02E-OS Y92 1.17E-OB O.
3.29E-10 O.
O.
1.7SE-OS 9.04E-OS Y93 1.07E-07
- o.
2.91 E-09 O.
- o.
S.46E-OS 1.19E-04 ZR93 2.24E-04 9.S1 E-OS 6.1BE-OS
- o.
3.19E-04 1.37E-03 1.4BE-OS ZR9S B.24E-OS 1.99E-OS 1.4SE-OS O.
2.22E-OS 1.2SE-03 1.SSE-OS ZR97 1.07E-07 1.B3E-OB B.36E-09
- o.
1.BSE-OB 7.BBE-OS 1.00E-04 N893M 1.3BE-04 3.S9E-OS 1.1SE-OS
- o.
3.6BE-OS 2.09E-04 2.47E-06 N89S 1.12E-OS 4.S9E-06 2.70E-06
- o.
3.37E-06 3.42E-04 9.0SE-06 N897 2.44E-10 S.21 E-11 1.BBE-11 O.
4.07E-11 2.37E-06 1.92E-OS M093
- o.
6.46E-06 2.22E-07
- o.
1.S4E-06 3.40E-04 3.76E-06 M099
- o.
1.1BE-07 2.31 E-OB O.
1.B9E-07 9.63E-OS 3.4BE-OS TC99M 9.9BE-13 2.06E-12 2.66E-11 O.
2.22E-11 S.79E-07 1.4SE-06 TC99 2.09E-07 2.6BE-07 B.BSE-OB O.
2.49E-06 6.77E-04 7.B2E-06 TC101 4.6SE-14 S.BBE-14 S.BOE-13 O.
6.99E-13 4.17E-07 6.03E-07 RU103 1.44E-06 O.
4.BSE-07 O.
3.03E-06 3.94E-04 1.1SE-OS RU10S B.74E-10 O.
2.93E-10 O.
6.42E-10 1.12E-OS 3.46E-OS RU106 6.20E-OS O.
7.77E-06
- o.
7.61 E-OS B.26E-03 1.17E-04 RH10S B.26E-09 S.41 E-09 3.63E-09
- o.
1.S0E-OB 2.OBE-OS 1.37E-OS PD107
- o.
4.92E-07 4.11 E-OB O.
2.7SE-06 6.34E-OS 7.33E-07 PD109 O.
3.92E-09 1.0SE-09 O.
1.2BE-OB 1.6BE-OS 2.BSE-OS AG110M 7.13E-06 S.16E-06 3.S7E-06 O.
7.BOE-06 2.62E-03 2.36E-OS AG111 3.7SE-07 1.4SE-07 7.7SE-OB O.
3.0SE-07 2.06E-04 3.02E-OS CD113M O.
6.67E-04 2.64E-OS O.
S.BOE-04 1.40E-03 1.6SE-OS CD11SM O.
1.73E-04 6.19E-06
- o.
9.41 E-OS 1.47E-03 S.02E-OS SN123 2.09E-04 4.21E-06 7.2BE-06 4.27E-06
- o.
2.22E-03 4.0BE-OS SN12S 1.01 E-OS 2.S1 E-07 6.00E-07 2.47E-07 O.
6.43E-04 7.26E-OS SN126 B.30E-04 1.44E-OS 3.S2E-OS 3.B4E-06 O.
4.93E-03 1.6SE-OS S8124 2.71 E-OS 3.97E-07 B.S6E-06 7.1BE-OB O.
1.B9E-03 4.22E-OS S812S 3.69E-OS 3.41 E-07 7.7BE-06 4.4SE-OB O.
1.17E-03 1.0SE-OS S8126 3.0BE-06 6.01 E-OB 1.11 E-06 2.3SE-OB O.
6.BBE-04 S.33E-OS S8127 2.B2E-07 S.04E-09 B.76E-OB 3.60E-09 O.
1.S4E-04 3.7BE-OS TE12SM 3.40E-06 1.42E-06 4.70E-07 1.16E-06 O.
3.19E-04 9.22E-06 TE127M 1.19E-OS 4.93E-06 1.4BE-06 3.4BE-06 2.6BE-OS 9.37E-04 1.9SE-OS TE127 1.S9E-09 6.B1 E-10 3.49E-10 1.32E-09 3.47E-09 7.39E-06 1.74E-OS TE129M 1.01 E-OS 4.3SE-06 1.S9E-06 3.91 E-06 2.27E-OS 1.20E-03 4.93E-OS TE129 S.63E-11 2.4BE-11 1.34E-11 4.B2E-11 1.2SE-10 2.14E-06 1.BBE-OS TE131M 7.62E-OB 3.93E-OB 2.S9E-OB 6.3BE-OB 1.B9E-07 1.42E-04 B.S1 E-OS TE131 1.24E-11 S.B7E-12 3.S7E-12 1.13E-11 2.BSE-11 1.47E-06 S.B7E-06 TE132 2.66E-07 1.69E-07 1.26E-07 1.99E-07 7.39E-07 2.43E-04 3.1SE-OS TE133M 6.13E-11 3.S9E-11 2.74E-11 S.S2E-11 1.72E-10 3.92E-06 1.S9E-OS TE134 3.1BE-11 2.04E-11 1.6BE-11 2.91 E-11 9.S9E-11 2.93E-06 2.S3E-06 1129 2.16E-OS 1.S9E-OS 1.16E-OS 1.04E-02 1.BBE-OS
- o.
2.12E-07 1130 4.S4E-06 9.91 E-06 3.9BE-06 1.14E-03 1.09E-OS
- o.
1.42E-06 1131 2.71 E-OS
'3.17E-OS 1.40E-OS 1.06E-02 3.70E-OS O.
7.S6E-07
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 3 of 16 INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.21 E-06 2.S3E-06 8.99E-07 1.21 E-04 2.82E-06
- o.
1.36E-06 1133 9.46E-06 1.37E-OS 4.00E-06 2.S4E-03 1.60E-OS O.
1.S4E-06 1134 6.S8E-07 1.34E-06 4.7SE-07 3.18E-OS 1.49E-06
- o.
9.21 E-07 113S 2.76E-06 S.43E-06 1.98E-06 4.97E-04 6.0SE-06
- o.
1.31 E-06 XE131M
- o.
O.
- o.
- o.
O.
6.77E-09
- o.
XE133M
- o.
O.
- o.
- o.
- o.
8.89E-09
- o.
XE133
- o.
- o.
- o.
- o.
- o.
7.41 E-09
- o.
XE13SM
- o.
- o.
- o.
- o.
O.
8.0SE-09
- o.
XE13S
- o.
O.
- o.
O.
- o.
1.80E-08
- o.
XE137
- o.
- o.
- o.
- o.
- o.
8.30E-08
- o.
XE138
- o.
- o.
- o.
- o.
- o.
9.78E-08
- o.
CS134M 1.32E-07 2.10E-07 1.11 E-07
- o.
8.S0E-08 2.00E-08 1.16E-07 CS134 2.83E-04 S.02E-04 S.32E-OS
- o.
1.36E-04 S.69E-OS 9.S3E-07 CS13S 1.00E-04 8.66E-OS 4.73E-06
- o.
2.S8E-OS 1.01 E-OS 2.18E-07 CS136 3.4SE-05 9.61 E-OS 3.78E-05 O.
4.03E-05 8.40E-06 1.02E-06 CS137 3.92E-04 4.37E-04 3.25E-05
- o.
1.23E-04 5.09E-05 9.53E-07 CS138 3.61 E-07 5.S8E-07 2.84E-07
- o.
2.93E-07 4.67E-08 6.26E-07 CS139 2.32E-07 3.03E-07 1.22E-07 O.
1.65E-07 2.53E-08 1.33E-08 BA139 1.06E-09 7.03E-13 3.07E-11
- o.
4.23E-13 4.2SE-06 3.64E-05 BA140 4.00E-05 4.00E-08 2.07E-06 O.
9.59E-09 1.14E-03 2.74E-05 BA141 1.12E-10 7.70E-14 3.S5E-12
- o.
4.64E-14 2.12E-06 3.39E-06 BA142 2.84E-11 2.36E-14 1.40E-12
- o.
1.36E-14 1.11 E-06 4.95E-07 LA140 3.61 E-07 1.43E-07 3.68E-08 O.
- o.
1.20E-04 6.06E-05 LA141 4.85E-09 1.40E-09 2.4SE-10 O.
O.
1.22E-05 5.96E-05 LA142 7.36E-10 2.69E-10 6.46E-11
- o.
- o.
5.87E-06 4.25E-05 CE141 1.98E-05 1.19E-05 1.42E-06
- o.
3.75E-06 3.69E-04 1.54E-05 CE143 2.09E-07 1.38E-07 1.58E-08
- o.
4.03E-08 8.30E-05 3.55E-05 CE144 2.28E-03 8.6SE-04 1.26E-04 O.
3.84E-04 7.03E-03 1.06E-04 PR143 1.00E-05 3.74E-06 4.99E-07
- o.
1.41 E-06 3.09E-04 2.66E-05 PR144 3.42E-11 1.32E-11 1.72E-12 O.
4.80E-12 1.1SE-06 3.06E-06 ND147 5.67E-06 5.81 E-06 3.S7E-07
- o.
2.25E-06 2.30E-04 2.23E-05 PM147 3.91 E-04 3.07E-OS 1.56E-05 O.
4.93E-05 4.55E-04 5.75E-06 PM148M 5.00E-05 1.24E-OS 9.94E-06 O.
1.45E-05 1.22E-03 3.37E-05 PM148 3.34E-06 4.82E-07 2.44E-07 O.
5.76E-07 3.20E-04 6.04E-05 PM149 3.10E-07 4.08E-08 1.78E-08
- o.
4.96E-08 6.S0E-05 3.01 E-05 PM1S1 7.52E-08 1.10E-08 5.55E-09
- o.
1.30E-08 3.2SE-05 2.58E-05 SM151 3.38E-04 6.45E-OS 1.63E-05
- o.
5.24E-05 2.98E-04 3.46E-06 SM153 1.S3E-07 1.18E-07 9.06E-09
- o.
2.47E-08 3.70E-OS 1.93E-05 EU152 7.83E-04 1.77E-04 1.72E-04 O.
5.94E-04 1.48E-03 9.88E-06 EU154 2.96E-03 3.46E-04 2.45E-04
- o.
1.14E-03 3.0SE-03 2.84E-05 EU15S 5.97E-04 5.72E-OS 3.46E-05
- o.
1.58E-04 5.20E-04 5.19E-05 EU156 1.56E-05 9.S9E-06 1.54E-06
- o.
4.48E-06 6.12E-04 4.14E-05 TB160 1.12E-04 O.
1.40E-05
- o.
3.20E-OS 1.11 E-03 2.14E-05 H0166M 1.45E-03 3.07E-04 2.51 E-04
- o.
4.22E-04 2.05E-03 1.65E-05 W181 4.86E-08 1.46E-08 1.67E-09
- o.
- o.
1.33E-05 2.63E-07 W185 1.S7E-06 4.83E-07 5.58E-08 O.
- o.
4.48E-04 1.12E-05 W187 9.26E-09 6.44E-09 2.23E-09 O.
- o.
2.83E-05 2.54E-05
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 4 of 16 INFANT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 B.62E-02 2.02E-02 3.43E-03 O.
6.BSE-02 1.76E-01 3.79E-OS BI210 O.
1.33E-OS 1.1BE-06 O.
1.03E-04 9.96E-03 3.27E-OS P0210 2.9BE-03 S.63E-03 7.12E-04 O.
1.30E-02 2.40E-01 4.36E-OS RN222 O.
O.
- o.
- o.
O.
9.BBE-06 O.
RA223 1.S6E-03 2.26E-06 3.12E-04 O.
4.16E-OS 2.2SE-01 3.04E-04 RA224 1.77E-04 4.00E-07 3.S4E-OS O.
7.30E-06 7.91 E-02 3.42E-04 RA22S 2.S7E-03 2.BBE-06 S.13E-04 O.
S.31 E-OS 2.S7E-01 2.B7E-04 RA226 2.4BE-01 1.46E-OS 2.0SE-01 O.
2.94E-04 7.B3E-01 3.0SE-04 RA22B 1.60E-01 7.61 E-06 1.BOE-01 O.
1.S3E-04 1.09E-00 S.19E-OS AC22S 3.69E-03 4.72E-03 2.4BE-04 O.
3.49E-04 1.96E-01 2.71 E-04 AC227 S.29E+00 B.76E-01 3.2BE-01 O.
1.B6E-01 1.62E+00 S.27E-OS TH227 1.B2E-03 3.03E-OS S.24E-OS O.
1.13E-04 3.27E-01 3.S3E-04 TH22B B.46E-01 1.10E-02 2.B6E-02 O.
S.61 E-02 4.6SE+00 3.62E-04 TH229 1.34E+01 1.B2E-01 6.62E-01 O.
B.99E-01 1.22E+01 3.29E-04 TH230 3.46E+00 1.79E-01 9.6SE-02 O.
B.B2E-01 2.1BE+00 3.B7E-OS TH232 3.B6E+00 1.S3E-01 2.29E-01 O.
7.S4E-01 2.09E+00 3.29E-OS TH234 1.33E-OS 7.17E-07 3.B4E-07 O.
2.70E-06 1.62E-03 7.40E-OS PA231 9.10E+00 3.00E-01 3.62E-01 O.
1.62E+00 3.BSE-01 4.61 E-OS PA233 6.B4E-06 1.32E-06 1.19E-06 O.
3.6BE-06 2.19E-04 9.04E-06 U232 2.S7E-01 O.
2.13E-02 O.
2.40E-02 1.49E+00 4.36E-OS U233 S.44E-02 O.
3.B3E-03 O.
1.09E-02 3.S6E-01 4.03E-OS U234 S.22E-02 O.
3.7SE-03 O.
1.07E-02 3.49E-01 3.9SE-OS U23S S.01 E-02 O.
3.S2E-03 O.
1.01 E-02 3.2BE-01 S.02E-OS U236 S.01 E-02 O.
3.60E-03 O.
1.03E-02 3.3SE-01 3.71 E-OS U237 3.2SE-07 O.
B.6SE-OB O.
B.OBE-07 9.13E-OS 1.31 E-OS U23B 4.79E-02 O.
3.29E-03 O.
9.40E-03 3.06E-01 3.S4E-OS NP237 3.03E+00 2.32E-01 1.26E-01 O.
7.69E-01 3.49E-01 S.10E-OS NP23B 2.67E-06 6.73E-OB 4.16E-OB O.
1.47E-07 9.19E-OS 2.SBE-OS NP239 2.6SE-07 2.37E-OB 1.34E-OB O.
4.73E-OB 4.2SE-OS 1.7BE-OS PU23B S.02E+00 6.33E-01 1.27E-01 O.
4.64E-01 9.03E-01 4.69E-OS PU239 S.SOE+OO 6.72E-01 1.34E-01 O.
4.9SE-01 B.47E-01 4.2BE-OS PU240 6.49E+00 6.71E-01 1.34E-01 O.
4.94E-01 B.47E-01 4.36E-OS PU241 1.SSE-01 6.69E-03 3.11 E-03 O.
1.1SE-02 7.62E-04 B.97E-07 PU242 S.09E+00 6.47E-01 1.29E-01 O.
4.77E-01 B.1SE-01 4.20E-OS PU244 S.9SE+00 7.40E-01 1.4BE-01 O.
S.46E-01 9.33E-01 6.26E-OS AM241 1.B4E+00 B.44E-01 1.31 E-01 O.
7.94E-01 4.06E-01 4.7BE-OS AM242M 1.90E+00 B.24E-01 1.3SE-01 O.
B.03E-01 1.64E-01 6.01 E-OS AM243 1.B2E+00 B.10E-01 1.27E-01 O.
7.72E-01 3.BSE-01 S.60E-OS CM242 B.SBE-02 7.44E-02 S.70E-03 O.
1.69E-02 2.97E-01 S.10E-OS CM243 1.73E+00 7.94E-01 1.06E-01 O.
3.91 E-01 4.24E-01 S.02E-OS CM244 1.43E+00 7.04E-01 B.B9E-02 O.
3.21 E-01 4.0BE-01 4.B6E-OS CM24S 2.26E+00 B.BOE-01 1.36E-01 O.
S.23E-01 3.92E-01 4.S3E-OS CM246 2.24E+00 B.79E-01 1.36E-01 O.
S.23E-01 3.99E-01 4.4SE-OS CM247 2.1BE+00 B.64E-01 1.33E-01 O.
S.1SE-01 3.92E-01 S.BSE-OS CM24B 1.B2E+01 7.12E+00 1.10E+00 O.
4.24E+00 3.23E+00 9.43E-04 CF2S2 4.26E+00 O.
1.01 E-01 O.
O.
1.37E+00 1.BSE-04
INHALATION DOSE COMMITMENT FACTORS Proc No ODCM Revision 26 Page 5 of 16 CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3*
O.
3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 BE10 B.43E-04 9.B3E-OS 2.12E-OS O.
O.
7.41 E-04 1.72E-OS C14 9.70E-06 1.B2E-06 1.B2E-06 1.B2E-06 1.B2E-06 1.B2E-06 1.B2E-06 N13 2.33E-OB 2.33E-OB 2.33E-OB 2.33E-OB 2.33E-OB 2.33E-OB 2.33E-OB F1B 1.BBE-06 O.
1.BSE-07 O.
O.
O.
3.37E-07 NA22 4.41 E-OS 4.41 E-OS 4.41 E-OS 4.41 E-OS 4.41 E-OS 4.41 E-OS 4.41E-OS NA24 4.3SE-06 4.3SE-06 4.3SE-06 4.3SE-06 4.3SE-06 4.3SE-06 4.3SE-06 P32 7.04E-04 3.09E-OS 2.67E-OS O.
O.
O.
1.14E-OS AR39 O.
O.
O.
O.
O.
4.B9E-09 O.
AR41 O.
O.
O.
O.
O.
1.6BE-OB O.
CA41 7.06E-OS O.
7.70E-06 O.
O.
7.21 E-02 2.94E-07 SC46 1.97E-04 2.70E-04 1.04E-04 O.
2.39E-04 O.
2.4SE-OS CRS1 O.
O.
4.17E-OB 2.31 E-OB 6.S7E-09 4.S9E-06 2.93E-07 MNS4 O.
1.16E-OS 2.S7E-06 O.
2.71 E-06 4.26E-04 6.19E-06 MNS6 O.
4.4BE-10 B.43E-11 O.
4.S2E-10 3.SSE-06 3.33E-OS FESS 1.2BE-OS 6.BOE-06 2.10E-06 O.
O.
3.00E-OS 7.7SE-07 FES9 S.S9E-06 9.04E-06 4.S1 E-06 O.
O.
3.43E-04 1.91 E-OS COS7 O.
2.44E-07 2.BBE-07 O.
O.
1.37E-04 3.SBE-06 COSB O.
4.79E-07 B.SSE-07 O.
O.
2.99E-04 9.29E-06 C060 O.
3.SSE-06 6.12E-06 O.
O.
1.91 E-03 2.60E-OS NIS9 1.66E-OS 4.67E-06 2.B3E-06 O.
O.
2.73E-OS 6.29E-07 NI63 2.22E-04 1.2SE-OS 7.S6E-06 O.
O.
7.43E-OS 1.71 E-06 NI6S B.OBE-10 7.99E-11 4.44E-11 O.
O.
2.21 E-06 2.27E-OS CU64 O.
S.39E-10 2.90E-10 O.
1.63E-09 2.S9E-06 9.92E-06 ZN6S 1.1SE-OS 3.06E-OS 1.90E-OS O.
1.93E-OS 2.69E-04 4.41 E-06 ZN69M 4.26E-09 7.2BE-09 B.S9E-10 O.
4.22E-09 7.36E-06 2.71 E-OS ZN69 1.B1E-11 2.61 E-11 2.41E-12 O.
1.SBE-11 3.B4E-07 2.7SE-06 SE79 O.
1.23E-06 2.60E-07 O.
1.71 E-06 1.49E-04 3.43E-06 BRB2 O.
O.
S.66E-06 O.
O.
O.
O.
BRB3 O.
O.
1.2BE-07 O.
O.
O.
O.
BRB4 O.
O.
1.4BE-07 O.
O.
O.
O.
BRBS O.
O.
6.B4E-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
1.22E-09 O.
KRBSM O.
O.
O.
O.
O.
6.SBE-09 O.
KRBS O.
O.
O.
O.
O.
S.66E-09 O.
KRB7 O.
O.
O.
O.
O.
3.3BE-OB O.
KRBB O.
O.
O.
O.
O.
6.99E-OB O.
KRB9 O.
O.
O.
O.
O.
4.SSE-OB O.
RBB6 O.
S.36E-OS 3.09E-OS O.
O.
O.
2.16E-06 RBB7 O.
3.16E-OS 1.37E-OS O.
O.
O.
2.96E-07 RBBB O.
1.S2E-07 9.90E-OB O.
O.
O.
4.66E-09 RBB9 O.
9.33E-OB 7.B3E-OB O.
O.
O.
S.11E-10 SRB9 1.62E-04 O.
4.66E-06 O.
O.
S.B3E-04 4.S2E-OS SR90 2.73E-02 O.
1.74E-03 O.
O.
3.99E-03 9.2BE-OS SR91 3.2BE-OB O.
1.24E-09 O.
O.
1.44E-OS 4.70E-OS SR92 3.S4E-09 O.
1.42E-10 O.
O.
6.49E-06 6.SSE-OS
- Includes a SO% increase to account for percutaneous transpiration.
INHALATION DOSE COMMITMENT FACTORS Proc No ODCM Revision 26 Page 6 of 16 CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 1.11 E-06 O.
2.99E-OB O.
O.
7.07E-OS 7.24E-OS Y91M 1.37E-10 O.
4.9BE-12 O.
O.
7.60E-07 4.64E-07 Y91 2.47E-04 O.
6.S9E-06 O.
O.
7.10E-04 4.97E-OS Y92 S.SOE-09 O.
1.S7E-10 O.
O.
6.46E-06 6.46E-OS Y93 S.04E-OB O.
1.3BE-09 O.
O.
2.01E-OS 1.0SE-04 ZR93 2.07E-04 7.BOE-OS S.SSE-OS O.
3.00E-04 7.10E-04 1.47E-OS ZR9S S.13E-OS 1.13E-OS 1.00E-OS O.
1.61 E-OS 6.03E-04 1.6SE-OS ZR97 S.07E-OB 7.34E-09 4.32E-09 O.
1.0SE-OB 3.06E-OS 9.49E-OS NB93M 1.27E-04 3.17E-OS 1.04E-OS O.
3.44E-OS 1.04E-04 2.4SE-06 NB9S 6.3SE-06 2.4BE-06 1.77E-06 O.
2.33E-06 1.66E-04 1.00E-OS NB97 1.16E-10 2.0BE-11 9.74E-12 O.
2.31 E-11 9.23E-07 7.S2E-06 M093 O.
3.76E-06 1.3SE-07 O.
1.06E-06 1.70E-04 3.7BE-06 M099 O.
4.66E-OB 1.1SE-OB O.
1.06E-07 3.66E-OS 3.42E-OS TC99M 4.B1 E-13 9.41E-13 1.S6E-11 O.
1.37E-11 2.S7E-07 1.30E-06 TC99 1.34E-07 1.49E-07 S.3SE-OB O.
1.7SE-06 3.37E-04 7.7SE-06 TC101 2.19E-14 2.30E-14 2.91 E-13 O.
3.92E-13 1.SBE-07 4.41 E-09 RU103 7.SSE-07 O.
2.90E-07 O.
1.90E-06 1.79E-04 1.21 E-OS RU10S 4.13E-10 O.
1.S0E-10 O.
3.63E-10 4.30E-06 2.69E-OS RU106 3.6BE-OS O.
4.S7E-06 O.
4.97E-OS 3.B7E-03 1.16E-04 RH10S 3.91 E-09 2.10E-09 1.79E-09 O.
B.39E-09 7.B2E-06 1.33E-OS PD107 O.
2.6SE-07 2.S1 E-OB O.
1.97E-06 3.16E-OS 7.26E-07 PD109 O.
1.4BE-09 4.9SE-10 O.
7.06E-09 6.16E-06 2.S9E-OS AG110M 4.S6E-06 3.0BE-06 2.47E-06 O.
S.74E-06 1.4BE-03 2.71E-OS AG111 1.B1 E-07 S.6BE-OB 3.7SE-OB O.
1.71 E-07 7.73E-OS 2.9BE-OS CD113M O.
4.93E-04 2.12E-OS O.
S.13E-04 6.94E-04 1.63E-OS CD11SM O.
7.BBE-OS 3.39E-06 O.
S.93E-OS S.B6E-04 4.97E-OS 8N123 1.29E-04 2.14E-06 4.19E-06 2.27E-06 O.
9.S9E-04 4.0SE-OS 8N12S 4.9SE-06 9.94E-OB 2.9SE-07 1.03E-07 O.
2.43E-04 7.17E-OS 8N126 6.23E-04 1.04E-OS 2.36E-OS 2.B4E-06 O.
3.02E-03 1.63E-OS 8B124 1.SSE-OS 2.00E-07 S.41 E-06 3.41 E-OB O.
B.76E-04 4.43E-OS 8B12S 2.66E-OS 2.0SE-07 S.S9E-06 2.46E-OB O.
6.27E-04 1.09E-OS 8B126 1.72E-06 2.62E-OB 6.16E-07 1.00E-OB O.
2.B6E-04 S.67E-OS 8B127 1.36E-07 2.09E-09 4.70E-OB 1.S1 E-09 O.
6.17E-OS 3.B2E-OS TE12SM 1.B2E-06 6.29E-07 2.47E-07 S.20E-07 O.
1.29E-04 9.13E-06 TE127M 6.72E-06 2.31 E-06 B.16E-07 1.64E-06 1.72E-OS 4.00E-04 1.93E-OS TE127 7.49E-10 2.S7E-10 1.6SE-10 S.30E-10 1.91 E-09 2.71E-06 1.S2E-OS TE129M S.19E-06 1.BSE-06 B.22E-07 1.71 E-06 1.36E-OS 4.76E-04 4.91 E-OS TE129 2.64E-11 9.4SE-12 6.44E-12 1.93E-11 6.94E-11 7.93E-07 6.B9E-06 TE131M 3.63E-OB 1.60E-OB 1.37E-OB 2.64E-OB 1.0BE-07 S.S6E-OS B.32E-OS TE131 S.87E-12 2.2BE-12 1.7BE-12 4.S9E-12 1.S9E-11 S.SSE-07 3.60E-07 TE132 1.30E-07 7.36E-OB 7.12E-OB B.SBE-OB 4.79E-07 1.02E-04 3.72E-OS TE133M 2.93E-11 1.S1E-11 1.S0E-11 2.32E-11 1.01E-10 1.60E-06 4.77E-06 TE134 1.S3E-11 B.B1 E-12 9.40E-12 1.24E-11 S.71E-11 1.23E-06 4.B7E-07 1129 1.0SE-OS 6.40E-06 S.71E-06 4.2BE-03 1.0BE-OS O.
2.1SE-07 1130 2.21 E-06 4.43E-06 2.2BE-06 4.99E-04 6.61 E-06 O.
1.3BE-06 1131 1.30E-OS 1.30E-OS 7.37E-06 4.39E-03 2.13E-OS O.
7.6BE-07
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 7 of 16 CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 S.72E-07 1.10E-06 S.07E-07 S.23E-OS 1.69E-06 O.
B.6SE-07 1133 4.4BE-06 S.49E-06 2.0BE-06 1.04E-03 9.13E-06 O.
1.4BE-06 1134 3.17E-07 S.B4E-07 2.69E-07 1.37E-OS B.92E-07 O.
2.SBE-07 113S 1.33E-06 2.36E-06 1.12E-06 2.14E-04 3.62E-06 O.
1.20E-06 XE131M O.
O.
O.
O.
O.
3.30E-09 O.
XE133M O.
O.
O.
O.
O.
4.36E-09 O.
XE133 O.
O.
O.
O.
O.
3.66E-09 O.
XE13SM O.
O.
O.
O.
O.
4.4BE-09 O.
XE13S O.
O.
O.
O.
O.
9.09E-09 O.
XE137 O.
O.
O.
O.
O.
4.07E-OB O.
XE13B O.
O.
O.
O.
O.
S.17E-OB O.
CS134M 6.33E-OB B.92E-OB 6.12E-OB O.
4.94E-OB B.3SE-09 7.92E-OB CS134 1.76E-04 2.74E-04 6.07E-OS O.
B.93E-OS 3.27E-OS 1.04E-06 CS13S 6.23E-OS 4.13E-OS 4.4SE-06 O.
1.S3E-OS S.22E-06 2.17E-07 CS136 1.76E-OS 4.62E-OS 3.14E-OS O.
2.SBE-OS 3.93E-06 1.13E-06 CS137 2.4SE-04 2.23E-04 3.47E-OS O.
7.63E-OS 2.B1 E-OS 9.7BE-07 CS13B 1.71 E-07 2.27E-07 1.S0E-07 O.
1.6BE-07 1.B4E-OB 7.29E-OB CS139 1.09E-07 1.1SE-07 S.BOE-OB O.
9.0BE-OB 9.36E-09 7.23E-12 BA139 4.9BE-10 2.66E-13 1.4SE-11 O.
2.33E-13 1.S6E-06 1.S6E-OS BA140 2.00E-OS 1.7SE-OB 1.17E-06 O.
S.71 E-09 4.71E-04 2.7SE-OS BA141 S.29E-11 2.9SE-14 1.72E-12 O.
2.S6E-14 7.B9E-07 7.44E-OB BA142 1.3SE-11 9.73E-1S 7.S4E-13 O.
7.B7E-1S 4.44E-07 7.41 E-10 LA140 1.74E-07 6.0BE-OB 2.04E-OB O.
O.
4.94E-OS 6.10E-OS LA141 2.2BE-09 S.31 E-1 0 1.1SE-10 O.
O.
4.4BE-06 4.37E-OS LA142 3.S0E-10 1.11 E-1 0 3.49E-11 O.
O.
2.3SE-06 2.0SE-OS CE141 1.06E-OS S.2BE-06 7.B3E-07 O.
2.31 E-06 1.47E-04 1.S3E-OS CE143 9.B9E-OB S.37E-OB 7.77E-09 O.
2.26E-OB 3.12E-OS 3.44E-OS CE144 1.B3E-03 S.72E-04 9.77E-OS O.
3.17E-04 3.23E-03 1.0SE-04 PR143 4.99E-06 1.S0E-06 2.47E-07 O.
B.11 E-07 1.17E-04 2.63E-OS PR144 1.61E-11 4.99E-12 B.10E-13 O.
2.64E-12 4.23E-07 S.32E-OB ND147 2.92E-06 2.36E-06 1.B4E-07 O.
1.30E-06 B.B7E-OS 2.22E-OS PM147 3.S2E-04 2.S2E-OS 1.36E-OS O.
4.4SE-OS 2.20E-04 S.70E-06 PM14BM 3.31 E-OS 6.SSE-06 6.SSE-06 O.
9.74E-06 S.72E-04 3.SBE-OS PM14B 1.61 E-06 1.94E-07 1.2SE-07 O.
3.30E-07 1.24E-04 6.01 E-OS PM149 1.47E-07 1.S6E-OB B.4SE-09 O.
2.7SE-OB 2.40E-OS 2.92E-OS PM1S1 3.S7E-OB 4.33E-09 2.B2E-09 O.
7.3SE-09 1.24E-OS 2.S0E-OS SM1S1 3.14E-04 4.7SE-OS 1.49E-OS O.
4.B9E-OS 1.4BE-04 3.43E-06 SM1S3 7.24E-OB 4.S1 E-OB 4.3SE-09 O.
1.37E-OB 1.37E-OS 1.B7E-OS EU1S2 7.42E-04 1.37E-04 1.61 E-04 O.
S.73E-04 9.00E-04 1.14E-OS EU1S4 2.74E-03 2.49E-04 2.27E-04 O.
1.09E-03 1.66E-03 2.9BE-OS EU1SS S.60E-04 4.0SE-OS 3.1BE-OS O.
1.S1 E-04 2.79E-04 S.39E-OS EU1S6 7.B9E-06 4.23E-06 B.7SE-07 O.
2.72E-06 2.S4E-04 4.24E-OS TB160 7.79E-OS O.
9.67E-06 O.
2.32E-OS S.34E-04 2.2BE-OS H0166M 1.34E-03 2.B1 E-04 2.37E-04 O.
4.01 E-04 1.13E-03 1.63E-OS W1B1 2.66E-OB 6.S2E-09 B.99E-10 O.
O.
S.71E-06 2.61 E-07 W1BS B.31 E-07 2.0BE-07 2.91 E-OB O.
O.
1.B6E-04 1.11 E-OS W1B7 4.41 E-09 2.61 E-09 1.17E-09 O.
O.
1.11 E-OS 2.46E-OS
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 8 of 16 CHILD INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 8.03E-02 1.8SE-02 3.18E-03 O.
6.31 E-02 8.74E-02 3.7SE-OS BI210 O.
S.11 E-06 S.6SE-07 O.
S.76E-OS 3.70E-03 3.21 E-OS P0210 1.70E-03 2.76E-03 4.09E-04 O.
8.8SE-03 1.0SE-01 4.32E-OS RN222 O.
O.
O.
O.
O.
4.82E-06 O.
RA223 7.69E-04 8.89E-07 1.S4E-04 O.
2.36E-OS 8.48E-02 3.00E-04 RA224 8.44E-OS 1.S3E-07 1.69E-OS O.
4.06E-06 2.92E-02 3.34E-04 RA22S 1.28E-03 1.14E-06 2.S6E-04 O.
3.02E-OS 9.74E-02 2.84E-04 RA226 2.34E-01 7.66E-06 1.92E-01 O.
2.03E-04 3.90E-01 3.02E-04 RA228 1.49E-01 3.94E-06 1.68E-01 O.
1.04E-04 S.37E-01 S.14E-OS AC22S 1.81 E-03 1.87E-03 1.21 E-04 O.
1.99E-04 7.37E-02 2.67E-04 AC227 4.96E+00 8.0SE-01 3.07E-01 O.
1.77E-01 8.04E-01 S.22E-OS TH227 9.24E-04 1.26E-OS 2.67E-OS O.
6.67E-OS 1.26E-01 3.49E-04 TH228 8.06E-01 1.04E-02 2.72E-02 O.
S.41 E-02 3.34E+00 3.S9E-04 TH229 1.28E+01 1.76E-01 6.31 E-01 O.
8.68E-01 1.04E+01 3.27E-04 TH230 3.30E+00 1.73E-01 9.20E-02 O.
8.S2E-01 1.8SE+00 3.84E-OS TH232 3.68E+OO 1.47E-01 1.28E-01 O.
7.28E-01 1.77E+00 3.27E-OS TH234 6.94E-06 3.07E-07 2.00E-07 O.
1.62E-06 6.31 E-04 7.32E-OS PA231 8.62E+00 2.86E-01 3.43E-01 O.
1.S6E+00 1.92E-01 4.S7E-OS PA233 4.14E-06 6.48E-07 7.2SE-07 O.
2.38E-06 9.77E-OS 8.9SE-06 U232 2.19E-01 O.
1.S6E-02 O.
1.67E-02 7.42E-01 4.33E-OS U233 4.64E-02 O.
2.82E-03 O.
7.62E-03 1.77E-01 4.00E-OS U234 4.46E-02 O.
2.76E-03 O.
7.47E-03 1.74E-01 3.92E-OS U23S 4.27E-02 O.
2.S9E-03 O.
7.01 E-03 1.63E-01 4.98E-OS U236 4.27E-02 O.
2.6SE-03 O.
7.16E-03 1.67E-01 3.67E-OS U237 1.S7E-07 O.
4.17E-08 O.
4.S3E-07 3.40E-OS 1.29E-OS U238 4.09E-02 O.
2.42E-03 O.
6.SSE-03 1.S3E-01 3.S1 E-OS NP237 2.88E+00 2.21 E-01 1.19E-01 O.
7.41E-01 1.74E-01 S.06E-OS NP238 1.26E-06 2.S6E-08 1.97E-08 O.
8.16E-08 3.39E-OS 2.S0E-OS NP239 1.26E-07 9.04E-09 6.3SE-09 O.
2.63E-08 1.S7E-OS 1.73E-OS PU238 4.77E+00 6.0SE-01 1.21 E-01 O.
4.47E-01 6.08E-01 4.6SE-OS PU239 S.24E+00 6.44E-01 1.28E-01 O.
4.78E-01 S.72E-01 4.24E-OS PU240 S.23E+00 6.43E-01 1.27E-01 O.
4.77E-01 S.71E-01 4.33E-OS PU241 1.46E-01 6.33E-03 2.93E-03 O.
1.10E-02 S.06E-04 8.90E-07 PU242 4.8SE+00 6.20E-01 1.23E-01 O.
4.60E-01 S.SOE-01 4.16E-OS PU244 S.67E+00 7.10E-01 1.41 E-01 O.
S.27E-01 6.30E-01 6.20E-OS AM241 1.74E+00 7.8SE-01 1.24E-01 O.
7.63E-01 2.02E-01 4.73E-OS AM242M 1.79E+00 7.6SE-01 1.27E-01 O.
7.71 E-01 8.14E-02 S.96E-OS AM243 1.72E+00 7.S3E-01 1.20E-01 O.
7.42E-01 1.92E-01 S.SSE-OS CM242 6.33E-02 4.84E-02 4.20E-03 O.
1.34E-02 1.31E-01 S.06E-OS CM243 1.61 E+OO 7.33E-01 9.9SE-02 O.
3.74E-01 2.10E-01 4.98E-OS CM244 1.33E+00 6.48E-01 8.31 E-02 O.
3.06E-01 2.02E-01 4.82E-OS CM24S 2.14E+00 8.16E-01 1.28E-01 O.
S.03E-01 1.9SE-01 4.49E-OS CM246 2.13E+00 8.1SE-01 1.28E-01 O.
S.03E-01 1.99E-01 4.41 E-OS CM247 2.07E+00 8.02E-01 1.26E-01 O.
4.9SE-01 1.9SE-01 S.80E-OS CM248 1.72E+01 6.61E+00 1.04E+00 O.
4.08E+00 1.61 E+OO 9.3SE-04 CF2S2 3.92E+OO O.
9.33E-02 O.
O.
6.62E-01 1.84E-04
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 9 of 16 TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3*
O.
1.S9E-07 1.S9E-07 1.S9E-07 1.S9E-07 1.S9E-07 1.S9E-07 BE10 2.7BE-04 4.33E-OS 7.09E-06 O.
O.
3.B4E-04 1.77E-OS C14 3.2SE-06 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 6.09E-07 N13 B.6SE-09 B.6SE-09 B.6SE-09 B.6SE-09 B.6SE-09 B.6SE-09 B.6SE-09 F1B 6.S2E-07 O.
7.10E-OB O.
O.
O.
3.B9E-OB NA22 1.76E-OS 1.76E-OS 1.76E-OS 1.76E-OS 1.76E-OS 1.76E-OS 1.76E-OS NA24 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 1.72E-06 P32 2.36E-04 1.37E-OS B.9SE-06 O.
O.
O.
1.16E-OS AR39 O.
O.
O.
O.
O.
4.00E-09 O.
AR41 O.
O.
O.
O.
O.
1.44E-OB O.
CA41 4.0SE-OS O.
4.3BE-06 O.
O.
1.01 E-01 3.03E-07 SC46 7.24E-OS 1.41 E-04 4.1BE-OS O.
1.3SE-04 O.
2.9BE-OS CRS1 O.
O.
1.69E-OB 9.37E-09 3.B4E-09 2.62E-06 3.7SE-07 MNS4 O.
6.39E-06 1.0SE-06 O.
1.S9E-06 2.4BE-04 B.3SE-06 MNS6 O.
2.12E-10 3.1SE-11 O.
2.24F-10 1.90E-06 7.1BE-06 FESS 4.1BE-06 2.9BE-06 6.93E-07 O.
O.
1.SSE-OS 7.99E-07 FES9 1.99E-06 4.62E-06 1.79E-06 O.
O.
1.91 E-04 2.23E-OS COS7 O.
1.1BE-07 1.1SE-07 O.
O.
7.33E-OS 3.93E-06 COSB O.
2.S9E-07 3.47E-07 O.
O.
1.6BE-04 1.19E-OS C060 O.
1.B9E-06 2.4BE-06 O.
O.
1.09E-03 3.24E-OS NIS9 S.44E-06 2.02E-06 9.24E-07 O.
O.
1.41 E-OS 6.4BE-07 NI63 7.2SE-OS S.43E-06 2.47E-06 O.
O.
3.B4E-OS 1.77E-06 NI6S 2.73E-10 3.66E-11 1.S9E-11 O.
O.
1.17E-06 4.S9E-06 CU64 O.
2.S4E-10 1.06E-10 O.
B.01 E-10 1.39E-06 7.6BE-06 ZN6S 4.B2E-06 1.67E-OS 7.BOE-06 O.
1.0BE-OS 1.SSE-04 S.B3E-06 ZN69M 1.44E-09 3.39E-09 3.11E-10 O.
2.06E-09 3.92E-06 2.14E-OS ZN69 6.04E-12 1.1SE-11 B.07E-13 O.
7.S3E-12 1.9BE-07 3.S6E-OB SE79 O.
S.43E-07 B.71 E-OB O.
B.13E-07 7.71 E-OS 3.S3E-06 BRB2 O.
O.
2.2BE-06 O.
O.
O.
O.
BRB3 O.
O.
4.30E-OB O.
O.
O.
O.
BRB4 O.
O.
S.41 E-OB O.
O.
O.
O.
BRBS O.
O.
2.29E-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
9.97E-10 O.
KRBSM O.
O.
O.
O.
O.
S.46E-09 O.
KRBS O.
O.
O.
O.
O.
4.63E-09 O.
KRB7 O.
O.
O.
O.
O.
2.B2E-OB O.
KRBB O.
O.
O.
O.
O.
S.B1 E-OB O.
KRB9 O.
O.
O.
O.
O.
3.BSE-OB O.
RBB6 O.
2.3BE-OS 1.0SE-OS O.
O.
O.
2.21 E-06 RBB7 O.
1.40E-OS 4.SBE-06 O.
O.
O.
3.0SE-07 RBBB O.
6.B2E-OB 3.40E-OB O.
O.
O.
3.6SE-1S RBB9 O.
4.40E-OB 2.91 E-OB O.
O.
O.
4.22E-17 SRB9 S.43E-OS O.
1.S6E-06 O.
O.
3.02E-04 4.64E-OS SR90 1.3SE-02 O.
B.3SE-04 O.
O.
2.06E-03 9.S6E-OS SR91 1.10E-OB O.
4.39E-10 O.
O.
7.S9E-06 3.24E-OS SR92 1.19E-09 O.
S.OBE-11 O.
O.
3.43E-06 1.49E-OS
- /ncludes a SO% increase to account for percutaneous transpiration.
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 10 of 16 TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 3.73E-07 O.
1.00E-OB O.
O.
3.66E-OS 6.99E-OS Y91M 4.63E-11 O.
1.77E-12 O.
O.
4.00E-07 3.77E-09 Y91 B.26E-OS O.
2.21 E-06 O.
O.
3.67E-04 S.11 E-OS Y92 1.B4E-09 O.
S.36E-11 O.
O.
3.3SE-06 2.06E-OS Y93 1.69E-OB O.
4.6SE-10 O.
O.
1.04E-OS 7.24E-OS ZR93 6.B3E-OS 3.3BE-OS 1.B4E-OS O.
1.16E-04 3.67E-04 1.60E-OS ZR9S 1.B2E-OS S.73E-06 3.94E-06 O.
B.42E-06 3.36E-04 1.B6E-OS ZR97 1.72E-OB 3.40E-09 1.S7E-09 O.
S.1SE-09 1.62E-OS 7.BBE-OS NB93M 4.14E-OS 1.36E-OS 3.41 E-06 O.
1.S9E-OS S.36E-OS 2.S2E-06 NB9S 2.32E-06 1.29E-06 7.0BE-07 O.
1.2SE-06 9.39E-OS 1.21 E-OS NB97 3.92E-11 9.72E-12 3.SSE-12 O.
1.14E-11 4.91 E-07 2.71 E-07 M093 O.
1.66E-06 4.S2E-OB O.
S.06E-07 B.B1 E-OS 3.99E-06 M099 O.
2.11 E-OB 4.03E-09 O.
S.14E-OB 1.92E-OS 3.36E-OS TC99M 1.73E-13 4.B3E-13 6.24E-12 O.
7.20E-12 1.44E-07 7.66E-07 TC99 4.4BE-OB 6.SBE-OB 1.79E-OB O.
B.3SE-07 1.74E-04 7.99E-06 TC101 7.40E-1S 1.0SE-14 1.03E-13 O.
1.90E-13 B.34E-OB 1.09E-16 RU103 2.63E-07 O.
1.12E-07 O.
9.29E-07 9.79E-OS 1.36E-OS RU10S 1.40E-10 O.
S.42E-11 O.
1.76E-10 2.27E-06 1.13E-OS RU106 1.23E-OS O.
1.SSE-06 O.
2.3BE-OS 2.01 E-03 1.20E-04 RH10S 1.32E-09 9.4BE-10 6.24E-10 O.
4.04E-09 4.09E-06 1.23E-OS PD107 O.
1.17E-07 B.39E-09 O.
9.39E-07 1.63E-OS 7.49E-07 PD109 O.
6.S6E-10 1.66E-10 O.
3.36E-09 3.19E-06 1.96E-OS AG110M 1.73E-06 1.64E-06 9.99E-07 O.
3.13E-06 B.44E-04 3.41 E-OS AG111 6.07E-OB 2.S2E-OB 1.26E-OB O.
B.17E-OB 4.00E-OS 3.00E-OS CD113M O.
2.17E-04 7.10E-06 O.
2.43E-04 3.S9E-04 1.6BE-OS CD11SM O.
3.4BE-OS 1.14E-06 O.
2.B2E-OS 3.03E-04 S.10E-OS SN123 4.31 E-OS 9.44E-07 1.40E-06 7.SSE-07 O.
4.96E-04 4.16E-OS SN12S 1.66E-06 4.42E-OB 9.99E-OB 3.4SE-OB O.
1.26E-04 7.29E-OS SN126
- 2. 1 BE-04 S.39E-06 B.24E-06 1.42E-06 O.
1.72E-03 1.6BE-OS SB124 S.3BE-06 9.92E-OB 2.10E-06 1.22E-OB O.
4.B1 E-04 4.9BE-OS SB12S 9.23E-06 1.01 E-07 2.1SE-06 B.BOE-09 O.
3.42E-04 1.24E-OS SB126 6.19E-07 1.27E-OB 2.23E-07 3.S0E-09 O.
1.SSE-04 6.01 E-OS SB127 4.64E-OB 9.92E-10 1.7SE-OB S.21 E-10 O.
3.31 E-OS 3.94E-OS TE12SM 6.10E-07 2.BOE-07 B.34E-OB 1.7SE-07 O.
6.70E-OS 9.3BE-06 TE127M 2.2SE-06 1.02E-06 2.73E-07 S.4BE-07 B.17E-06 2.07E-04 1.99E-OS TE127 2.S1E-10 1.14E-10 S.S2E-11 1.77E-10 9.10E-10 1.40E-06 1.01 E-OS TE129M 1.74E-06 B.23E-07 2.B1 E-07 S.72E-07 6.49E-06 2.47E-04 S.06E-OS TE129 B.B7E-12 4.22E-12 2.20E-12 6.4BE-12 3.32E-11 4.12E-07 2.02E-07 TE131M 1.23E-OB 7.S1 E-09 S.03E-09 9.06E-09 S.49E-OB 2.97E-OS 7.76E-OS TE131 1.97E-12 1.04E-12 6.30E-13 1.SSE-12 7.72E-12 2.92E-07 1.B9E-09 TE132 4.S0E-OB 3.63E-OB 2.74E-OB 3.07E-OB 2.44E-07 S.61 E-OS S.79E-OS TE133M 1.01E-11 7.33E-12 S.71E-12 B.1BE-12 S.07E-11 B.71 E-07 1.23E-07 TE134 S.31E-12 4.3SE-12 3.64E-12 4.46E-12 2.91E-11 6.7SE-07 1.37E-09 1129 3.S3E-06 2.94E-06 4.90E-06 3.66E-03 S.26E-06 O.
2.29E-07 1130 7.BOE-07 2.24E-06 B.96E-07 1.B6E-04 3.44E-06 O.
1.14E-06 1131 4.43E-06 6.14E-06 3.30E-06 1.B3E-03 1.0SE-OS O.
B.11 E-07
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 11 of 16 TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.99E-07 S.47E-07 1.97E-07 1.B9E-OS B.6SE-07 O.
1.S9E-07 1133 1.S2E-06 2.S6E-06 7.7BE-07 3.6SE-04 4.49E-06 O.
1.29E-06 1134 1.11 E-07 2.90E-07 1.0SE-07 4.94E-06 4.SBE-07 O.
2.SSE-09 113S 4.62E-07 1.1BE-06 4.36E-07 7.76E-OS 1.B6E-06 O.
B.69E-07 XE131M O.
O.
O.
O.
O.
2.70E-09 O.
XE133M O.
O.
O.
O.
O.
3.S9E-09 O.
XE133 O.
O.
O.
O.
O.
2.99E-09 O.
XE13SM O.
O.
O.
O.
O.
3.BBE-09 O.
XE13S O.
O.
O.
O.
O.
7.SSE-09 O.
XE137 O.
O.
O.
O.
O.
3.33E-OB O.
XE13B O.
O.
O.
O.
O.
4.3BE-OB O.
CS134M 2.20E-OB 4.3SE-OB 2.3SE-OB O.
2.S4E-OB 4.S6E-09 2.02E-OB CS134 6.2BE-OS 1.41 E-04 6.B6E-OS O.
4.69E-OS 1.B3E-OS 1.22E-06 CS13S 2.0BE-OS 1.B2E-OS 4.47E-06 O.
7.30E-06 2.70E-06 2.23E-07 CS136 6.44E-06 2.42E-OS 1.71 E-OS O.
1.3BE-OS 2.22E-06 1.36E-06 CS137 B.3BE-OS 1.06E-04 3.B9E-OS O.
3.BOE-OS 1.S1 E-OS 1.06E-06 CS13B S.B2E-OB 1.07E-07 S.SBE-OB O.
B.2BE-OB 9.B4E-09 3.3BE-11 CS139 3.6SE-OB S.12E-OB 1.97E-OB O.
4.34E-OB 4.B6E-09 1.66E-23 BA139 1.67E-10 1.1BE-13 4.B7E-12 O.
1.11 E-13 B.OBE-07 B.06E-07 BA140 6.B4E-06 B.3BE-09 4.40E-07 O.
2.BSI=-09 2.S4E-04 2.B6E-OS BA141 1.7BE-11 1.32E-14 S.93E-13 O.
1.23E-14 4.11 E-07 9.33E-14 BA142 4.62E-12 4.63E-1S 2.B4E-13 O.
3.92E-1S 2.39E-07 S.99E-20 LA140 S.99E-OB 2.9SE-OB 7.B2E-09 O.
O.
2.6BE-OS 6.09E-OS LA141 7.63E-10 2.3SE-10 3.B7E-11 O.
O.
2.31 E-06 1.S4E-OS LA142 1.20E-10 S.31E-11 1.32E-11 O.
O.
1.27E-06 1.S0E-06 CE141 3.SSE-06 2.37E-06 2.71 E-07 O.
1.11 E-06 7.67E-OS 1.SBE-OS CE143 3.32E-OB 2.42E-OB 2.70E-09 O.
1.0BE-OB 1.63E-OS 3.19E-OS CE144 6.11 E-04 2.S3E-04 3.2BE-OS O.
1.S1E-04 1.67E-03 1.0BE-04 PR143 1.67E-06 6.64E-07 B.2BE-OB O.
3.B6E-07 6.04E-OS 2.67E-OS PR144 S.37E-12 2.20E-12 2.72E-13 O.
1.26E-12 2.19E-07 2.94E-14 ND147 9.B3E-07 1.07E-06 6.41 E-OB O.
6.2BE-07 4.6SE-OS 2.2BE-OS PM147 1.1SE-04 1.10E-OS 4.S0E-06 O.
2.10E-OS 1.14E-04 S.B7E-06 PM14BM 1.32E-OS 3.3SE-06 2.62E-06 O.
S.07E-06 3.20E-04 4.10E-OS PM14B S.44E-07 B.BBE-OB 4.4BE-OB O.
1.60E-07 6.S2E-OS 6.14E-OS PM149 4.91 E-OB 6.B9E-09 2.B4E-09 O.
1.31 E-OB 1.24E-OS 2.79E-OS PM1S1 1.20E-OB 1.99E-09 1.01 E-09 O.
3.S7E-09 6.S6E-06 2.27E-OS SM1S1 1.07E-04 2.10E-OS 4.B6E-06 O.
2.27E-OS 7.6BE-OS 3.S3E-06 SM1S3 2.43E-OB 2.01 E-OB 1.47E-09 O.
6.S6E-09 7.11 E-06 1.77E-OS EU1S2 2.96E-04 7.19E-OS 6.30E-OS O.
3.34E-04 S.01 E-04 1.3SE-OS EU1S4 9.43E-04 1.23E-04 B.60E-OS O.
S.44E-04 9.12E-04 3.34E-OS EU1SS 2.00E-04 1.96E-OS 1.21 E-OS O.
7.6SE-OS 1.S1 E-03 S.97E-OS EU1S6 2.70E-06 2.03E-06 3.30E-07 O.
1.36E-06 1.37E-04 4.S6E-OS TB160 3.04E-OS O.
3.79E-06 O.
1.20E-OS 2.97E-04 2.60E-OS H0166M 4.40E-04 1.36E-04 9.B7E-OS O.
2.00E-04 6.24E-04 1.6BE-OS W1B1 B.90E-09 2.BBE-09 3.01 E-1 0 O.
O.
2.9SE-06 2.69E-07 W1BS 2.7BE-07 9.17E-OB 9.73E-09 O.
O.
9.60E-OS 1.14E-OS W1B7 1.S0E-09 1.22E-09 4.29E-10 O.
O.
S.92E-06 2.21 E-OS
INHALATION DOSE COMMITMENT FACTORS Proc No aDeM Revision 26 Page 12 of 16 TEEN INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 3.09E-02 8.28E-03 1.07E-03
- o.
2.9SE-02 4.S2E-02 3.87E-OS BI210
- o.
2.26E-06 1.89E-07
- o.
2.74E-OS 1.91 E-03 3.19E-OS P0210 S.68E-04 1.22E-03 1.37E-04
- o.
4.21E-03 S.41 E-02 4.4SE-OS RN222
- o.
- o.
O.
- o.
- o.
3.94E-06
- o.
RA223 2.S7E-04 3.93E-07 S.14E-OS
- o.
1.12E-OS 4.39E-02 3.04E-04 RA224 2.83E-OS 6.77E-08 S.6SE-06
- o.
1.93E-06 1.S1 E-02 3.29E-04 RA22S 4.28E-04 S.04E-07 8.S6E-OS
- o.
1.44E-OS S.04E-02 2.89E-04 RA226 1.33E-01 3.38E-06 9.87E-02
- o.
9.67E-OS 2.02E-01 3.11 E-04 RA228 S.34E-02 1.74E-06 S.88E-02
- o.
4.97E-OS 2.78E-01 S.30E-OS AC22S 6.04E-04 8.2SE-04 4.06E-OS
- o.
9.47E-OS 3.81 E-02 2.70E-04 AC227 2.49E+00 3.69E-01 1.48E-01
- o.
1.07E-01 4.16E-01 S.38E-OS TH227 3.09E-04 S.S6E-06 8.93E-06
- o.
3.18E-OS 6.S0E-02 3.S7E-04 TH228 2.60E-01 4.37E-03 8.78E-03
- o.
2.4SE-02 1.69E+00 3.70E-04 TH229 9.06E+00 1.36E-01 4.4SE-01
- o.
6.67E-01 S.OSE+OO 3.36E-04 TH230 2.34E+00 1.34E-01 6.49E-02 O.
6.SSE-01 8.98E-01 3.9SE-OS TH232 2.61E+00 1.14E-01 9.21 E-02
- o.
S.60E-01 8.60E-01 3.36E-OS TH234 2.32E-06 1.3SE-07 6.71E-08
- o.
7.73E-07 3.26E-04 7.49E-OS PA231 S.32E+00 2.00E-01 2.07E-01
- o.
1.12E+00 9.91 E-02 4.71 E-OS PA233 1.68E-06 3.24E-07 2.89E-07 O.
1.22E-06 S.39E-OS 1.00E-OS U232 7.31 E-02 O.
S.23E-03 O.
7.94E-03 3.84E-01 4.46E-OS U233 1.SSE-02 O.
9.42E-04 O.
3.63E-03 9.18E-02 4.12E-OS U234 1.48E-02 O.
9.23E-04 O.
3.SSE-03 8.99E-02 4.04E-OS U23S 1.42E-02 O.
8.67E-04 O.
3.34E-03 8.44E-02 S.13E-OS U236 1.42E-02 O.
8.86E-04 O.
3.41 E-03 8.62E-02 3.79E-OS U237 S.2SE-08
- o.
1.40E-08
- o.
2.16E-07 1.76E-OS 1.29E-OS U238 1.36E-02
- o.
8.10E-04
- o.
3.12E-03 7.89E-02 3.62E-OS NP237 1.77E+00 1.S4E-01 7.21 E-02
- o.
S.3SE-01 8.99E-02 S.22E-OS NP238 4.23E-07 1.13E-08 6.S9E-09
- o.
3.88E-08 1.7SE-OS 2.38E-OS NP239 4.23E-08 3.99E-09 2.21 E-09
- o.
1.2SE-08 8.11 E-06 1.6SE-OS PU238 2.86E+00 4.06E-01 7.22E-02
- o.
3.10E-01 3.12E-01 4.79E-OS PU239 3.31 E+OO 4.S0E-01 8.0SE-02 O.
3.44E-01 2.93E-01 4.37E-OS PU240 3.31E+00 4.49E-01 8.04E-02 O.
3.43E-01 2.93E-01 4.46E-OS PU241 6.97E-02 3.S7E-03 1.40E-03 O.
6.47E-03 2.60E-04 9.17E-07 PU242 3.07E+00 4.33E-01 7.7SE-02 O.
3.31 E-01 2.82E-01 4.29E-OS PU244 3.S9E+00 4.96E-01 8.88E-02 O.
3.79E-01 3.23E-01 6.39E-OS AM241 1.06E+00 4.07E-01 7.10E-02 O.
S.32E-01 1.0SE-01 4.88E-OS AM242M 1.07E+00 3.93E-01 7.1SE-02 O.
S.30E-01 4.21 E-02 6.14E-OS AM243 1.06E+00 3.92E-01 6.9SE-02
- o.
S.21 E-01 9.91 E-02 S.72E-OS CM242 2.12E-02 2.14E-02 1.41 E-03
- o.
6.40E-03 6.76E-02 S.21 E-OS CM243 8.4SE-01 3.S0E-01 S.00E-02
- o.
2.34E-01 1.09E-01 S.13E-OS CM244 6.46E-01 3.03E-01 3.88E-02
- o.
1.81 E-01 1.0SE-01 4.96E-OS CM24S 1.32E+00 4.11E-01 7.S3E-02
- o.
3.S2E-01 1.01E-01 4.63E-OS CM246 1.31 E+OO 4.11E-01 7.S2E-02 O.
3.S1 E-01 1.03E-01 4.S4E-OS CM247 1.28E+00 4.04E-01 7.41 E-02
- o.
3.46E-01 1.01 E-01 S.97E-OS CM248 1.06E+01 3.33E+00 6.11 E-01
- o.
2.8SE+00 8.32E-01 9.63E-04 CF2S2 1.29E+00
- o.
3.07E-02
- o.
- o.
3.43E-01 1.89E-04
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 13 of 16 ADULT INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3*
O.
1.SBE-07 1.SBE-07 1.SBE-07 1.SBE-07 1.SBE-07 1.SBE-07 BE10 1.9BE-04 3.06E-OS 4.96E-06 O.
O.
2.22E-04 1.67E-OS C14 2.27E-06 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 4.26E-07 N13 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 6.27E-09 F1B 4.71E-07 O.
S.19E-OB O.
O.
O.
9.24E-09 NA22 1.30E-OS 1.30E-OS 1.30E-OS 1.30E-OS 1.30E-OS 1.30E-OS 1.30E-OS NA24 1.2BE-06 1.2BE-06 1.2BE-06 1.2BE-06 1.2BE-06 1.2BE-06 1.2BE-06 P32 1.6SE-04 9.64E-06 6.26E-06 O.
O.
O.
1.0BE-OS AR39 O.
O.
O.
O.
O.
2.0BE-09 O.
AR41 O.
O.
O.
O.
O.
B.06E-09 O.
CA41 3.B3E-OS O.
4.13E-06 O.
O.
3.B3E-06 2.B6E-07 SC46 S.S1 E-OS 1.07E-04 3.11 E-OS O.
9.99E-OS O.
3.23E-OS CRS1 O.
O.
1.2SE-OB 7.44E-09 2.BSE-09 1.BOE-06 4.1SE-07 MNS4 O.
4.9SE-06 7.B7E-07 O.
1.23E-06 1.7SE-04 9.67E-06 MNS6 O.
1.SSE-10 2.29E-11 O.
1.63E-10 1.1BE-06 2.S3E-06 FESS 3.07E-06 2.12E-06 4.93E-07 O.
O.
9.01 E-06 7.S4E-07 FES9 1.47E-06 3.47E-06 1.32E-06 O.
O.
1.27E-04 2.3SE-OS COS7 O.
B.6SE-OB B.39E-OB O.
O.
4.62E-OS 3.93E-06 COSB O.
1.9BE-07 2.S9E-07 O.
O.
1.16E-04 1.33E-OS C060 O.
1.44E-06 1.BSE-06 O.
O.
7.46E-04 3.S6E-OS NIS9 4.06E-06 1.46E-06 6.77E-07 O.
O.
B.20E-06 6.11 E-07 NI63 S.40E-OS 3.93E-06 1.B1 E-06 O.
O.
2.23E-OS 1.67E-06 NI6S 1.92E-10 2.62E-11 1.14E-11 O.
O.
7.00E-07 1.S4E-06 CU64 O.
1.B3E-10 7.69E-11 O.
S.7BE-10 B.4BE-07 6.12E-06 ZN6S 4.0SE-06 1.29E-OS S.B2E-06 O.
B.62E-06 1.0BE-04 6.6BE-06 ZN69M 1.02E-09 2.4SE-09 2.24E-10 O.
1.4BE-09 2.3BE-06 1.71 E-OS ZN69 4.23E-12 B.14E-12 S.6SE-13 O.
S.27E-12 1.1SE-07 2.04E-09 SE79 O.
3.B3E-07 6.09E-OB O.
S.69E-07 4.47E-OS 3.33E-06 BRB2 O.
O.
1.69E-06 O.
O.
O.
1.30E-06 BRB3 O.
O.
3.01 E-OB O.
O.
O.
2.90E-OB BRB4 O.
O.
3.91 E-OB O.
O.
O.
2.0SE-13 BRBS O.
O.
1.60E-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
S.19E-10 O.
KRBSM O.
O.
O.
O.
O.
2.91 E-09 O.
KRBS O.
O.
O.
O.
O.
2.41 E-09 O.
KRB7 O.
O.
O.
O.
O.
1.S3E-OB O.
KRBB O.
O.
O.
O.
O.
3.13E-OB O.
KRB9 O.
O.
O.
O.
O.
2.13E-OB O.
RBB6 O.
1.69E-OS 7.37E-06 O.
O.
O.
2.0BE-06 RBB7 O.
9.B6E-06 3.21 E-06 O.
O.
O.
2.BBE-07 RBBB O.
4.B4E-OB 2.41 E-OB O.
O.
O.
4.1BE-19 RBB9 O.
3.20E-OB 2.12E-OB O.
O.
O.
1.16E-21 SRB9 3.BOE-OS O.
1.09E-06 O.
O.
1.7SE-04 4.37E-OS SR90 1.24E-02 O.
7.62E-04 O.
O.
1.20E-03 9.02E-OS SR91 7.74E-09 O.
3.13E-10 O.
O.
4.S6E-06 2.39E-OS SR92 B.43E-10 O.
3.64E-11 O.
O.
2.06E-06 S.3BE-06
- Includes a SO% increase to account for percutaneous transpiration.
INHALATION DOSE COMMITMENT FACTORS Proc No ODCM Revision 26 Page 14 of 16 ADUL T INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 2.61 E-07 O.
7.01 E-09 O.
O.
2.12E-OS 6.32E-OS Y91M 3.26E-11 O.
1.27E-12 O.
O.
2.40E-07 1.66E-10 Y91 S.7BE-OS O.
1.SSE-06 O.
O.
2.13E-04 4.B1 E-OS Y92 1.29E-09 O.
3.77E-11 O.
O.
1.96E-06 9.19E-06 Y93 1.1BE-OB O.
3.26E-10 O.
O.
6.06E-06 S.27E-OS ZR93 S.22E-OS 2.92E-06 1.37E-06 O.
1.11 E-OS 2.13E-OS 1.S1 E-06 ZR9S 1.34E-OS 4.30E-06 2.91 E-06 O.
6.77E-06 2.21 E-04 1.BBE-OS ZR97 1.21 E-OB 2.4SE-09 1.13E-09 O.
3.71 E-09 9.B4E-06 6.S4E-OS NB93M 3.10E-OS 1.01 E-OS 2.49E-06 O.
1.16E-OS 3.11 E-OS 2.3BE-06 NB9S 1.76E-06 9.77E-07 S.26E-07 O.
9.67E-07 6.31 E-OS 1.30E-OS NB97 2.7BE-11 7.03E-12 2.S6E-12 O.
B.1BE-12 3.00E-07 3.02E-OB M093 O.
1.17E-06 3.17E-OB O.
3.SSE-07 S.11 E-OS 3.79E-06 M099 O.
1.S1 E-OB 2.B7E-09 O.
3.64E-OB 1.14E-OS 3.10E-OS TC99M 1.29E-13 3.64E-13 4.63E-12 O.
S.S2E-12 9.SSE-OB S.20E-07 TC99 3.13E-OB 4.64E-OB 1.2SE-OB O.
S.BSE-07 1.01 E-04 7.S4E-06 TC101 S.22E-1S 7.S2E-1S 7.3BE-14 O.
1.3SE-13 4.99E-OB 1.36E-21 RU103 1.91 E-07 O.
B.23E-OB O.
7.29E-07 6.31 E-OS 1.3BE-OS RU10S 9.BBE-11 O.
3.B9E-11 O.
1.27E-10 1.37E-06 6.02E-06 RU106 B.64E-06 O.
1.09E-06 O.
1.67E-OS 1.17E-03 1.14E-04 RH10S 9.24E-10 6.73E-10 4.43E-10 O.
2.B6E-09 2.41 E-06 1.09E-OS PD107 O.
B.27E-OB S.B7E-09 O.
6.S7E-07 9.47E-06 7.06E-07 PD109 O.
4.63E-10 1.16E-10 O.
2.3SE-09 1.BSE-06 1.S2E-OS AG110M 1.3SE-06 1.2SE-06 7.43E-07 O.
2.46E-06 S.79E-04 3.7BE-OS AG111 4.2SE-OB 1.7BE-OB B.B7E-09 O.
S.74E-OB 2.33E-OS 2.79E-OS CD113M O.
1.S4E-04 4.97E-06 O.
1.71 E-04 2.0BE-04 1.S9E-OS CD11SM O.
2.46E-OS 7.9SE-07 O.
1.9BE-OS 1.76E-04 4.BOE-OS 8N123 3.02E-OS 6.67E-07 9.B2E-07 S.67E-07 O.
2.BBE-04 3.92E-OS 8N12S 1.16E-06 3.12E-OB 7.03E-OB 2.S9E-OB O.
7.37E-OS 6.B1 E-OS 8N126 1.SBE-04 4.1BE-06 6.00E-06 1.23E-06 O.
1.17E-03 1.S9E-OS 8B124 3.90E-06 7.36E-OB 1.SSE-06 9.44E-09 O.
3.10E-04 S.OBE-OS 8B12S 6.67E-06 7.44E-OB 1.SBE-06 6.7SE-09 O.
2.1BE-04 1.26E-OS 8B126 4.S0E-07 9.13E-09 1.62E-07 2.7SE-09 O.
9.S7E-OS 6.01 E-OS 8B127 3.30E-OB 7.22E-10 1.27E-OB 3.97E-10 O.
2.0SE-OS 3.77E-OS TE12SM 4.27E-07 1.9BE-07 S.B4E-OB 1.31 E-07 1.SSE-06 3.92E-OS B.B3E-06 TE127M 1.SBE-06 7.21E-07 1.96E-07 4.11 E-07 S.72E-06 1.20E-04 1.B7E-OS TE127 1.7SE-10 B.03E-11 3.B7E-11 1.32E-10 6.37E-10 B.14E-07 7.17E-06 TE129M 1.22E-06 S.B4E-07 1.9BE-07 4.30E-07 4.S7E-06 1.4SE-04 4.79E-OS TE129 6.22E-12 2.99E-12 1.SSE-12 4.B7E-12 2.34E-11 2.42E-07 1.96E-OB TE131M B.74E-09 S.4SE-09 3.63E-09 6.BBE-09 3.B6E-OB 1.B2E-OS 6.9SE-OS TE131 1.39E-12 7.44E-13 4.49E-13 1.17E-12 S.46E-12 1.74E-07 2.30E-09 TE132 3.2SE-OB 2.69E-OB 2.02E-OB 2.37E-OB 1.B2E-07 3.60E-OS 6.37E-OS TE133M 7.24E-12 S.40E-12 4.17E-12 6.27E-12 3.74E-11 S.S1 E-07 S.49E-OB TE134 3.B4E-12 3.22E-12 1.S7E-12 3.44E-12 2.1BE-11 4.343-07 2.97E-11 1129 2.4BE-06 2.11 E-06 6.91 E-06 S.S4E-03 4.S3E-06 O.
2.22E-07 1130 S.72E-07 1.6BE-06 6.60E-07 1.42E-04 2.61 E-06 O.
9.61 E-07 1131 3.1SE-06 4.47E-06 2.S6E-06 1.49E-03 7.66E-06 O.
7.BSE-07
INHALATION DOSE COMMITMENT FACTORS Proc No ODeM Revision 26 Page 15 of 16 ADUL T INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 1.45E-07 4.07E-07 1.45E-07 1.43E-05 6.4BE-07
- o.
5.OBE-OB 1133 1.0BE-06 1.B5E-06 5.65E-07 2.69E-04 3.23E-06
- o.
1.11 E-06 1134 8.05E-OB 2.16E-07 7.69E-OB 3.73E-06 3.44E-07
- o.
1.26E-10 1135 3.35E-07 B.73E-07 3.21 E-07 5.60E-05 1.39E-06
- o.
6.56E-07 XE131M
- o.
- o.
- o.
- o.
- o.
1.40E-09
- o.
XE133M
- o.
- o.
- o.
- o.
- o.
1.B9E-09
- o.
XE133
- o.
- o.
- o.
- o.
- o.
1.57E-09
- o.
XE135M
- o.
O.
- o.
- o.
- o.
2.22E-09
- o.
XE135
- o.
- o.
- o.
- o.
O.
4.05E-09
- o.
XE137
- o.
- o.
- o.
- o.
- o.
1.74E-OB
- o.
XE13B
- o.
- o.
- o.
- o.
- o.
2.44E-OB
- o.
CS134M 1.59E-OB 3.20E-OB 1.72E-OB
- o.
1.B3E-OB 2.93E-09 7.92E-09 CS134 4.66E-05 1.06E-04 9.10E-05
- o.
3.59E-05 1.22E-05 1.30E-06 CS135 1.46E-05 1.29E-05 5.99E-06
- o.
5.11 E-06 1.57E-06 2.11 E-07 CS136 4.BBE-06 1.B3E-05 1.3BE-05
- o.
1.07E-05 1.50E-06 1.46E-06 CS137 5.9BE-05 7.76E-05 5.35E-05
- o.
2.7BE-05 9.40E-06 1.D5E-06 CS13B 4.14E-OB 7.76E-OB 4.05E-OB
- o.
6.00E-OB 6.07E-09 2.33E-13 CS139 2.56E-OB 3.63E-OB 1.39E-OB
- o.
3.05E-OB 2.B4E-09 5.49E-31 BA139 1.17E-10 B.32E-14 3.42E-12
- o.
7.7BE-14 4.70E-07 1.12E-07 BA140 4.BBE-06 6.13E-09 3.21 E-07
- o.
2.09E-09 1.59E-04 2.73E-05 BA141 1.25E-11 9.41E-15 4.20E-13
- o.
B.75E-15 2.42E-07 1.45E-17 BA142 3.29E-12 3.3BE-15 2.07E-13
- o.
2.B6E-15 1.49E-07 1.96E-26 LA140 4.30E-OB 2.17E-OB 5.73E-09
- o.
- o.
1.70E-05 5.73E-05 LA141 5.34E-10 1.66E-10 2.71E-11
- o.
- o.
1.35E-06 7.31 E-06 LA142 B.54E-11 3.BBE-11 9.65E-12
- o.
- o.
7.91 E-07 2.64E-07 CE141 2.49E-06 1.69E-06 1.91 E-07
- o.
7.B3E-07 4.52E-05 1.50E-05 CE143 2.33E-OB 1.72E-OB 1.91 E-09
- o.
7.60E-09 9.97E-06 2.B3E-05 CE144 4.29E-04 1.79E-04 2.30E-05
- o.
1.06E-04 9.72E-04 1.02E-04 PR143 1.17E-06 4.69E-07 5.BOE-OB
- o.
2.70E-07 3.51 E-05 2.50E-05 PR144 3.76E-12 1.56E-12 1.91E-13
- o.
B.B1 E-13 1.27E-07 2.69E-1B ND147 6.59E-07 7.62E-07 4.56E-OB
- o.
4.45E-07 2.76E-05 2.16E-05 PM147 B.37E-05 7.B7E-06 3.19E-06 O.
1.49E-05 6.60E-05 5.54E-06 PM14BM 9.B2E-06 2.54E-06 1.94E-06
- o.
3.B5E-06 2.14E-04 4.1BE-05 PM14B 3.B4E-07 6.37E-OB 3.20E-OB
- o.
1.20E-07 3.91 E-05 5.BOE-05 PM149 3.44E-OB 4.B7E-09 1.99E-09
- o.
9.19E-09 7.21 E-06 2.50E-05 PM151 B.50E-09 1.42E-09 7.21E-10 O.
2.55E-09 3.94E-06 2.00E-05 SM151 B.59E-05 1.4BE-05 3.55E-06
- o.
1.66E-05 4.45E-05 3.25E-06 SM153 1.70E-OB 1.42E-OB 1.04E-09
- o.
4.59E-09 4.14E-06 1.5BE-05 EU152 2.3BE-04 5.41 E-05 4.76E-05
- o.
3.35E-04 3.43E-04 1.59E-05 EU154 7.40E-04 9.1 DE-05 6.4BE-05
- o.
4.36E-04 5.B4E-04 3.40E-05 EU155 1.01 E-04 1.43E-05 9.21 E-06
- o.
6.59E-05 9.46E-05 5.95E-06 EU156 1.93E-06 1.4BE-06 2.40E-07
- o.
9.95E-07 B.56E-05 4.50E-05 TB160 2.21 E-05
- o.
2.75E-06
- o.
9.10E-06 1.92E-04 2.6BE-05 H0166M 3.37E-04 1.05E-04 B.00E-05
- o.
1.57E-04 3.94E-04 1.59E-05 W1B1 6.23E-09 2.03E-09 2.17E-10
- o.
- o.
1.71 E-06 2.53E-07 W1B5 1.95E-07 6.47E-OB 6.B1 E-09
- o.
- o.
5.57E-05 1.07E-05 W1B7 1.06E-09 B.B5E-10 3.10E-10 O.
- o.
3.63E-06 1.94E-05
INHALATION DOSE COMMITMENT FACTORS Proc No ODCM Revision 26 Page 16 of 16 ADUL T INHALATION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINHALED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 2.64E-02 6.73E-03 B.37E-04
- o.
2.12E-02 2.62E-02 3.6SE-OS BI210
- o.
1.S9E-06 1.32E-07
- o.
1.92E-OS 1.11 E-03 2.9SE-OS P0210 3.97E-04 B.60E-04 9.SBE-OS
- o.
2.9SE-03 3.14E-02 4.19E-OS RN222
- o.
- o.
- o.
- o.
- o.
2.0SE-06
- o.
RA223 1.BOE-04 2.77E-07 3.60E-OS
- o.
7.BSE-06 2.SSE-02 2.B4E-04 RA224 1.9BE-OS 4.7BE-OB 3.96E-06
- o.
1.3SE-06 B.77E-03 3.01 E-04 RA22S 3.00E-04 3.S6E-07 S.99E-OS
- o.
1.01 E-OS 2.92E-02 2.71 E-04 RA226 1.2SE-01 2.39E-06 9.14E-02
- o.
6.77E-OS 1.17E-01 2.94E-04 RA22B 4.41 E-02 1.23E-06 4.7BE-02
- o.
3.4BE-OS 1.61 E-01 S.OOE-OS AC22S 4.23E-04 S.B2E-04 2.B4E-OS O.
6.63E-OS 2.21 E-02 2.S2E-04 AC227 2.30E+00 3.0SE-01 1.36E-01
- o.
9.B2E-02 2.41 E-01 S.OBE-OS TH227 2.17E-04 3.92E-06 6.2SE-06
- o.
2.22E-OS 3.77E-02 3.34E-04 TH226 2.00E-01 3.39E-03 6.77E-03
- o.
1.B9E-02 1.01 E+OO 3.49E-04 TH229 B.BBE+OO 1.33E-01 4.36E-01
- o.
6.S2E-01 3.49E+00 3.17E-04 TH230 2.29E+00 1.31 E-01 6.36E-02
- o.
6.40E-01 6.21 E-01 3.73E-OS TH232 2.S6E+00 1.12E-01 9.04E-02
- o.
S.47E-01 S.96E-01 3.17E-OS TH234 1.63E-06 9.S6E-OB 4.70E-OB
- o.
S.41 E-07 1.B9E-04 7.03E-OS PA231 S.OBE+OO 1.91 E-01 1.9BE-01
- o.
1.07E+00 S.7SE-02 4.44E-OS PA233 1.21 E-06 2.42E-07 2.09E-07
- o.
9.1SE-07 3.S2E-OS 1.02E-OS U232 S.14E-02
- o.
3.66E-03
- o.
S.S6E-03 2.22E-01 4.21 E-OS U233 1.09E-02
- o.
6.60E-04 O.
2.S4E-03 S.32E-02 3.B9E-OS U234 1.04E-02
- o.
6.46E-04
- o.
2.49E-03 S.22E-02 3.B1 E-OS U23S 1.00E-02
- o.
6.07E-04
- o.
2.34E-03 4.90E-02 4.B4E-OS U236 1.00E-02
- o.
6.20E-04
- o.
2.39E-03 S.00E-02 3.S7E-OS U237 3.67E-OB
- o.
9.77E-09
- o.
1.S1 E-07 1.02E-OS 1.20E-OS U23B 9.SBE-03
- o.
S.67E-04 O.
2.1BE-03 4.SBE-02 3.41 E-OS NP237 1.69E+00 1.47E-01 6.B7E-02
- o.
S.10E-01 S.22E-02 4.92E-OS NP23B 2.96E-07 B.00E-09 4.61 E-09
- o.
2.72E-OB 1.02E-OS 2.13E-OS NP239 2.B7E-OB 2.B2E-09 1.SSE-09
- o.
B.7SE-09 4.70E-06 1.49E-OS PU23B 2.74E+00 3.B7E-01 6.90E-02
- o.
2.96E-01 1.B2E-01 4.S2E-OS PU239 3.19E+00 4.31 E-01 7.7SE-02 O.
3.30E-01 1.72E-01 4.13E-OS PU240 3.1BE+00 4.30E-01 7.73E-02 O.
3.29E-01 1.72E-01 4.21 E-OS PU241 6.41 E-02 3.2BE-03 1.29E-03
- o.
S.93E-03 1.S2E-04 B.6SE-07 PU242 2.9SE+00 4.1SE-01 7.46E-02
- o.
3.17E-01 1.6SE-01 4.0SE-OS PU244 3.4SE+00 4.76E-01 B.S4E-02
- o.
3.64E-01 1.B9E-01 6.03E-OS AM241 1.01 E+OO 3.S9E-01 6.71 E-02 O.
S.04E-01 6.06E-02 4.60E-OS AM242M 1.02E+00 3.46E-01 6.73E-02
- o.
S.01 E-01 2.44E-02 S.79E-OS AM243 1.01 E+OO 3.47E-01 6.S7E-02
- o.
4.9SE-01 S.7SE-02 S.40E-OS CM242 1.4BE-02 1.S1 E-02 9.B4E-04
- o.
4.4BE-03 3.92E-02 4.91 E-OS CM243 7.B6E-01 2.97E-01 4.61 E-02 O.
2.1SE-01 6.31 E-02 4.B4E-OS CM244 S.90E-01 2.S4E-01 3.S1 E-02 O.
1.64E-01 6.06E-02 4.6BE-OS CM24S 1.26E+00 3.S9E-01 7.14E-02
- o.
3.33E-01 S.BSE-02 4.36E-OS CM246 1.2SE+00 3.S9E-01 7.13E-02
- o.
3.33E-01 S.96E-02 4.29E-OS CM247 1.22E+00 3.S3E-01 7.03E-02
- o.
3.2BE-01 S.BSE-02 S.63E-OS CM24B 1.01 E+01 2.91 E+OO S.79E-01
- o.
2.70E+00 4.B2E-01 9.09E-04 CF2S2 9.7BE-01
- o.
2.33E-02
- o.
- o.
1.99E-01 1.7BE-04
Proc No aDeM Revision 26 Page 1 of2 EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (DFG,l (mrem/hr per pCi/m2)
ELEMENT TOTAL BODY SKIN H-3 0.0 0.0 C-14 0.0 0.0 Na-24 2.50E-08 2.90E-08 P-32 0.0 0.0 Cr-51 2.20E-10 2.60E-10 Mn-54 5.80E-09 6.80E-09 Mn-56 1.10E-08 1.30E-08 Fe-55 0.0 0.0 Fe-59 8.00E-09 9.40E-09 Co-58 7.00E-09 8.20E-09 Co-60 1.70E-08 2.00E-08 Ni-63 0.0 0.0 Ni-65 3.70E-09 4.30E-09 Cu-64 1.50E-09 1.70E-09 Zn-65 4.00E-09 4.60E-09 Zn-69 0.0 0.0 Br-83 6.40E-11 9.30E-11 Br-84 1.20E-08 1.40E-08 Br-85 0.0 0.0 Rb-86 6.30E-10 7.20E-10 Rb-88 3.50E-09 4.00E-09 Rb-89 1.50E-08 1.80E-08 Sr-89 5.60E-13 6.50E-13 Sr-91 7.10E-09 8.30E-09 Sr-92 9.00E-09 1.00E-08 Y-90 2.20E-12 2.60E-12 Y-91m 3.80E-09 4.40E-09 Y-91 2.40E-11 2.70E-11 Y-92 1.60E-09 1.90E-09 Y-93 5.70E-10 7.80E-10 Zr-95 5.00E-09 5.80E-09 Zr-97 5.50E-09 6.40E-09 Nb-95 5.10E-09 6.00E-09 Mo-99 1.90E-09 2.20E-09 Tc-99m 9.60E-10 1.10E-09 Tc-101 2.70E-09 3.00E-09
Proc No ODeM Revision 26 Page 2 of2 EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND (DFG,l (mrem/hr per pCi/m2)
ELEMENT TOTAL BODY SKIN Ru-103 3.60E-09 4.20E-09 Ru-105 4.50E-09 5.10E-09 Ru-106 1.50E-09 1.BOE-09 Ag-110m 1.BOE-OB 2.10E-OB Te-125m 3.50E-11 4.BOE-11 Te-127m 1.10E-12 1.30E-12 Te-127 1.00E-11 1.10E-11 Te-129m 7.70E-10 9.00E-10 Te-129 7.10E-10 B.40E-10 Te-131m B.40E-09 9.90E-09 Te-131 2.20E-09 2.60E-06 Te-132 1.70E-09 2.00E-09 1-130 1.40E-OB 1.70E-OB 1-131 2.BOE-09 3.40E-09 1-132 1.70E-OB 2.00E-OB 1-133 3.70E-09 4.50E-09 1-134 1.60E-OB 1.90E-OB 1-135 1.20E-OB 1.40E-OB Cs-134 1.20E-OB 1.40E-OB Cs-136 1.50E-OB 1.70E-OB Cs-137 4.20E-09 4.90E-09 Cs-13B 2.10E-OB 2.40E-OB Ba-139 2.40E-09 2.70E-09 Ba-140
- 2. 1 OE-09 2.40E-09 Ba-141 4.30E-09 4.90E-09 Ba-142 7.90E-09 9.00E-09 La-140 1.50E-OB 1.70E-OB La-142 1.50E-OB 1.BOE-OB Ce-141 5.50E-10 6.20E-10 Ce-143 2.20E-09 2.50E-09 Ce-144 3.20E-10 3.70E-10 Pr-143 0.0 0.0 Pr-144 2.00E-10 2.30E-10 Nd-147 1.00E-09 1.20E-09 W-1B7 3.10E-09 3.60E-09 Np-239 9.50E-10 1.10E-09
ELEMENT H
C NA P
CR MN FE CO NI CU ZN BR RB SR Y
NP BIOACCUMULATION FACTORS uCi/gm per uCi/ml Proc No aDeM Revision 26 Page 1 of 1 FRESHWATER FISH 9.0E-01 4.6E 03 1.0E 02 1.0E OS 2.0E 02 4.0E 02 1.0E 02 S.OE 01 1.0E 02 S.OE 01 2.0E 03 4.2E 02 2.0E 03 3.0E 01 2.SE 01 3.3E 00 3.0E 04 1.0E 01 1.SE 01 1.0E 01 1.0E 01 4.0E 02 1.SE 01 2.0E 03 4.0E 00 2.SE 01 1.0E 00 2.SE 01 2.SE 01 1.2E 03 1.0E 01
Proc No ODCM Revision 26 Page 1 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3
- o.
3.0BE-07 3.0BE-07 3.0BE-07 3.0BE-07 3.0BE-07 3.0B3-07 BE10 1.71 E-OS 2.49E-06 S.16E-07 O.
1.64E-06 O.
2.7BE-OS C14 2.37E-OS S.06E-06 S.06E-06 S.06E-06 S.06E-06 S.06E-06 S.06E-06 N13 S.BSE-OB S.BSE-OB S.BSE-OB S.B3SE-OB S.BSE-OB S.BSE-OB S.BSE-OB F1B S.19E-06 O.
4.43E.07 O.
O.
O.
1.22E-06 NA22 9.B3E-OS 9.B3E-OS 9.B3E-OS 9.B3E-OS 9.B3E-OS 9.B3E-OS 9.B3E-OS NA24 1.01 E-OS 1.01 E-OS 1.01 E-OS 1.01 E-OS 1.01 E-OS 1.01 E-OS 1.01 E-OS P32 1.70E-03 1.00E-04 6.S9E-OS O.
- o.
O.
2.30E-OS AR39 O.
O.
O.
O.
O.
- o.
O.
AR41 O.
O.
- o.
O.
- o.
O.
O.
CA41 3.74E-04 O.
4.0BE-OS
- o.
O.
- o.
1.91 E-07 SC46 3.7SE-OB S.41 E-OB 1.69E-OB O.
3.S6E-OB O.
3.S3E-OS CRS1 O.
O.
1.41 E-OB 9.20E-09 2.01 E-09 1.79E-OB 4.11 E-07 MNS4 O.
1.99E-OS 4.S1 E-06 O.
4.41 E-06
- o.
7.31 E-06 MNS6
- o.
B.1BE-07 1.41 E-07 O.
7.03E-07 O.
7.43E-OS FESS 1.39E-OS B.9BE-06 2.40E-06 O.
O.
4.39E-06 1.14E-06 FES9 3.0BE-OS S.3BE-OS 2.12E-OS O.
- o.
1.S9E-OS 2.S7E-OS COS7 O.
1.1SE-06 1.B7E-06 O.
O.
- o.
3.92E-06 COSB O.
3.60E-06 B.9BE-06 O.
- o.
O.
B.97E-06 C060
- o.
1.0BE-OS 2.SSE-OS O.
O.
O.
2.S7E-OS NIS9 4.7BE-OS 1.4SE-OS B.17E-06 O.
- o.
O.
7.16E-07 NI63 6.34E-04 3.92E-OS 2.20E-OS O.
O.
O.
1.9SE-06 NI6S 4.70E-06 S.32E-07 2.42E-07
- o.
O.
- o.
4.0SE-OS CU64
- o.
6.09E-07 2.B2E-07 O.
1.03E-06 O.
1.2SE-OS ZN6S 1.B4E-OS 6.31 E-OS 2.91 E-OS
- o.
3.06E-OS O.
S.33E-OS ZN69M 1.S0E-06 3.06E-06 2.79E-07 O.
1.24E-06 O.
4.24E-OS ZN69 9.33E-OB 1.6BE-07 1.2SE-OB O.
6.9BE-OB O.
1.37E-OS SE79 O.
2.10E-OS 3.90E-06 O.
2.43E-OS
- o.
S.SBE-07 BRB2 O.
O.
1.27E-OS O.
- o.
O.
- o.
BRB3
- o.
- o.
3.63E-07
- o.
O.
- o.
O.
BRB4 O.
O.
3.B2E-07 O.
O.
O.
O.
BRBS
- o.
O.
1.94E-OB O.
O.
O.
O.
KRB3M
- o.
O.
O.
- o.
O.
O.
O.
KRBSM O.
- o.
O.
O.
O.
- o.
O.
KRBS O.
O.
- o.
O.
- o.
O.
- o.
KRB7
- o.
O.
- o.
O.
- o.
O.
- o.
KRBB
- o.
- o.
O.
O.
O.
- o.
O.
KRB9 O.
- o.
O.
O.
O.
- o.
O.
RBB6 O.
1.70E-04 B.40E-OS O.
O.
- o.
4.3SE-06 RBB7 O.
B.BBE-OS 3.S2E-OS O.
O.
O.
S.9BE-07 RBBB O.
4.9BE-07 2.73E-07 O.
O.
O.
4.BSE-07 RBB9 O.
2.B6E-07 1.97E-07 O.
O.
O.
9.74E-OB SRB9 2.S1 E-03
- o.
7.20E-OS O.
O.
O.
S.16E-OS SR90 1.BSE-02 O.
4.71 E-03 O.
O.
O.
2.31 E-04 SR91 S.OOE-OS O.
1.B1 E-06 O.
O.
- o.
S.92E-OS SR92 1.92E-OS O.
7.13E-07 O.
O.
- o.
2.07E-04
Proc No ODCM Revision 26 Page 2 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 B.69E-OB O.
2.33E-09 O.
O.
O.
1.20E-04 Y91M B.10E-10 O.
2.76E-11 O.
O.
- o.
2.70E-06 Y91 1.13E-06 O.
3.01 E-OB O.
- o.
O.
B.10E-OS Y92 7.6SE-09 O.
2.1SE-10 O.
O.
- o.
1.46E-04 Y93 2.43E-OB
- o.
6.62E-10 O.
O.
- o.
1.92E-04 ZR93 1.93E-07 9.1BE-OB S.S4E-OB O.
2.71 E-07 O.
2.39E-OS ZR9S 2.06E-07 S.02E-OB 3.S6E-OB O.
S.41 E-OB O.
2.S0E-OS ZR97 1.4BE-OB 2.S4E-09 1.16E-09 O.
2.S6E-09 O.
1.62E-04 NB93M 1.23E-07 3.33E-OB 1.04E-OB O.
3.2SE-OB O.
3.9BE-06 NB9S 4.20E-OB 1.73E-OB 1.00E-OB O.
1.24E-OB O.
1.46E-OS NB97 4.S9E-10 9.79E-11 3.S3E-11 O.
7.6SE-11 O.
3.09E-OS M093 O.
S.6SE-OS 1.B2E-06 O.
1.13E-OS O.
1.21 E-06 M099 O.
3.40E-OS 6.63E-06 O.
S.OBE-OS O.
1.12E-OS TC99M 1.92E-09 3.96E-09 S.10E-OB O.
4.26E-OB 2.07E-09 1.1SE-06 TC99 1.0BE-06 1.46E-06 4.SSE-07 O.
1.23E-OS 1.42E-07 6.31 E-06 TC101 2.27E-09 2.B6E-09 2.B3E-OB
- o.
3.40E-OB 1.S6E-09 4.B6E-07 RU103 1.4BE-06
- o.
4.9SE-07 O.
3.0BE-06 O.
1.BOE-OS RU10S 1.36E-07 O.
4.SBE-OB
- o.
1.00E-06 O.
S.41 E-OS RU106 2.41 E-OS O.
3.01 E-06 O.
2.BSE-OS O.
1.B3E-04 RH10S 1.09E-06 7.13E-07 4.79E-07
- o.
1.9BE-06 O.
1.77E-OS PD107 O.
1.19E-06 B.4SE-OB O.
6.79E-06 O.
9.46E-07 PD109 O.
1.S0E-06 3.62E-07 O.
S.S1 E-06 O.
3.6BE-OS AG110M 9.96E-07 7.27E-07 4.B1 E-07 O.
1.04E-06
- o.
3.77E-OS AG111 S.20E-07 2.02E-07 1.07E-07 O.
4.22E-07 O.
4.B2E-OS CD113M O.
1.77E-OS 6.S2E-07 O.
1.34E-OS
- o.
2.66E-OS CD11SM O.
1.42E-OS 4.93E-07 O.
7.41 E-06 O.
B.09E-OS SN123 2.49E-04 3.B9E-06 6.S0E-06 3.91 E-06 O.
O.
6.SBE-OS SN12S 7.41 E-OS 1.3BE-06 3.29E-06 1.36E-06 O.
O.
1.11 E-04 SN126 S.S3E-04 7.26E-06 1.BOE-OS 1.91 E-06 O.
O.
2.S2E-OS SB124 2.14E-OS 3.1SE-07 6.63E-06 S.6BE-OB O.
1.34E-OS 6.60E-OS SB12S 1.23E-OS 1.19E-07 2.S3E-06 1.S4E-OB O.
7.72E-06 1.64E-OS SB126 B.06E-06 1.SBE-07 2.91 E-06 6.19E-OB O.
S.07E-06 B.3SE-OS SB127 2.23E-06 3.9BE-OB 6.90E-07 2.B4E-OB O.
1.1SE-06 S.91 E-OS TE12SM 2.33E-OS 7.79E-06 3.1SE-06 7.B4E-06 O.
O.
1.11 E-OS TE127M S.BSE-OS 1.94E-OS 7.0BE-06 1.69E-OS 1.44E-04 O.
2.36E-OS TE127 1.00E-06 3.3SE-07 2.1SE-07 B.14E-07 2.44E-06 O.
2.10E-OS TE129M 1.00E-04 3.43E-OS 1.S4E-OS 3.B4E-OS 2.S0E-04 O.
S.97E-OS TE129 2.B4E-07 9.79E-OB 6.63E-OB 2.3BE-07 7.07E-07 O.
2.27E-OS TE131M 1.S2E-OS 6.12E-06 S.OSE-06 1.24E-OS 4.21 E-OS O.
1.03E-04 TE131 1.76E-07 6.S0E-OB 4.94E-OB 1.S7E-07 4.S0E-07 O.
7.11 E-06 TE132 2.0BE-OS 1.03E-OS 9.61 E-06 1.S2E-OS 6.44E-OS O.
3.B1 E-OS TE133M 3.91 E-07 1.79E-07 1.71 E-07 3.4SE-07 1.22E-06 O.
1.93E-OS TE134 2.67E-07 1.34E-07 1.3BE-07 2.39E-07 9.03E-07 O.
3.06E-06 1129 2.B6E-OS 2.12E-OS 1.SSE-OS 1.36E-02 2.S1 E-OS O.
4.24E-07 1130 6.00E-06 1.32E-OS S.30E-06 1.4BE-03 1.4SE-OS O.
2.B3E-06 1131 3.S9E-OS 4.23E-OS 1.B6E-OS 1.39E-02 4.94E-OS O.
1.S1 E-06
Proc No ODeM Revision 26 Page 3 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI*LLI 1132 1.66E-06 3.37E-06 1.20E-06 1.SBE-04 3.76E-06 O.
2.73E.06 1133 1.2SE-OS 1.B2E-OS S.33E-06 3.31 E-03 2.14E-OS O.
3.OBE-06 1134 B.69E-07 1.7BE-06 6.33E-07 4.1SE-OS 1.99E-06 O.
1.B4E-06 113S 3.64E-06 7.24E-06 2.64E-06 6.49E-04 B.07E-06 O.
2.62E-06 XE131M O.
O.
O.
O.
O.
O.
O.
XE133M O.
O.
O.
O.
O.
O.
O.
XE133 O.
O.
O.
O.
O.
O.
O.
XE13SM O.
O.
O.
O.
O.
O.
O.
XE13S O.
O.
O.
O.
O.
O.
O.
XE137 O.
O.
O.
O.
O.
O.
O.
XE13B O.
O.
O.
O.
O.
O.
O.
CS134M 1.76E-07 2.93E-07 1.4BE-07 O.
1.13E-07 2.60E-OB 2.32E-07 CS134 3.77E-04 7.03E-04 7.10E-OS O.
1.B1 E-04 7.42E-OS 1.91 E-06 CS13S 1.33E-04 1.21 E-04 6.30E-06 O.
3.44E-OS 1.31 E-OS 4.37E-07 CS136 4.S9E-OS 1.3SE-04 S.04E-OS O.
S.3BE-OS 1.10E-OS 2.0SE-06 CS137 S.22E-04 6.11 E-04 4.33E-OS O.
1.64E-04 6.64E-OS 1.91 E-06 CS13B 4.B1 E-07 7.B2E-07 3.79E-07 O.
3.90E-07 6.09E-OB 1.2SE-06 CS139 3.10E-07 4.24E-07 1.62E-07 O.
2.19E-07 3.30E-OB 2.66E-OB BA139 B.B1 E-07 S.B4E-10 2.SSE-OB O.
3.S1E-10 3.S4E-10 S.SBE-OS BA140 1.71 E-04 1.71 E-07 B.B1 E-06 O.
4.06E-OB 1.0SE-07 4.20E-OS BA141 4.2SE-07 2.91E-10 1.34E-OB O.
1.7SE-10 1.77E-10 S.19E-06 BA142 1.B4E-07 1.S3E-10 9.06E-09 O.
B.B1 E-11 9.26E-11 7.S9E-07 LA140 2.11E-OB B.32E-09 2.14E-09 O.
O.
O.
9.77E-OS LA141 2.B9E-09 B.3BE-10 1.46E-10 O.
O.
O.
9.61 E-OS LA142 1.10E-09 4.04E-10 9.67E-11 O.
O.
O.
6.B6E-OS CE141 7.B7E-OB 4.BOE-OB S.6SE-09 O.
1.4BE-OB O.
2.4BE-OS CE143 1.4BE-OB 9.B2E-06 1.12E-09 O.
2.B6E-09 O.
S.73E-OS CE144 2.9BE-06 1.22E-06 1.67E-07 O.
4.93E-07 O.
1.71 E-04 PR143 B.1BE-OB 3.04E-OB 4.03E-09 O.
1.13E-OB O.
4.29E-OS PR144 2.74E-10 1.06E-10 1.3BE-11 O.
3.B4E-11 O.
4.93E-06 ND147 S.S3E-OB S.6BE-OB 3.4BE-09 O.
2.19E-OB O.
3.60E-OS PM147 3.BBE-07 3.27E-OB 1.S9E-OB O.
4.BBE-OB O.
9.27E-06 PM14BM 1.6SE-07 4.1BE-OB 3.2BE-OB O.
4.BOE-OB O.
S.443-0S PM14B 6.32E-OB 9.13E-09 4.60E-09 O.
1.09E-OB O.
9.74E-OS PM149 1.3BE-OB 1.B1 E-09 7.90E-10 O.
2.20E-09 O.
4.B6E-OS PM1S1 6.1BE-09 9.01 E-10 4.S6E-10 O.
1.07E-09 O.
4.17E-OS SM1S1 2.90E-07 6.67E-OB 1.44E-OB O.
4.S3E-OB O.
S.SBE-06 SM1S3 7.72E-09 S.97E-09 4.SBE-10 O.
1.2SE-09 O.
3.12E-OS EU1S2 6.74E-07 1.79E-07 1.S1 E-07 O.
S.02E-07 O.
1.S9E-OS EU1S4 2.64E-06 3.67E-07 2.20E-07 O.
9.9SE-07 O.
4.SBE-OS EU1SS S.42E-07 6.2SE-OB 3.23E-OB O.
1.40E-07 O.
B.37E-OS EU1S6 1.14E-07 7.06E-OB 1.12E-OB O.
3.26E-OB O.
6.67E-OS TB160 2.S9E-07 O.
3.24E-OB O.
7.37E-OB O.
3.4SE-OS H0166M 1.2SE-06 2.69E-07 2.13E-07 O.
3.S7E-07 O.
O.
W1B1 B.BSE-OB 2.72E-OB 3.04E-09 O.
O.
O.
3.B2E-07 W1BS 3.62E-06 1.13E-06 1.29E-07 O.
O.
O.
1.62E-OS W1B7 9.03E-07 6.2BE-07 2.17E-07 O.
O.
O.
3.69E-OS
Proc No ODCM Revision 26 Page 4 of 16 INGESTION DOSE COMMITMENT FACTORS INFANT INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 S.28E-02 1.42E-02 2.38E-03 O.
4.33E-02 O.
S.62E-OS BI210 4.16E-06 2.68E-OS 3.S8E-07 O.
2.08E-04 O.
S.27E-OS P0210 3.10E-03 S.93E-03 7.41 E-04 O.
1.26E-02 O.
6.61 E-OS RN222 O.
O.
O.
O.
O.
- o.
O.
RA223 4.41 E-02 6.42E-OS 8.82E-03 O.
1.17E-03 O.
3.43E-04 RA224 1.46E-02 3.29E-OS 2.91 E-03 O.
6.00E-04 O.
3.86E-04 RA22S S.78E-02 6.42E-OS 1.1SE-02 O.
1.19E-03 O.
3.24E-04 RA226 6.20E-01 4.76E-OS S.14E-01 O.
8.71 E-04 O.
3.44E-04 RA228 4.32E-01 2.S8E-OS 4.86E-01 O.
4.73E-04 O.
S.86E-OS AC22S 3.92E-OS S.03E-OS 2.63E-06 O.
3.69E-06 O.
4.36E-04 AC227 4.49E-03 7.67E-04 2.79E-04 O.
1.S6E-04 O.
8.S0E-OS TH227 1.20E-04 2.01 E-06 3.4SE-06 O.
7.41 E-06 O.
S.70E-04 TH228 2.47E-03 3.38E-OS 8.36E-OS O.
1.S8E-04 O.
S.84E-04 TH229 1.48E-02 1.94E-04 7.29E-04 O.
9.29E-04 O.
S.31 E-04 TH230 3.80E-03 1.90E-04 1.06E-04 O.
9.12E-04 O.
6.24E-OS TH232 4.24E-03 1.63E-04 1.6SE-04 O.
7.79E-04 O.
S.31 E-OS TH234 6.92E-07 3.77E-08 2.00E-08 O.
1.39E-07 O.
1.19E-04 PA231 7.S7E-03 2.S0E-04 3.02E-04 O.
1.34E-03 O.
7.44E-OS PA233 3.11 E-08 6.09E-09 S.43E-09 O.
1.67E-08 O.
1.46E-OS U232 2.42E-02 O.
2.16E-03 O.
2.37E-03 O.
7.04E-OS U233 S.08E-03 O.
3.87E-04 O.
1.08E-03 O.
6.S1 E-OS U234 4.88E-03 O.
3.80E-04 O.
1.06E-03 O.
6.37E-OS U23S 4.67E-03 O.
3.S6E-04 O.
9.93E-04 O.
8.10E-OS U236 4.67E-03 O.
3.64E-04 O.
1.01 E-03 O.
S.98E-OS U237 4.9SE-07 O.
1.32E-07 O.
1.23E-06 O.
2.11 E-OS U238 4.47E-03 O.
3.33E-04 O.
9.28E-04 O.
S.71 E-OS NP237 2.S3E-03 1.93E-04 1.0SE-04 O.
6.34E-04 O.
8.23E-OS NP238 1.24E-07 3.12E-09 1.92E-09 O.
6.81 E-09 O.
4.17E-OS NP239 1.11 E-08 9.93E-10 S.61 E-1 0 O.
1.98E-09 O.
2.87E-OS PU238 1.34E-03 1.69E-04 3.40E-OS O.
1.21 E-04 O.
7.S7E-OS PU239 1.4SE-03 1.77E-04 3.S4E-OS O.
1.28E-04 O.
6.91 E-OS PU240 1.4SE-03 1.77E-04 3.S4E-OS O.
1.28E-04 O.
7.04E-OS PU241 4.38E-OS 1.90E-06 8.82E-07 O.
3.17E-06 O.
1.4SE-06 PU242 1.3SE-03 1.70E-04 3.41 E-OS O.
1.23E-04 O.
6.77E-OS PU244 1.S7E-03 1.9SE-04 3.91 E-OS O.
1.41 E-04 O.
1.01 E-04 AM241 1.S3E-03 7.18E-04 1.09E-04 O.
6.SSE-04 O.
7.70E-OS AM242M 1.S8E-03 7.02E-04 1.13E-04 O.
6.64E-04 O.
9.69E-OS AM243 1.S1 E-03 6.88E-04 1.06E-04 O.
6.36E-04 O.
9.03E-OS CM242 1.37E-04 1.24E-04 9.10E-06 O.
2.62E-OS O.
8.23E-OS CM243 1.4SE-03 6.88E-04 8.98E-OS O.
3.27E-04 O.
8.10E-OS CM244 1.22E-03 6.16E-04 7.S9E-OS O.
2.71E-04 O.
7.84E-OS CM24S 1.88E-03 7.49E-04 1.13E-04 O.
4.32E-04 O.
7.30E-OS CM246 1.87E-03 7.49E-04 1.13E-04 O.
4.31E-04 O.
7.17E-OS CM247 1.82E-03 7.36E-04 1.11 E-04 O.
4.24E-04 O.
9.43E-OS CM248 1.S1 E-02 6.07E-03 9.16E-04 O.
3.S0E-03 O.
1.S2E-03 CF2S2 1.24E-03 O.
2.9SE-OS 0
O.
O.
2.99E-04
Proc No ODCM Revision 26 Page 5 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 O.
2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 BE10 1.3SE-OS 1.S7E-06 3.39E-07 O.
1.11 E-06 O.
2.7SE-OS C14 1.21 E-OS 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 2.42E-06 N13 3.10E-OB 3.10E-OB 3.10E-OB 3.10E-OB 3.10E-OB 3.10E-OB 3.10E-OB F1B 2.49E-06 O.
2.47E-07 O.
O.
O.
6.74E-07 NA22 S.BBE-OS S.BBE-OS S.BBE-OS S.BBE-OS S.BBE-OS S.BBE-OS S.BBE-OS NA24 S.BOE-06 S.BOE-06 S.BOE-06 S.BOE-06 S.BOE-06 S.BOE-06 S.BOE-06 P32 B.2SE-04 3.B6E-OS 3.1BE-OS O.
O.
O.
2.2BE-OS AR39 O.
O.
O.
O.
O.
- o.
O.
AR41 O.
O.
- o.
O.
O.
O.
O.
CA41 3.47E-04 O.
3.79E-OS O.
O.
O.
1.90E-07 SC46 1.97E-OB 2.70E-OB 1.04E-OB O.
2.30E-OB O.
3.9SE-OS CRS1 O.
O.
B.90E-09 4.94E-09 1.3SE-09 9.02E-09 4.72E-07 MNS4 O.
1.07E-OS 2.BSE-06 O.
3.00E-06 O.
B.9BE-06 MNS6 O.
3.34E-07 7.S4E-OB O.
4.04E-07 O.
4.B4E-OS FESS 1.1SE-OS 6.10E-06 1.B9E-06 O.
O.
3.4SE-06 1.13E-06 FES9 1.6SE-OS 2.67E-OS 1.33E-OS O.
O.
7.74E-06 2.7BE-OS COS7 O.
4.93E-07 9.9BE-07 O.
O.
O.
4.04E-06 COSB O.
1.BOE-06 S.S1 E-06 O.
O.
O.
1.0SE-OS C060 O.
S.29E-06 1.S6E-OS O.
O.
O.
2.93E-OS NIS9 4.02E-OS 1.07E-OS 6.B2E-06 O.
O.
O.
7.10E-07 NI63 S.3BE-04 2.BBE-OS 1.B3E-OS O.
O.
O.
1.94E-06 NI6S 2.22E-06 2.09E-07 1.22E-07 O.
O.
O.
2.S6E-OS CU64 O.
2.4SE-07 1.4BE-07 O.
S.92E-07 O.
1.1SE-OS ZN6S 1.37E-OS 3.6SE-OS 2.27E-OS O.
2.30E-OS O.
6.41 E-06 ZN69M 7.10E-07 1.21 E-06 1.43E-07 O.
7.03E-07 O.
3.94E-OS ZN69 4.3BE-OB 6.33E-OB S.BSE-09 O.
3.B4E-OB O.
3.99E-06 SE79 O.
B.43E-06 1.B7E-06 O.
1.37E-OS O.
S.S3E-07 BRB2 O.
O.
7.SSE-06 O.
O.
O.
O.
BRB3 O.
O.
1.71 E-07 O.
O.
O.
O.
BRB4 O.
O.
1.9BE-07 O.
O.
O.
O.
BRBS 0
O.
9.12E-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
O.
O.
KRBSM O.
O.
O.
O.
O.
O.
O.
KRBS O.
O.
O.
O.
O.
O.
O.
KRB7 O.
O.
O.
O.
O.
O.
O.
KRBB O.
O.
O.
O.
O.
O.
O.
KRB9 O.
O.
O.
O.
O.
O.
O.
RBB6 O.
6.70E-OS 4.12E-OS O.
O.
O.
4.31 E-06 RBB7 O.
3.9SE-OS 1.B3E-OS O.
O.
O.
S.92E-07 RBBB O.
1.90E-07 1.32E-07 O.
O.
O.
9.32E-09 RBB9 O.
1.17E-07 1.04E-07 O.
O.
O.
1.02E-09 SRB9 1.32E-03 O.
3.77E-OS O.
O.
O.
S.11 E-OS SR90 1.70E-02 O.
4.31 E-03 O.
O.
O.
2.29E-04 SR91 2.40E-OS O.
9.06E-07 O.
O.
O.
S.30E-OS SR92 9.03E-06 O.
3.62E-07 O.
O.
O.
1.71 E-04
Proc No ODCM Revision 26 Page 6 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 4.11 E-OB O.
1.10E-09 O.
O.
O.
1.17E-04 Y91M 3.B2E-10 O.
1.39E-11 O.
O.
O.
7.4BE-07 Y91 6.02E-07 O.
1.61 E-OB O.
O.
O.
B.02E-OS Y92 3.60E-09 O.
1.03E-10 O.
O.
O.
1.04E-04 Y93 1.14E-OB O.
3.13E-10 O.
O.
O.
1.70E-04 ZR93 1.67E-07 6.2SE-OB 4.4SE-OB O.
2.42E-07 O.
2.37E-OS ZR9S 1.16E-07 2.SSE-OB 2.27E-OB O.
3.6SE-OB O.
2.66E-OS ZR97 6.99E-09 1.01 E-09 S.96E-10 O.
1.4SE-09 O.
1.S3E-04 NB93M 1.0SE-07 2.62E-OB B.61 E-09 O.
2.B3E-OB O.
3.9SE-06 NB9S 2.2SE-OB B.76E-09 6.26E-09 O.
B.23E-09 O.
1.62E-OS NB97 2.17E-10 3.92E-11 1.B3E-11 O.
4.3SE-11 O.
1.21 E-OS M093 O.
2.41 E-OS B.6SE-07 O.
6.3SE-06 O.
1.22E-06 M099 O.
1.33E-OS 3.29E-06 O.
2.B4E-OS O.
1.10E-OS TC99M 9.23E-10 1.B1 E-09 3.00E-OB O.
2.63E-OB 9.19E-10 1.03E-06 TC99 S.3SE-07 S.96E-07 2.14E-07 O.
7.02E-06 S.27E-OB 6.2SE-06 TC101 1.07E-09 1.12E-09 1.42E-OB O.
1.91 E-OB S.92E-10 3.S6E-09 RU103 7.31 E-07 O.
2.B1 E-07 O.
1.B4E-06 O.
1.B9E-OS RU10S 6.4SE-OB O.
2.34E-OB O.
S.67E-07 O.
4.21 E-OS RU106 1.17E-OS O.
1.46E-06 O.
1.SBE-OS O.
1.B2E-04 RH10S S.14E-07 2.76E-07 2.36E-07 O.
1.10E-06 O.
1.71 E-OS PD107 O.
4.72E-07 4.01 E-OB O.
3.9SE-06 O.
9.37E-07 PD109 O.
S.67E-07 1.70E-07 O.
3.04E-06 O.
3.3SE-OS AG110M S.39E-07 3.64E-07 2.91 E-07 O.
6.7BE-07 O.
4.33E-OS AG111 2.4BE-07 7.76E-OB S.12E-OB O.
2.34E-07 O.
4.7SE-OS CD113M O.
1.02E-OS 4.34E-07 O.
1.0SE-OS O.
2.63E-OS CD11SM O.
S.B9E-06 2.S1 E-07 O.
4.3BE-06 O.
B.01 E-OS SN123 1.33E-04 1.6SE-06 3.24E-06 1.7SE-06 O.
O.
6.S2E-OS SN12S 3.SSE-OS S.3SE-07 1.S9E-06 S.SSE-07 O.
O.
1.10E-04 SN126 3.33E-04 4.1SE-06 9.46E-06 1.14E-06 O.
O.
2.S0E-OS SB124 1.11 E-OS 1.44E-07 3.B9E-06 2.4SE-OB O.
6.16E-06 6.94E-OS SB12S 7.16E-06 S.S2E-OB 1.S0E-06 6.63E-09 O.
3.99E-06 1.71 E-OS SB126 4.40E-06 6.73E-OB 1.SBE-06 2.SBE-OB O.
2.10E-06 B.B7E-OS SB127 1.06E-06 1.64E-OB 3.6BE-07 1.1BE-OB O.
4.60E-07 S.97E-OS TE12SM 1.14E-OS 3.09E-06 1.S2E-06 3.20E-06 O.
O.
1.10E-OS TE127M 2.B9E-OS 7.7BE-06 3.43E-06 6.91 E-06 B.24E-OS O.
2.34E-OS TE127 4.71 E-07 1.27E-07 1.01 E-07 3.26E-07 1.34E-06 O.
1.B4E-OS TE129M 4.B7E-OS 1.36E-OS 7.S6E-06 1.S7E-OS 1.43E-04 O.
S.94E-OS TE129 1.34E-07 3.74E-OB 3.1BE-OB 9.S6E-OB 3.92E-07 O.
B.34E-06 TE131M 7.20E-06 2.49E-06 2.6SE-06 S.12E-06 2.41 E-OS O.
1.01 E-04 TE131 B.30E-OB 2.S3E-OB 2.47E-OB 6.3SE-OB 2.S1 E-07 O.
4.36E-07 TE132 1.01 E-OS 4.47E-06 S.40E-06 6.S1 E-06 4.1SE-OS O.
4.S0E-OS TE133M 1.B7E-07 7.S6E-OB 9.37E-OB 1.4SE-07 7.1BE-07 O.
S.77E-06 TE134 1.29E-07 S.BOE-OB 7.74E-OB 1.02E-07 S.37E-07 O.
S.B9E-07 1129 1.39E-OS B.S3E-06 7.62E-06 S.SBE-03 1.44E-OS O.
4.29E-07 1130 2.92E-06 S.90E-06 3.04E-06 6.S0E-04 B.B2E-06 O.
2.76E-06 1131 1.72E-OS 1.73E-OS 9.B3E-06 S.72E-03 2.B4E-OS O.
1.S4E-06
Proc No ODCM Revision 26 Page 7 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 B.00E-07 1.47E-06 6.76E-07 6.B2E-OS 2.2SE-06 O.
1.73E-06 1133 S.92E-06 7.32E-06 2.77E-06 1.36E-03 1.22E-OS O.
2.9SE-06 1134 4.19E-07 7.7BE-07 3.SBE-07 1.79E-OS 1.19E-06 O.
S.16E-07 113S 1.7SE-06 3.1SE-06 1.49E-06 2.79E-04 4.B3E-06 O.
2.40E-06 XE131M O.
O.
O.
O.
O.
O.
O.
XE133M O.
O.
O.
O.
O.
O.
0:
XE133 O.
O.
O.
O.
O.
O.
O.
XE13SM O.
O.
O.
O.
O.
O.
O.
XE13S O.
O.
O.
O.
O.
O.
O.
XE137 O.
O.
O.
O.
O.
O.
O.
XE13B O.
O.
O.
O.
O.
O.
O.
CS134M B.44E-OB 1.2SE-07 B.16E-OB O.
6.S9E-OB 1.09E-OB 1.SBE-07 CS134 2.34E-04 3.B4E-04 B.10E-OS O.
1.19E-04 4.27E-OS 2.07E-06 CS13S B.30E-OS S.7BE-OS S.93E-06 O.
2.04E-OS 6.B1 E-06 4.33E-07 CS136 2.3SE-OS 6.46E-OS 4.1BE-OS O.
3.44E-OS S.13E-06 2.27E-06 CS137 3.27E-04 3.13E-04 4.62E-OS O.
1.02E-04 3.67E-OS 1.96E-06 CS13B 2.2BE-07 3.17E-07 2.01 E-07 O.
2.23E-07 2.40E-OB 1.46E-07 CS139 1.4SE-07 1.61 E-07 7.74E-OB O.
1.21 E-07 1.22E-OB 1.4SE-11 BA139 4.14E-07 2.21 E-1 0 1.20E-OB O.
1.93E-10 1.30E-10 2.39E-OS BA140 B.31 E-OS 7.2BE-OB 4.BSE-06 O.
2.37E-OB 4.34E-OB 4.21 E-OS BA141 2.00E-07 1.12E-10 6.S1 E-09 O.
9.69E-11 6.SBE-10 1.14E-07 BA142 B.74E-OB 6.29E-11 4.BBE-09 O.
S.09E-11 3.70E-11 1.14E-09 LA140 1.01 E-OB 3.S3E-09 1.19E-09 O.
O.
O.
9.B4E-OS LA141 1.3SE-09 3.17E-10 6.BBE-11 O.
O.
O.
7.0SE-OS LA142 S.24E-10 1.67E-10 S.23E-11 O.
O.
O.
3.31 E-OS CE141 3.97E-OB 1.9BE-OB 2.94E-09 O.
B.6BE-09 O.
2.47E-OS CE143 6.99E-09 3.79E-06 S.49E-10 O.
1.S9E-09 O.
S.SSE-OS CE144 2.0BE-06 6.S2E-07 1.11 E-07 O.
3.61 E-07 O.
1.70E-04 PR143 3.93E-OB 1.1BE-OB 1.9SE-09 O.
6.39E-09 O.
4.24E-OS PR144 1.29E-10 3.99E-11 6.49E-12 O.
2.11E-11 O.
B.S9E-OB ND147 2.79E-OB 2.26E-OB 1.7SE-09 O.
1.24E-OB O.
3.SBE-OS PM147 3.1BE-07 2.27E-OB 1.22E-OB O.
4.01 E-OB O.
9.19E-06 PM14BM 1.03E-07 2.0SE-OB 2.0SE-OB O.
3.04E-OB O.
S.7BE-OS PM14B 3.02E-OB 3.63E-09 2.3SE-09 O.
6.17E-09 O.
9.70E-OS PM149 6.49E-09 6.90E-10 3.74E-10 O.
1.22E-09 O.
4.71 E-OS PM1S1 2.92E-09 3.SSE-10 2.31 E-1 0 O.
6.02E-10 O.
4.03E-OS SM1S1 2.S6E-07 3.B1 E-OB 1.20E-OB O.
3.94E-OB O.
S.S3E-06 SM1S3 3.6SE-09 2.27E-09 2.19E-10 O.
6.91 E-10 O.
3.02E-OS EU1S2 6.1SE-07 1.12E-07 1.33E-07 O.
4.73E-07 O.
1.B4E-OS EU1S4 2.30E-06 2.07E-07 1.B9E-07 O.
9.09E-07 O.
4.B1 E-OS EU1SS 4.B2E-07 3.47E-OB 2.72E-OB O.
1.30E-07 O.
B.69E-OS EU1S6 S.62E-OB 3.01 E-OB 6.23E-09 O.
1.94E-OB O.
6.B3E-OS TB160 1.66E-07 O.
2.06E-OB O.
4.94E-OB O.
3.6BE-OS H0166M 1.0BE-06 2.26E-07 1.91 E-07 O.
3.22E-07 O.
O.
W1B1 4.23E-06 1.04E-OB 1.43E-09 O.
O.
O.
3.79E-07 W1BS 1.73E-06 4.32E-07 6.0SE-OB O.
O.
O.
1.61 E-OS W1B7 4.29E-07 2.S4E-07 1.14E-07 O.
O.
O.
3.S7E-OS
Proc No ODeM Revision 26 Page 8 of 16 INGESTION DOSE COMMITMENT FACTORS CHILD INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 4.7SE-02 1.22E-02 2.09E-03 O.
3.67E-02 O.
S.S7E-OS BI210 1.97E-06 1.02E-OS 1.69E-07 O.
1.1SE-04
- o.
S.17E-OS P0210 1.S2E-03 2.43E-03 3.67E-04
- o.
7.S6E-03 O.
6.SSE-OS RN222
- o.
O.
O.
O.
O.
O.
- o.
RA223 2.12E-02 2.4SE-OS 4.24E-03 O.
6.S0E-04
- o.
3.3BE-04 RA224 6.B9E-03 1.2SE-OS 1.3BE-03 O.
3.31 E-04 O.
3.7BE-04 RA22S 2.BOE-02 2.S0E-OS S.S9E-03 O.
6.62E-04 O.
3.21 E-04 RA226 S.7SE-01 1.B4E-OS 4.72E-01 O.
4.BBE-04 O.
3.41 E-04 RA22B 3.BSE-01 9.99E-06 4.32E-01 O.
2.6SE-04 O.
S.B1E-OS AC22S 1.BBE-OS 1.94E-OS 1.26E-06 O.
2.07E-06 O.
4.31 E-04 AC227 4.12E-03 6.63E-04 2.SSE-04 O.
1.46E-04 O.
B.43E-OS TH227 S.BSE-OS 7.96E-07 1.69E-06 O.
4.22E-06 O.
S.63E-04 TH22B 2.07E-03 2.6SE-OS 7.00E-OS O.
1.3BE-04 O.
S.79E-04 TH229 1.3BE-02 1.B1 E-04 6.BOE-04 O.
B.B4E-04 O.
S.27E-04 TH230 3.SSE-03 1.7BE-04 9.91 E-OS O.
B.67E-04 O.
6.19E-OS TH232 3.96E-03 1.S2E-04 3.01 E-04 O.
7.41E-04 O.
S.27E-OS TH234 3.42E-07 1.S1 E-OB 9.BBE-09 O.
B.01 E-OB O.
1.1BE-04 PA231 7.07E-03 2.34E-04 2.B1 E-04 O.
1.2BE-03 O.
7.37E-OS PA233 1.B1 E-OB 2.B2E-09 3.16E-09 O.
1.04E-OB O.
1.44E-OS U232 1.76E-02 O.
1.26E-03 O.
1.34E-03 O.
6.9BE-OS U233 3.72E-03 O.
2.2SE-04 O.
6.10E-04 O.
6.4SE-OS U234 3.S7E-03 O.
2.21 E-04 O.
S.9BE-04 O.
6.32E-OS U23S 3.42E-03 O.
2.07E-04 O.
S.61 E-04 O.
B.03E-OS U236 3.42E-03 O.
2.12E-04 O.
S.73E-04 O.
S.92E-OS U237 2.36E-07 O.
6.27E-OB O.
6.B1 E-07 O.
2.0BE-OS U23B 3.27E-03 O.
1.94E-04 O.
S.24E-04 O.
S.66E-OS NP237 2.36E-03 1.B1 E-04 9.79E-OS O.
6.0SE-04 O.
B.16E-OS NP23B S.B3E-OB 1.1BE-09 9.0BE-10 O.
3.76E-09 O.
4.04E-OS NP239 S.2SE-09 3.77E-10 2.6SE-10 O.
1.09E-09 O.
2.79E-OS PU23B 1.2SE-03 1.S6E-04 3.16E-OS O.
1.1SE-04 O.
7.S0E-OS PU239 1.36E-03 1.6SE-04 3.31 E-OS O.
1.22E-04 O.
6.BSE-OS PU240 1.36E-03 1.6SE-04 3.31 E-OS O.
1.22E-04 O.
6.9BE-OS PU241 4.00E-OS 1.72E-06 B.04E-07 O.
2.96E-06 O.
1.44E-06 PU242 1.26E-03 1.S9E-04 3.19E-OS O.
1.17E-04 O.
6.71 E-OS PU244 1.47E-03 1.B2E-04 3.6SE-OS O.
1.3SE-04 O.
1.00E-04 AM241 1.43E-03 6.40E-04 1.02E-04 O.
6.23E-04 O.
7.64E-OS AM242M 1.47E-03 6.2SE-04 1.04E-04 O.
6.30E-04 O.
9.61 E-OS AM243 1.41 E-03 6.14E-04 9.B3E-OS O.
6.06E-04 O.
B.9SE-OS CM242 B.BOE-OS 6.73E-OS S.B4E-06 O.
1.B7E-OS O.
B.16E-OS CM243 1.33E-03 6.03E-04 B.24E-OS O.
3.0BE-04 O.
B.03E-OS CM244 1.11 E-03 S.36E-04 6.93E-OS O.
2.S4E-04 O.
7.77E-OS CM24S 1.76E-03 6.64E-04 1.0SE-04 O.
4.11 E-04 O.
7.24E-OS CM246 1.74E-03 6.64E-04 1.0SE-04 O.
4.10E-04 O.
7.11 E-OS CM247 1.70E-03 6.S3E-04 1.03E-04 O.
4.04E-04 O.
9.3SE-OS CM24B 1.41 E-02 S.3BE-03 B.S2E-04 O.
3.33E-03 O.
1.S1 E-03 CF2S2 1.07E-03 O.
2.S4E-OS O.
O.
O.
2.96E-04
Proc No ODeM Revision 26 Page 9 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 O.
1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E-07 BE10 4.4BE-06 6.94E-07 1.13E-07 O.
S.30E-07 O.
2.B4E-OS C14 4.06E-06 B.12E-07 B.12E-07 B.12E-07 B.12E-07 B.12E-07 B.12E-07 N13 1.1SE-OB 1.1SE-OB 1.1SE-OB 1.1SE-OB 1.1SE-OB 1.1SE-OB 1.1SE-OB F1B B.64E-07 O.
9.47E-OB O.
O.
O.
7.7BE-OB NA22 2.34E-OS 2.34E-OS 2.34E-OS 2.34E-OS 2.34E-OS 2.34E-OS 2.34E-OS NA24 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 P32 2.76E-04 1.71 E-OS 1.07E-OS O.
O.
O.
2.32E-OS AR39 O.
O.
O.
O.
O.
O.
O.
AR41 O.
O.
O.
O.
O.
O.
O.
CA41 1.97E-04 O.
2.13E-OS O.
O.
O.
1.9SE-07 SC46 7.24E-09 1.41 E-OB 4.1BE-09 O.
1.3SE-OB O.
4.BOE-OS CRS1 O.
O.
3.60E-09 2.00E-09 7.B9E-10 S.14E-09 6.0SE-07 MNS4 O.
S.90E-06 1.17E-06 O.
1.76E-06 O.
1.21 E-OS MNS6 O.
1.SBE-07 2.B1 E-OB O.
2.00E-07 O.
1.04E-OS FESS 3.7BE-06 2.6BE-06 6.2SE-07 O.
O.
1.70E-06 1.16E-06 FES9 S.B7E-06 1.37E-OS S.29E-06 O.
O.
4.32E-06 3.24E-OS COS7 O.
2.3BE-07 3.99E-07 O.
O.
O.
4.44E-06 COSB O.
9.72E-07 2.24E-06 O.
O.
O.
1.34E-OS C060 0
2.B1 E-06 6.33E-06 O.
O.
O.
3.66E-OS NIS9 1.32E-OS 4.66E-06 2.24E-06 O.
O.
O.
7.31 E-07 NI63 1.77E-04 1.2SE-OS 6.00E-06 O.
O.
O.
1.99E-06 NI6S 7.49E-07 9.S7E-OB 4.36E-OB O.
O.
O.
S.193-06 CU64 O.
1.1SE-07 S.41E-OB O.
2.91 E-07 O.
B.92E-06 ZN6S S.76E-06 2.00E-OS 9.33E-06 O.
1.2BE-OS O.
B.47E-06 ZN69M 2.40E-07 S.66E-07 S.19E-OB O.
3.44E-07 O.
3.11 E-OS ZN69 1.47E-OB 2.BOE-OB 1.96E-09 O.
1.B3E-OB O.
S.16E-OB SE79 O.
3.73E-06 6.27E-07 O.
6.S0E-06 O.
S.70E-07 BRB2 O.
O.
3.04E-06 O.
O.
O.
O.
BRB3 O.
O.
S.74E-OB O.
O.
O.
O.
BRB4 O.
O.
7.22E-OB O.
O.
O.
O.
BRBS O.
O.
3.0SE-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
O.
O.
KRBSM O.
O.
O.
O.
O.
O.
O.
KRBS O.
O.
O.
O.
O.
O.
O.
KRB7 O.
O.
O.
O.
O.
O.
O.
KRBB O.
O.
O.
O.
O.
O.
O.
KRB9 O.
O.
O.
O.
O.
O.
O.
RBB6 O.
2.9BE-OS 1.40E-OS O.
O.
O.
4.41 E-06 RBB7 O.
1.7SE-OS 6.11 E-06 O.
O.
O.
6.11 E-07 RBBB O.
B.S2E-OB 4.S4E-OB O.
O.
O.
7.30E-1S RBB9 O.
S.SOE-OB 3.B9E-OB O.
O.
O.
B.43E-17 SRB9 4.40E-04 O.
1.26E-OS O.
O.
O.
S.24E-OS SR90 B.30E-03 O.
2.0SE-03 O.
O.
O.
2.33E-04 SR91 B.07E-06 O.
3.21 E-07 O.
O.
O.
3.66E-OS SR92 3.0SE-06 O.
1.30E-07 O.
O.
O.
7.77E-OS
Proc No ODeM Revision 26 Page 10 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 1.37E-OB O.
3.69E-10 O.
O.
- o.
1.13E-04 Y91M 1.29E-10 O.
4.93E-12 O.
O.
- o.
6.09E-09 Y91 2.01 E-07 O.
S.39E-09 O.
O.
O.
B.24E-OS Y92 1.21 E-09 O.
3.S0E-11 O.
O.
O.
3.32E-OS Y93 3.B3E-09 O.
1.0SE-10 O.
O.
O.
1.17E-04 ZR93 S.S3E-OB 2.73E-OB 1.49E-OB O.
9.6SE-OB O.
2.SBE-OS ZR9S 4.12E-OB 1.30E-OB B.94E-09 O.
1.91E-OB O.
3.00E-OS ZR97 2.37E-09 4.69E-10 2.16E-10 O.
7.11E-10 O.
1.27E-04 N893M 3.44E-OB 1.13E-OB 2.B3E-09 O.
1.32E-OB O.
4.07E-06 N89S B.22E-09 4.S6E-09 2.S1 E-09 O.
4.42E-09 O.
1.9SE-OS N897 7.37E-11 1.B3E-11 6.6BE-12 O.
2.14E-11 O.
4.37E-07 M093 O.
1.06E-OS 2.90E-07 O.
3.04E-06 O.
1.29E-06 M099 O.
6.03E-06 1.1SE-06 O.
1.3BE-OS O.
1.0BE-OS TC99M 3.32E-10 9.26E-10 1.20E-OB O.
1.3BE-OB S.14E-10 6.0BE-07 TC99 1.79E-07 2.63E-07 7.17E-OB O.
3.34E-06 2.72E-OB 6.44E-06 TC101 3.60E-10 S.12E-10 S.03E-09 O.
9.26E-09 3.12E-10 B.7SE-17 RU103 2.SSE-07 O.
1.09E-07 O.
B.99E-07 O.
2.13E-OS RU10S 2.1BE-OB O.
B.46E-09 O.
2.7SE-07 O.
1.76E-OS RU106 3.92E-06 O.
4.94E-07 O.
7.S6E-06 O.
1.BBE-04 RH10S 1.73E-07 1.2SE-07 B.20E-OB O.
S.31 E-07 O.
1.S9E-OS PD107 O.
2.0BE-07 1.34E-OB O.
1.BBE-06 O.
9.66E-07 PD109 O.
2.S1 E-07 S.70E-OB O.
1.4SE-06 O.
2.S3E-OS AG110M 2.0SE-07 1.94E-07 1.1BE-07 O.
3.70E-07 O.
S.4SE-OS AG111 B.29E-OB 3.44E-OB 1.73E-OB O.
1.12E-07 O.
4.BOE-OS CD113M O.
4.S1 E-06 1.4SE-07 O.
4.99E-06 O.
2.71E-OS CD11SM O.
2.60E-06 B.39E-OB O.
2.0BE-06 O.
B.23E-OS SN123 4.44E-OS 7.29E-07 1.0BE-06 S.B4E-07 O.
O.
6.71 E-OS SN12S 1.19E-OS 2.37E-07 S.37E-07 1.B6E-07 O.
O.
1.12E-04 SN126 1.16E-04 2.16E-06 3.30E-06 S.69E-07 O.
O.
2.SBE-OS S8124 3.B7E-06 7.13E-OB 1.S1 E-06 B.7BE-09 O.
3.3BE-06 7.BOE-OS S812S 2.4BE-06 2.71 E-OB S.BOE-07 2.37E-09 O.
2.1BE-06 1.93E-OS S8126 1.S9E-06 3.2SE-OB S.71 E-07 B.99E-09 O.
1.14E-06 9.41 E-OS S8127 3.63E-07 7.76E-09 1.37E-07 4.0BE-09 O.
2.47E-07 6.16E-OS TE12SM 3.B3E-06 1.3BE-06 S.12E-07 1.07E-06 O.
O.
1.13E-OS TE127M 9.67E-06 3.43E-06 1.1SE-06 2.30E-06 3.92E-OS O.
2.41 E-OS TE127 1.SBE-07 S.60E-OB 3.40E-OB 1.09E-07 6.40E-07 O.
1.22E-OS TE129M 1.63E-OS 6.0SE-06 2.SBE-06 S.26E-06 6.B2E-OS O.
6.12E-OS TE129 4.4BE-OB 1.67E-OB 1.09E-OB 3.20E-OB 1.BBE-07 O.
2.4SE-07 TE131M 2.44E-06 1.17E-06 9.76E-07 1.76E-06 1.22E-OS O.
9.39E-OS TE131 2.79E-OB 1.1SE-OB B.72E-09 2.1SE-OB 1.22E-07 O.
2.29E-09 TE132 3.49E-06 2.21 E-06 2.0BE-06 2.33E-06 2.12E-OS O.
7.00E-OS TE133M 6.44E-OB 3.66E-OB 3.S6E-OB S.11 E-OB 3.62E-07 O.
1.4BE-07 TE134 4.47E-OB 2.B7E-OB 3.00E-OB 3.67E-OB 2.74E-07 O.
1.66E-09 1129 4.66E-06 3.92E-06 6.S4E-06 4.77E-03 7.01 E-06 O.
4.S7E-07 1130 1.03E-06 2.9BE-06 1.19E-06 2.43E-04 4.S9E-06 O.
2.29E-06 1131 S.BSE-06 B.19E-06 4.40E-06 2.39E-03 1.41 E-OS O.
1.62E-06
Proc No ODeM Revision 26 Page 11 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 2.79E-07 7.30E-07 2.62E-07 2.46E-OS 1.1SE-06 O.
3.1BE-07 1133 2.01 E-06 3.41 E-06 1.04E-06 4.76E-04 S.9BE-06 O.
2.5BE-06 1134 1.46E-07 3.B7E-07 1.39E-07 6.45E-06 6.10E-07 O.
S.10E-09 113S 6.10E-07 1.S7E-06 S.B2E-07 1.01 E-04 2.4BE-06 O.
1.74E-06 XE131M O.
O.
O.
O.
O.
O.
O.
XE133M O.
O.
O.
O.
O.
O.
O.
XE133 O.
O.
O.
O.
O.
O.
O.
XE13SM O.
O.
O.
O.
O.
O.
O.
XE13S O.
O.
O.
O.
O.
O.
O.
XE137 O.
O.
O.
O.
O.
O.
O.
XE13B O.
O.
O.
O.
O.
O.
O.
CS134M 2.94E-OB 6.09E-OB 3.13E-OB O.
3.39E-OB S.9SE-09 4.0SE-OB CS134 B.37E-OS 1.97E-04 9.14E-OS O.
6.26E-OS 2.39E-OS 2.4SE-06 CS13S 2.7BE-OS 2.SSE-OS S.96E-06 O.
9.73E-06 3.S2E-06 4.46E-07 CS136 B.S9E-06 3.3BE-OS 2.27E-OS O.
1.B4E-OS 2.90E-06 2.72E-06 CS137 1.12E-04 1.49E-04 S.19E-OS O.
S.07E-OS 1.97E-OS 2.12E-06 CS13B 7.76E-OB 1.49E-07 7.4SE-OB O.
1.10E-07 1.2BE-OB 6.76E-11 CS139 4.B7E-OB 7.17E-OB 2.63E-OB O.
5.79E-OB 6.34E-09 3.33E-23 BA139 1.39E-07 9.7BE-11 4.0SE-09 O.
9.22E-11 6.74E-11 1.24E-06 BA140 2.B4E-OS 3.4BE-OB 1.B3E-06 O.
1.1BE-OB 2.34E-OB 4.3BE-OS BA141 6.71 E-OB S.01 E-11 2.24E-09 O.
4.6SE-11 3.43E-11 1.43E-13 BA142 2.99E-OB 2.99E-11 1.B4E-09 O.
2.S3E-11 1.99E-11 9.1BE-20 LA140 3.4BE-09 1.71 E-09 4.SSE-10 O.
O.
O.
9.B2E-OS LA141 4.SSE-10 1.40E-10 2.31 E-11 O.
O.
O.
2.4BE-OS LA142 1.79E-10 7.9SE-11 1.9BE-11 O.
O.
O.
2.42E-06 CE141 1.33E-OB B.BBE-09 1.02E-09 O.
4.1BE-09 O.
2.54E-OS CE143 2.3SE-09 1.71 E-06 1.91E-10 O.
7.67E-10 O.
S.14E-OS CE144 6.96E-07 2.BBE-07 3.74E-OB O.
1.72E-07 O.
1.75E-04 PR143 1.31 E-OB S.23E-09 6.S2E-10 O.
3.04E-09 O.
4.31 E-OS PR144 4.30E-11 1.76E-11 2.1BE-12 O.
1.01E-11 O.
4.74E-14 ND147 9.3BE-09 1.02E-OB 6.11E-10 O.
S.99E-09 O.
3.6BE-OS PM147 1.0SE-07 9.96E-09 4.06E-09 O.
1.90E-OB O.
9.47E-06 PM14BM 4.14E-OB 1.05E-OB B.21 E-09 O.
1.S9E-OB O.
6.61 E-OS PM14B 1.02E-OB 1.66E-09 B.36E-10 O.
3.00E-09 O.
9.90E-OS PM149 2.17E-09 3.0SE-10 1.2SE-10 O.
5.B1 E-1 0 O.
4.49E-OS PM1S1 9.B7E-10 1.63E-10 B.2SE-11 O.
2.93E-10 O.
3.66E-OS SM1S1 B.73E-OB 1.6BE-OB 3.94E-09 O.
1.B4E-OB O.
S.70E-06 SM1S3 1.22E-09 1.01 E-09 7.43E-11 O.
3.30E-10 O.
2.BSE-OS EU1S2 2.4SE-07 S.90E-OB S.20E-OB O.
2.74E-07 O.
2.17E-OS EU1S4 7.91 E-07 1.02E-07 7.19E-OB O.
4.S6E-07 O.
5.39E-OS EU1SS 1.74E-07 1.6BE-OB 1.04E-OB O.
6.S7E-OB O.
9.63E-OS EU1S6 1.92E-OB 1.44E-OB 2.3SE-09 O.
9.69E-09 O.
7.36E-OS TB160 6.47E-OB O.
B.07E-09 O.
2.S6E-OB O.
4.19E-OS H0166M 3.S7E-07 1.10E-07 7.96E-OB O.
1.61 E-07 O.
O.
W1B1 1.42E-OB 4.SBE-09 4.79E-10 O.
O.
O.
3.90E-07 W1BS S.79E-07 1.91 E-07 2.02E-OB O.
O.
O.
1.6SE-OS W1B7 1.46E-07 1.19E-07 4.17E-OB O.
O.
O.
3.22E-OS
Proc No ODeM Revision 26 Page 12 of 16 INGESTION DOSE COMMITMENT FACTORS TEEN INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 1.81 E-02 S.44E-03 7.01 E-04 O.
1.72E-02 O.
S.74E-OS BI210 6.S9E-07 4.S1 E-06 S.66E-08 O.
S.48E-OS O.
S.1SE-OS P0210 6.09E-04 1.07E-03 1.23E-04 O.
3.60E-03 O.
6.7SE-OS RN222 O.
O.
O.
O.
O.
O.
O.
RA223 7.11 E-03 1.08E-OS 1.42E-03 O.
3.10E-04 O.
3.43E-04 RA224 2.31 E-03 S.S2E-06 4.61E-04 O.
1.S8E-04 O.
3.71 E-04 RA22S 9.37E-03 1.10E-OS 1.87E-03 O.
3.1SE-04 O.
3.27E-04 RA226 3.22E-01 8.13E-06 2.39E-01 O.
2.32E-04 O.
3.S1 E-04 RA228 1.37E-01 4.41E-06 1.S1 E-01 O.
1.26E-04 O.
S.98E-OS AC22S 6.29E-06 8.S9E-06 4.22E-07 O.
9.8SE-07 O.
4.36E-04 AC227 2.0SE-03 3.03E-04 1.22E-04 O.
8.81 E-OS O.
8.68E-OS TH227 1.96E-OS 3.S2E-07 S.6SE-07 O.
2.01 E-06 O.
S.7SE-04 TH228 6.80E-04 1.14E-OS 2.30E-OS
- o.
6.41 E-OS O.
S.97E-04 TH229 8.39E-03 1.26E-04 4.11 E-04 O.
6.10E-04 O.
S.43E-04 TH230 2.16E-03 1.23E-04 6.00E-OS O.
S.99E-04 O.
6.38E-OS TH232 2.42E-03 1.0SE-04 1.63E-04 O.
S.11 E-04 O.
S.43E-OS TH234 1.14E-07 6.68E-09 3.31 E-09 O.
3.81 E-08 O.
1.21 E-04 PA231 4.31 E-03 1.62E-04 1.68E-04 O.
9.10E-04 O.
7.60E-OS PA233 7.33E-09 1.41 E-09 1.26E-09 O.
S.32E-09 O.
1.61 E-OS U232 S.89E-03 O.
4.21E-04 O.
6.38E-04 O.
7.19E-OS U233 1.24E-03 O.
7.S43-0S O.
2.90E-04 O.
6.6SE-OS U234 1.19E-03 O.
7.39E-OS O.
2.8SE-04 O.
6.S1 E-OS U23S 1.14E-03 O.
6.94E-OS O.
2.67E-04 O.
8.28E-OS U236 1.14E-03 O.
7.09E-OS O.
2.73E-04 O.
6.11 E-OS U237 7.89E-08 O.
2.10E-08 O.
3.24E-07 O.
2.09E-OS U238 1.09E-03 O.
6.49E-OS O.
2.S0E-04 O.
S.83E-OS NP237 1.44E-03 1.2SE-04 S.8SE-OS O.
4.33E-04 O.
8.41E-OS NP238 1.9SE-08 S.22E-10 3.04E-10 O.
1.79E-09 O.
3.83E-OS NP239 1.76E-09 1.66E-10 9.22E-11 O.
S.21 E-10 O.
2.67E-OS PU238 7.21 E-04 1.02E-04 1.82E-OS O.
7.80E-OS O.
7.73E-OS PU239 8.27E-04 1.12E-04 2.01 E-OS O.
8.S7E-OS O.
7.06E-OS PU240 8.26E-04 1.12E-04 2.01 E-OS O.
8.S6E-OS O.
7.19E-OS PU241 1.84E-OS 9.42E-07 3.69E-07 O.
1.71 E-06 O.
1.48E-06 PU242 7.66E-04 1.08E-04 1.94E-OS O.
8.2SE-OS
- o.
6.92E-OS PU244 8.9SE-04 1.23E-04 2.22E-OS O.
9.4SE-OS O.
1.03E-04 AM241 8.62E-04 3.29E-04 S.7SE-OS
- o.
4.31E-04 O.
7.87E-OS AM242M 8.70E-04 3.19E-04 S.80E-OS O.
4.30E-04 O.
9.90E-OS AM243 8.60E-04 3.17E-04 S.62E-OS O.
4.22E-04 O.
9.23E-OS CM242 2.94E-OS 2.97E-OS 1.9SE-06 O.
8.89E-06 O.
8.40E-OS CM243 6.91 E-04 2.86E-04 4.09E-OS O.
1.91 E-04 O.
8.28E-OS CM244 S.32E-04 2.49E-04 3.19E-OS O.
1.49E-04 O.
8.00E-OS CM24S 1.07E-03 3.33E-04 6.10E-OS O.
2.8SE-04 O.
7.46E-OS CM246 1.06E-03 3.32E-04 6.09E-OS O.
2.84E-04 O.
7.33E-OS CM247 1.03E-03 3.27E-04 6.00E-OS O.
2.80E-04 O.
9.63E-OS CM248 8.60E-03 2.69E-03 4.9SE-04 O.
2.31 E-03 O.
1.SSE-03 CR2S2 3.S1 E-04 O.
8.37E-06 O.
O.
O.
3.0SE-04
Proc No ODCM Revision 26 Page 13 of 16 INGESTION DOSE COMMITMENT FACTORS ADUL T INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCI INGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI H3 O.
1.0SE-07 1.0SE-07 1.0SE-07 1.0SE-07 1.0SE-07 1.0SE-07 BE10 3.1BE-06 4.91 E-07 7.94E-OB O.
3.71 E-07 O.
2.6BE-OS C14 2.B4E-06 S.6BE-07 S.6BE-07 S.6BE-07 S.6BE-07 S.6BE-07 S.6BE-07 N13 B.36E-09 B.36E-09 B.36E-09 B.36E-09 B.36E-09 B.36E-09 B.36E-09 F1B 6.24E-07 O.
6.92E-OB O.
O.
O.
1.BSE-OB NA22 1.74E-OS 1.74E-OS 1.74E-OS 1.74E-OS 1.74E-OS 1.74E-OS 1.74E-OS NA24 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 P32 1.93E-04 1.20E-OS 7.46E-06 O.
O.
O.
2.17E-OS AR39 O.
O.
O.
O.
O.
O.
O.
AR41 O.
O.
O.
O.
O.
O.
O.
CA41 1.B3E-OS O.
2.00E-OS O.
O.
O.
1.B4E-07 SC46 S.S1 E-09 1.07E-OB 3.11 E-09 O.
9.99E-09 O.
5.21 E-OS CRS1 O.
O.
2.66E-09 1.S9E-09 S.B6E-10 3.S3E-09 6.69E-07 MNS4 O.
4.S7E-06 B.72E-07 O.
1.36E-06 O.
1.40E-OS MNS6 O.
1.1SE-07 2.04E-OB O.
1.46E-07 O.
3.67E-06 FESS 2.7SE-06 1.90E-06 4.43E-07 O.
O.
1.06E-06 1.09E-06 FES9 4.34E-06 1.02E-OS 3.91 E-06 O.
O.
2.BSE-06 3.40E-OS COS7 O.
1.7SE-07 2.91 E-07 O.
O.
O.
4.44E-06 COSB O.
7.4SE-07 1.67E-06 O.
O.
O.
1.S1 E-OS C060 O.
2.14E-06 4.72E-06 O.
O.
O.
4.02E-OS NIS9 9.76E-06 3.3SE-06 1.63E-06 O.
O.
O.
6.90E-07 NI63 1.30E-04 9.01 E-06 4.36E-06 O.
O.
O.
1.BBE-06 NI6S S.2BE-07 6.B6E-OB 3.13E-OB O.
O.
O.
1.74E-06 CU64 O.
B.33E-OB 3.91 E-OB O.
2.10E-07 O.
7.10E-06 ZN6S 4.B4E-06 1.S4E-OS 6.96E-06 O.
1.03E-OS O.
9.70E-06 ZN69M 1.70E-07 4.0BE-07 3.73E-OB O.
2.47E-07 O.
2.49E-OS ZN69 1.03E-OB 1.97E-OB 1.37E-09 O.
1.2BE-OB O.
2.96E-09 SE79 O.
2.63E-06 4.39E-07 O.
4.S5E-06 O.
S.3BE-07 BRB2 O.
O.
2.26E-06 O.
O.
O.
2.S9E-06 BRB3 O.
O.
4.02E-OB O.
O.
O.
S.79E-OB BRB4 O.
O.
S.21E-OB O.
O.
O.
4.09E-13 BRBS O.
O.
2.14E-09 O.
O.
O.
O.
KRB3M O.
O.
O.
O.
O.
O.
O.
KRBSM O.
O.
O.
O.
O.
O.
O.
KRBS O.
O.
O.
O.
O.
O.
O.
KRB7 O.
O.
O.
O.
O.
O.
O.
KRBB O.
O.
O.
O.
O.
O.
O.
KRB9 O.
O.
O.
O.
O.
O.
O.
RBB6 O.
2.11E-OS 9.B3E-06 O.
O.
O.
4.16E-06 RBB7 O.
1.23E-OS 4.2BE-06 O.
O.
O.
S.76E-07 RBBB O.
6.0SE-OB 3.21 E-OB O.
O.
O.
B.36E-19 RBB9 O.
4.01 E-OB 2.B2E-OB O.
O.
O.
2.33E-21 SRB9 3.OBE-04 O.
B.B4E-06 O.
O.
O.
4.94E-OS SR90 7.SBE-03 O.
1.B6E-03 O.
O.
O.
2.19E-04 SR91 S.67E-06 O.
2.29E-07 O.
O.
O.
2.70E-OS SR92 2.1SE-06 O.
9.30E-OB O.
O.
O.
4.26E-OS
Proc No ODeM Revision 26 Page 14 of 16 INGESTION DOSE COMMITMENT FACTORS ADUL T INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI Y90 9.62E-09 O.
2.SBE-10 O.
O.
O.
1.02E-04 Y91M 9.09E-11 O.
3.S2E-12 O.
O.
O.
2.67E-10 Y91 1.41 E-07 O.
3.77E-09 O.
O.
O.
7.76E-OS Y92 B.4SE-10 O.
2.47E-11 O.
O.
O.
1.4BE-OS Y93 2.6BE-09 O.
7.40E-11 O.
O.
O.
B.SOE-OS ZR93 4.1BE-OB 2.34E-09 1.09E-09 O.
B.B7E-09 O.
2.43E-06 ZR9S 3.04E-OB 9.7SE-09 6.60E-09 O.
1.S3E-OB O.
3.09E-OS ZR97 1.6BE-09 3.39E-10 1.SSE-10 O.
S.12E-10 O.
1.0SE-04 NB93M 2.SSE-OB B.32E-09 2.0SE-09 O.
9.S7E-09 O.
3.B4E-06 NB9S 6.22E-09 3.46E-09 1.B6E-09 O.
3.42E-09 O.
2.10E-OS NB97 S.22E-11 1.32E-11 4.B2E-12 O.
1.S4E-11 O.
4.B7E-OB M093 O.
7.S1 E-06 2.03E-07 O.
2.13E-06 O.
1.22E-06 M099 O.
4.31 E-06 B.20E-07 O.
9.76E-06 O.
9.99E-06 TC99M 2.47E-10 6.9BE-10 B.B9E-09 O.
1.06E-OB 3.42E-10 4.13E-07 TC99 1.2SE-07 1.B6E-07 S.02E-OB O.
2.34E-06 1.SBE-OB 6.0BE-06 TC101 2.S4E-10 3.66E-10 3.S9E-09 O.
6.S9E-09 1.B7E-10 1.10E-21 RU103 1.BSE-07 O.
7.97E-OB O.
7.06E-07 O.
2.16E-OS RU10S 1.S4E-OB O.
6.0BE-09 O.
1.99E-07 O.
9.42E-06 RU106 2.7SE-06 O.
3.4BE-07 O.
S.31 E-06 O.
1.7BE-04 RH10S 1.21 E-07 B.BSE-OB S.B3E-OB O.
3.76E-07 O.
1.41 E-OS PD107 O.
1.47E-07 9.40E-09 O.
1.32E-06 O.
9.11 E-07 PD109 O.
1.77E-07 3.99E-OB O.
1.01 E-06 O.
1.96E-OS AG110M 1.60E-07 1.4BE-07 B.79E-OB O.
2.91 E-07 O.
6.04E-OS AG111 S.B1 E-OB 2.43E-OB 1.21 E-OB O.
7.B4E-OB O.
4.46E-OS CD113M O.
3.1BE-06 1.02E-07 O.
3.S0E-06 O.
2.S6E-OS CD11SM O.
1.B4E-06 S.B7E-OB O.
1.46E-06 O.
7.74E-OS SN123 3.11 E-OS S.1SE-07 7.S9E-07 4.3BE-07 O.
O.
6.33E-OS SN12S B.33E-06 1.6BE-07 3.7BE-07 1.39E-07 O.
O.
1.04E-04 SN126 B.4SE-OS 1.67E-06 2.40E-06 4.92E-07 O.
O.
2.43E-OS SB124 2.BOE-06 S.29E-OB 1.11 E-06 6.79E-09 O.
2.1BE-06 7.9SE-OS SB12S 1.79E-06 2.00E-OB 4.26E-07 1.B2E-09 O.
1.3BE-06 1.97E-OS SB126 1.1SE-06 2.34E-OB 4.1SE-07 7.04E-09 O.
7.0SE-07 9.40E-OS SB127 2.SBE-07 S.6SE-09 9.90E-OB 3.10E-09 O.
1.S3E-07 S.90E-OS TE12SM 2.6BE-06 9.71 E-07 3.S9E-07 B.06E-07 1.09E-OS O.
1.07E-OS TE12SM 6.77E-06 2.42E-06 B.2SE-07 1.73E-06 2.7SE-OS O.
2.27E-OS TE127 1.10E-07 3.9SE-OB 2.3BE-OB B.1SE-OB 4.4BE-07 O.
B.6BE-06 TE129M 1.1SE-OS 4.29E-06 1.B2E-06 3.9SE-06 4.BOE-OS O.
S.79E-OS TE129 3.14E-OB 1.1BE-OB 7.6SE-09 2.41 E-OB 1.32E-07 O.
2.37E-OB TE131M 1.73E-06 B.46E-07 7.0SE-07 1.34E-06 B.S7E-06 O.
B.40E-OS TE131 1.97E-OB B.23E-09 6.22E-09 1.62E-OB B.63E-OB O.
2.79E-09 TE132 2.S2E-06 1.63E-06 1.S3E-06 1.BOE-06 1.S7E-OS O.
7.71 E-OS TE133M 4.62E-OB 2.70E-OB 2.60E-OB 3.91 E-OB 2.67E-07 O.
6.64E-OB TE134 3.24E-OB 2.12E-OB 1.30E-OB 2.B3E-OB 2.0SE-07 O.
3.S9E-11 1129 3.27E-06 2.B1 E-06 9.21 E-06 7.23E-03 6.04E-06 O.
4.44E-07 1130 7.S6E-07 2.23E-06 B.BOE-07 1.B9E-04 3.4BE-06 O.
1.92E-06 1131 4.16E-06 S.9SE-06 3.41 E-06 1.9SE-03 1.02E-OS O.
1.S7E-06
Proc No ODCM Revision 26 Page 15 of 16 INGESTION DOSE COMMITMENT FACTORS ADUL T INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI 1132 2.03E-07 S.43E-07 1.90E-07 1.90E-OS B.6SE-07 O.
1.02E-07 1133 1.42E-06 2.47E-06 7.S3E-07 3.63E-04 4.31 E-06 O.
2.22E-06 1134 1.06E-07 2.BBE-07 1.03E-07 4.99E-06 4.SBE-07 O.
2.S1 E-1 0 113S 4.43E-07 1.16E-06 4.2BE-07 7.6SE-OS 1.B6E-06 O.
1.31E-06 XE131M O.
O.
O.
O.
O.
O.
O.
XE133M O.
O.
O.
O.
O.
O.
O.
XE133 O.
O.
O.
O.
O.
O.
O.
XE13SM O.
O.
O.
O.
O.
O.
O.
XE13S O.
O.
O.
O.
O.
O.
O.
XE137 O.
O.
O.
O.
O.
O.
O.
XE13B O.
O.
O.
O.
O.
O.
O.
CS134M 2.13E-OB 4.4BE-OB 2.29E-OB O.
2.43E-OB 3.B3E-09 1.SBE-OB CS134 6.22E-OS 1.4BE-04 1.21 E-04 O.
4.79E-OS 1.S9E-OS 2.S9E-06 CS13S 1.9SE-OS 1.BOE-OS 7.99E-06 O.
6.B1 E-06 2.04E-06 4.21 E-07 CS136 6.S1E-06 2.S7E-OS 1.BSE-OS O.
1.43E-OS 1.96E-06 2.92E-06 CS137 7.97E-OS 1.09E-04 7.14E-OS O.
3.70E-OS 1.23E-OS 2.11 E-06 CS13B 6.S2E-OB 1.09E-07 S.40E-OB O.
B.01 E-OB 7.91 E-09 4.6SE-13 CS139 3.41 E-OB S.OBE-OB 1.BSE-OB O.
4.07E-OB 3.70E-09 1.10E-30 BA139 9.70E-OB 6.91 E-11 2.B4E-09 O.
6.46E-11 3.92E-11 1.72E-07 BA140 2.03E-OS 2.SSE-OB 1.33E-06 O.
B.67E-09 1.46E-OB 4.1BE-OS BA141 4.71 E-OB 3.S6E-11 1.S9E-09 O.
3.31 E-11 2.02E-11 2.22E-17 BA142 2.13E-OB 2.19E-11 1.34E-09 O.
1.BSE-11 1.24E-11 3.00E-26 LA140 2.S0E-09 1.26E-09 3.33E-10 O.
O.
O.
9.2SE-OS LA141 3.19E-10 9.90E-11 1.62E-11 O.
O.
O.
1.1BE-OS LA142 1.2BE-10 S.B2E-11 1.4SE-11 O.
O.
O.
4.2SE-07 CE141 9.36E-09 6.33E-09 7.1BE-10 O.
2.94E-09 O.
2.42E-OS CE143 1.6SE-09 1.22E-06 1.3SE-10 O.
S.37E-10 O.
4.S6E-OS CE144 4.BBE-07 2.04E-07 2.62E-OB O.
1.21 E-07 O.
1.6SE-04 PR143 9.20E-09 3.69E-09 4.S6E-10 O.
2.13E-09 O.
4.03E-OS PR144 3.01 E-11 1.2SE-11 1.S3E-12 O.
7.0SE-12 O.
4.33E-1B ND147 6.29E-09 7.27E-09 4.3SE-10 O.
4.2SE-09 O.
3.49E-OS PM147 7.S4E-OB 7.09E-09 2.B7E-09 O.
1.34E-OB O.
B.93E-06 PM14BM 3.07E-OB 7.9SE-09 6.0BE-09 O.
1.20E-OB O.
6.74E-OS PM14B 7.17E-09 1.19E-09 S.99E-10 O.
2.2SE-09 O.
9.3SE-OS PM149 1.S2E-09 2.1SE-10 B.7BE-11 O.
4.06E-10 O.
4.03E-OS PM1S1 6.97E-10 1.17E-10 S.91 E-11 O.
2.09E-10 O.
3.22E-OS SM1S1 6.90E-OB 1.19E-OB 2.BSE-09 O.
1.33E-OB O.
S.2SE-06 SM1S3 B.S7E-10 7.1SE-10 S.22E-11 O.
2.31 E-10 O.
2.SSE-OS EU1S2 1.9SE-07 4.44E-OB 3.90E-OB O.
2.7SE-07 O.
2.S6E-OS EU1S4 6.1SE-07 7.S6E-OB S.3BE-OB O.
3.62E-07 O.
S.4BE-OS EU1SS B.60E-OB 1.22E-OB 7.B7E-09 O.
S.63E-OB O.
9.60E-06 EU1S6 1.37E-OB 1.06E-OB 1.71 E-09 O.
7.0BE-09 O.
7.26E-OS TB160 4.70E-OB O.
S.B6E-09 O.
1.94E-OB O.
4.33E-OS H0166M 2.70E-07 B.43E-OB 6.40E-OB O.
1.26E-07 O.
O.
W1B1 9.91 E-09 3.23E-09 3.46E-10 O.
O.
O.
3.6BE-07 W1BS 4.0SE-07 1.3SE-07 1.42E-OB O.
O.
O.
1.S6E-OS W1B7 1.03E-07 B.61 E-OB 3.01 E-OB O.
O.
O.
.2.B2E-OS
Proc No ODeM Revision 26 Page 16 of 16 INGESTION DOSE COMMITMENT FACTORS ADUL T INGESTION DOSE COMMITMENT FACTORS (MREM/50Y PER PCIINGESTED IN FIRST YR)
ISOTOPE BONE LIVER TOTAL BODY THYROID KIDNEY LUNG GI-LLI PB210 1.S3E-02 4.37E-03 S.44E-04 O.
1.23E-02 O.
S.42E-OS BI210 4.61E-07 3.1BE-06 3.96E-OB O.
3.B3E-OS O.
4.7SE-OS P0210 3.S6E-04 7.S6E-04 B.S9E-OS O.
2.S2E-03 O.
6.36E-OS RN222 O.
O.
O.
O.
O.
O.
O.
RA223 4.97E-03 7.6SE-06 9.94E-04 O.
2.17E-04 O.
3.21 E-04 RA224 1.61 E-03 3.90E-06 3.23E-04 O.
1.10E-04 O.
3.40E-04 RA22S 6.S6E-03 7.7BE-06 1.31 E-03 O.
2.21 E-04 O.
3.06E-04 RA226 3.02E-01 S.74E-06 2.20E-01 O.
1.63E-04 O.
3.32E-04 RA22B 1.12E-01 3.12E-06 1.21 E-01 O.
B.B3E-OS O.
S.64E-OS AC22S 4.40E-06 6.06E-06 2.96E-07 O.
6.90E-07 O.
4.07E-04 AC227 1.B7E-03 2.4BE-04 1.11 E-04 O.
B.OOE-OS O.
B.19E-OS TH227 1.37E-OS 2.4BE-07 3.9SE-07 O.
1.41 E-06 O.
S.40E-04 TH22B 4.96E-04 B.40E-06 1.6BE-OS O.
4.67E-OS O.
S.63E-04 TH229 7.9BE-03 1.19E-04 3.91 E-04 O.
S.7SE-04 O.
S.12E-04 TH230 2.06E-03 1.17E-04 S.70E-OS O.
S.6SE-04 O.
6.02E-OS TH232 2.30E-03 1.00E-04 1.S0E-04 O.
4.B2E-04 O.
S.12E-OS TH234 B.01 E-OB 4.71 E-09 2.31 E-09 O.
2.67E-OB O.
1.13E-04 PA231 4.10E-03 1.S4E-04 1.S9E-04 O.
B.64E-04 O.
7.17E-OS PA233 S.26E-09 1.06E-09 9.12E-10 O.
3.99E-09 O.
1.64E-OS U232 4.13E-03 O.
2.9SE-04 O.
4.47E-04 O.
6.7BE-OS U233 B.71E-04 O.
S.2BE-OS O.
2.03E-04 O.
6.27E-OS U234 B.36E-04 O.
S.17E-OS O.
1.99E-04 O.
6.14E-OS U23S B.01 E-04 O.
4.B6E-OS O.
1.B7E-04 O.
7.B1 E-OS U236 B.01 E-04 O.
4.96E-OS O.
1.91 E-04 O.
S.76E-OS U237 S.S2E-B O.
1.47E-OB O.
2.27E-07 O.
1.94E-OS U23B 7.67E-04 O.
4.S4E-OS O.
1.7SE-04 O.
S.SOE-OS NP237 1.37E-03 1.19E-04 S.S4E-OS O.
4.12E-04 O.
7.94E-OS NP23B 1.37E-OB 3.69E-10 2.13E-10 O.
1.2SE-09 O.
3.43E-OS NP239 1.19E-09 1.17E-10 6.4SE-11 O.
3.6SE-10 O.
2.40E-OS PU23B 6.BOE-04 9.SBE-OS 1.71 E-OS O.
7.32E-OS O.
7.30E-OS PU239 7.B7E-04 1.06E-04 1.91 E-OS O.
B.11 E-OS O.
6.66E-OS PU240 7.BSE-04 1.06E-04 1.91 E-OS O.
B.10E-OS O.
6.7BE-OS PU241 1.6SE-OS B.44E-07 3.32E-07 O.
1.S3E-06 O.
1.40E-06 PU242 7.29E-04 1.02E-04 1.B4E-OS O.
7.B1 E-OS O.
6.S3E-OS PU244 B.S2E-04 1.17E-04 2.11 E-OS O.
B.9SE-OS O.
9.73E-OS AM241 B.19E-04 2.BBE-04 S.41 E-OS O.
4.07E-04 O.
7.42E-OS AM242M B.24E-04 2.7BE-04 S.43E-OS O.
4.0SE-04 O.
9.34E-OS AM243 B.1BE-04 2.7BE-04 S.30E-OS O.
3.99E-04 O.
B.70E-OS CM242 2.06E-OS 2.10E-OS 1.37E-06 O.
6.22E-06 O.
7.92E-OS CM243 6.39E-04 2.41 E-04 3.7SE-OS O.
1.7SE-04 O.
7.B1 E-OS CM244 4.B3E-04 2.07E-04 2.B7E-OS O.
1.34E-04 O.
7.SSE-OS CM24S 1.02E-03 2.B7E-04 S.76E-OS O.
2.69E-04 O.
7.04E-OS CM246 1.01 E-03 2.B7E-04 S.7SE-OS O.
2.6BE-04 O.
6.91 E-OS CM247 9.B4E-04 2.B3E-04 S.67E-OS O.
2.64E-04 O.
9.09E-OS CM24B B.1BE-03 2.33E-03 4.67E-04 O.
2.1BE-03 O.
1.47E-03 CF2S2 2.64E-04 O.
6.29E-06 O.
O.
O.
2.BBE-04
PALISADES 10 YEAR X1Q - D/Q DATA USNRC COHPUTER
- XOQDOQ, VERSION 2.
RUN DATE: 28FEBl FALISADES XOQDOQ82 USING 01/01/2004 -
GROUND LEVEL RELEASE -
OE' CoNTAINblENT BUILDING
~P~CIFIC PO~NTS O~ k~~RBS7 RELEASE ID A
A A
A A
A A
A A
A A
A A
A A
A A
A A
A A
A A
TYPE OF LOCA'l'ION SITE BOUNDARY SITE BOUNDAR!
SITE BOUNDARY SITE BOlJNDARY SITE BOUNDARY SITE BOUNDARY SITE BOUNDARY SITE BOUNDARY SITE BOUNDARY RESIDENCE RESIDENCE RESIDENCE RESIDENCE RESIDENCE RESIDENCE RESIDENCE RESIDENCE RESIDENCE GARDEN GARDEN GARDEN GARDEN GARDEN GARDEN GARDEN GARDEN GOAT GOAT BEEr' CATTLE DIRECTION FRON SI'rE NNE NE ENE E
ESE BE SSE S
SSW NNE NE ENE ESE SE SSi'1 ENE E
SE DISTANCE
.bIILES 1
( HE'l'ERS )
0.50 0.65 0.87 0.82 O.
- o.
0..
- o.
- a. 8
- 1. 68 1.1'1 1.19
- l.
0.99 0.90 O.
0,77 O.
- 1. 75
- 1.
- 2.
2.68
- 1. 3
- 1. 9 O.
.82 2.62
.25
,27 805.
1046.
1320..
1014.
676.
- e704.
18 1915.
- 88.
1593.
1448.
1239.
- 89.
~8I6~
1688.
- 16.
4313 *.
L945.
- e398.
1 10.
i757.
4216 6840.
6872..
/2013 blET DATA X/Q SEC/CCB.NETER UNDEPlETED 1.23E-06 5.B8B-O?
1.39B-06 2.28E-06
- 1.
1.16E-07 1.31E-06
- 4.
X/Q SEC/CUB. HETER) 2.260 DAY DECAY UUDEPLETED
.57E-06
.23E-06 5.8GE-07 6.9GE-07 8.31E-O
.3SE-06 2.28E-06
.95E-06
.2SE-06
.S7E-07 5.30E-07
.o7E-07
.41E-07
.58E-O
.98E-07
.04E-06
.84E-O 21E-06 2 43E-07 3.0IE-07
.14E~O
.20E-07
.22E-O']
3.7SE-0
.31E-06
,IBE-08 1 14E-07 OSE-08
.8SE-08 SEC ICUB. Z-1ETER l
.000 DA¥ DECAY DEPLETED
.44E-06
.1 5.19E-G7
.1
.42E-07
- 1.
.2. 09E-06 1.SOE-06 3.19E-07
.06E-08 D/Q Proc No aDeM Revision 26 Page 1 of 1 PER SQ.r.tETER}
7.61E-09 8.80E-09 4.27E-09
.29E-09 6.93E-09 I..2SE-OS 2.0IE-08 1.1
.2SE-09 83E-10 3.39E-09 2.50E-09 L 56E-09 4.43E-09 6.86E-09 S.64E-09 4.I2E-09
.04E-09
.16E-IO 1.76E-09 6.34E-10 6.83E-IO 1.S4E-09 2.89E-09
- 1. UE;-08 1.17E-I0 6.34E-10 3.QIE-10 4.S3E-10
ATTACHMENT 2 BIG ROCK POINT INDEPENDENT SPENT FUEL STORAGE INSTALLATION 2014 RADIOACTIVE EFFLUENT RELEASE REPORT This report provides information relating to radioactive effluent releases and solid radioactive waste disposal at Big Rock Point (BRP) for the year 2014. The report format is detailed in the BRP Offsite Dose Calculation Manual (ODCM). Effluent releases from BRP are controlled by the Defueled Technical Specifications and the ODCM requirements. The ODCM was not revised in 2014.
2014 Operating History On January 8,2007, the Nuclear Regulatory Commission (NRC) approved release of the former BRP Nuclear Plant property for unrestricted use in accordance with the BRP License Termination Plan 1. On April 11,2007, the license for BRP, DPR-06, was transferred to Entergy Nuclear Operations, Inc.
During 2014, normal Independent Spent Fuel Storage Installation (lSFSI) operations continued. There were no operational activities that generated any solid radioactive waste.
Liquid and gaseous effluent monitoring is no longer conducted as the former BRP nuclear plant property has been released from the license. Short-lived radionuclides, including iodines and noble gas, are neither expected nor reported.
- 1.
Supplemental Information A.
Batch Releases There were no batch releases of gaseous or liquid effluents during 2014. All batch releases of radioactive liquids as described in the ODCM ceased in 2004.
B.
Abnormal Releases There were no abnormal releases from BRP during 2014.
C.
Radioactive Effluent Monitoring Instrumentation BRP ODCM currently specifies required actions when less than the minimum number of radioactive effluent monitoring instrument channels are operable. The ODCM also specifies these actions be taken when installed effluent monitoring systems are removed from service for decommissioning.
All plant-installed liquid and gaseous radioactive effluent monitoring instrument channels have been permanently removed and dismantled.
1 Letter from the USNRC dated January 8,2007, "Release of Land from Part 50 License for Unrestricted Use" Page 1 of 8
- 2.
Gaseous Effluents Although there were no gaseous effluents released during 2014, Table 2 provides a summary of all gaseous radioactive effluent monitoring conducted during the reporting period as required by the aDCM.
- 3.
Liquid Effluents There were no liquid effluent batch releases during 2014. Table 3 lists and summarizes liquid effluent releases in accordance with the aDCM.
- 4.
Solid Waste There was no solid radioactive waste generated or shipped during 2014.
- 5.
Summary of Radiological Impact on Man The aDCM specifies that the annual effluent release report provide potential dose calculations based on measured effluent to liquid and gaseous pathways, if estimates of dose exceed one millirem to an organ or total body of any individual or more than one person-rem to the population within 50 miles. During 2014, there were no releases. Therefore, no calculations were required.
- 6.
affsite Dose Calculation Manual The aDCM describes the radiological release requirements for the BRP site.
There were no revisions to the aDCM in 2014.
- 7.
The Process Control Program (PCP) describes solid waste processing and disposal methods utilized at the BRP site. The PCP was not revised during 2014.
Page 2 of 8
A. GASEOUS B. LIQUID Number of Releases Total Release Time Maximum Release Time Average Release Time Minimum Release Time TABLE 1 Big Rock Point Batch Releases January 1,2014 to December 31,2014 Units 1ST QTR 2NDQTR 3RD QTR N/A N/A N/A Minutes N/A N/A N/A Minutes N/A N/A N/A Minutes N/A N/A N/A Minutes N/A N/A N/A Page 3 of 8 4TH QTR N/A N/A N/A N/A N/A
TABLE 2 Big Rock Point Gaseous Effluent Releases January 1, 2014 to December 31, 2014 1ST 2ND A. FISSION AND ACTIVATION GASES Units OTR OTR
- 1. Total release Ci N/A N/A
- 2. Average release rate for period
!-lCi/sec N/A N/A
- 3. Percent of annual avg EC N/A N/A B IODINES
- 1. Total iodine Ci N/A N/A
- 2. Average release rate for period
!-lCi/sec N/A N/A
- 3. Percent of annual avg EC N/A N/A C PARTICULATES
- 1. Particulates with half-life >8 day Ci N/A N/A
- 2. Average release rate for period I-lCi/sec N/A N/A
- 3. Percent of annual avg EC N/A N/A
- 4. Gross alpha radioactivity Ci N/A N/A D TRITIUM
- 1. Total Release Ci N/A N/A
- 2. Average release rate for period
!-lCi/sec N/A N/A
- 3. Percent of annual avg EC N/A N/A E WHOLE BODY DOSE
- 1. Beta Air dose at Site Boundary due to Noble Gases (ODCM Section 1, 1.3.2 a (1) (2))
mrads N/A N/A
- 2. Percent limit N/A N/A
- 3. Gamma Air dose at Site Boundary due to Noble Gas (ODCM Section 1, 1.3.2 a (1) (2))
mrads N/A N/A
- 4. Percent limit N/A N/A F. ORGAN DOSE (ODCM Section 1, 1.3.2b (1) (2))
- 1. Maximum organ dose to pubic based on Critical Receptors (child bone) mrem N/A N/A
- 2. Percent of limit (7.5 mrem/quarter)
N/A N/A Page 4 of 8 3RD 4TH Est Total OTR OTR Error %
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
- 1. FISSION GASES Krypton-85m Krypton-8?
Krypton-88 Xenon-133 Xenon-133m Xenon-135 Xenon-135m Xenon-138 Total for Period
- 2. IODINES lodine-131 lodine-132 lodine-133 lodine-134 lodine-135 Total for Period TABLE 2 Big Rock Point Gaseous Effluent Releases January 1,2014 to December 31,2014 Units 1ST aTR 2ND aTR 3RD aTR Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Page 5 of 8 4TH aTR N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
- 3. PARTICULATES*
Chromium-51 Manganese-54 Cobalt-58 Iron-59 Cobalt-60 Zinc-65 Silver-110m Cesium-134 Cesium-137 Barium-140 Europium-152 Strontium-89 Strontium-90 Net unidentified beta Total TABLE 2 Big Rock Point Gaseous Effluent Releases January 1, 2014 to December 31, 2014 Units 1ST aTR 2ND aTR 3RD aTR Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A Ci N/A N/A N/A
- PartIculates wIth half-lIfe >8 days Page 6 of 8 4TH aTR N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
TABLE 3 Big Rock Point Liquid Effluent Releases January 1,2014 to December 31,2014 A. FISSION AND ACTIVATION PRODUCTS Units 1ST OTR 2ND OTR
- 1. Total release (not including tritium, gases, alpha)
Ci N/A N/A
- 2. Average diluted concentration during period
~Ci/ml N/A N/A
- 3. Percent of EC N/A N/A B. TRITIUM
- 1. Total release Ci N/A N/A
- 2. Average diluted concentration during period j..JCi/ml N/A N/A
- 3. Percent of EC N/A N/A C DISSOLVED AND ENTRAINED GASES
- 1. Total release Ci N/A N/A
- 2. Average diluted concentration during period
~Ci/ml N/A N/A
- 3. Percent of EC N/A N/A D. GROSS ALPHA RADIOACTIVITY E. VOLUME OF WASTE RELEASED (Prior to dilution)
Liters N/A N/A F. VOLUME OF DILUTION WATER USED DURING PERIOD Liters N/A N/A G. MAXIMUM DOSE COMMITMENT WHOLEBODY mrem N/A N/A Percent of ODCM Section 1,2.3.2 a (1.5 mrem)
N/A N/A H.
MAXIMUM DOSE COMMITMENT - ORGAN Mrem N/A N/A Percent of ODCM Section 1, 2.3.2 b (3.0 mrem)
N/A N/A Page 7 of 8 Est Total 3RD OTR 4TH OTR Error %
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
- 1. NUCLIDES RELEASED Units Chromium-51 Ci Manganese 54 Ci Cobalt-58 Ci Iron-59 Ci Cobalt-60 Ci Zinc-65 Ci Strontium-89 Ci Strontium-90 Ci Molybdenum-99 Ci Silver-110m Ci lodine-131 Ci Cesium-134 Ci Cesium-137 Ci Antimony-125 Ci Tin-113 Ci Net Unidentified Beta Ci Fission & Activation Product Total Ci Xenon-133 Ci Tritium Ci Grand Total Ci TABLE 3 Big Rock Point Liquid Effluent Releases January 1,2014 to December 31,2014 1ST aTR 2ND aTR 3RD aTR Page 8 of 8 4TH aTR
--